From: <Salvato con Microsoft Internet Explorer 5>
Subject: Low-Grade Gliomas in Adults -- Grier and Batchelor 11 (6): 681 -- The Oncologist
Date: Fri, 23 Jun 2006 09:05:10 +0200
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----=_NextPart_000_0015_01C696A4.21509550"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2869

This is a multi-part message in MIME format.

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: text/html;
	charset="Windows-1252"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD><TITLE>Low-Grade Gliomas in Adults -- Grier and Batchelor 11 =
(6): 681 -- The Oncologist</TITLE>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Dwindows-1252">
<SCRIPT language=3DJavaScript>=0A=
        <!--=0A=
        function startTarget(windowname,wid,hei) {=0A=
        =0A=
        var dotpos =3D windowname.indexOf(".");=0A=
        if (dotpos > -1)=0A=
        {=0A=
        var tempwn =3D windowname.substring(0,dotpos) +=0A=
                windowname.substring(dotpos + 1, windowname.length);=0A=
        windowname =3D tempwn;=0A=
        }=0A=
        var sizestring =3D 'width=3D' + wid + ',height=3D' + hei;=0A=
        window.open('',windowname,'scrollbars,resizable,' + sizestring + =
'\'');=0A=
        }=0A=
        // -->=0A=
        </SCRIPT>
<!-- has inhead tag -->
<SCRIPT language=3DJavaScript>=0A=
	<!--=0A=
	if ( top !=3D self )=0A=
	{=0A=
		top.location.href =3D unescape(window.location.pathname);=0A=
	}=0A=
	//-->=0A=
	</SCRIPT>

<STYLE type=3Dtext/css>TABLE.content_box_outer_table {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 0px
}
TABLE.content_box_outer_table_in_sidebar_frame {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 10px
}
TABLE.content_box_inner_table {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 65%; PADDING-BOTTOM: =
5px; PADDING-TOP: 0px; FONT-FAMILY: Verdana,Arial,Helvetica,sans-serif; =
BACKGROUND-COLOR: #f0f0f0
}
TABLE.content_box_pdfinframes {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 4px; =
PADDING-TOP: 0px
}
TD.content_box_title_highlight {
	PADDING-RIGHT: 1px; PADDING-LEFT: 1px; FONT-WEIGHT: bold; FONT-SIZE: =
120%; PADDING-BOTTOM: 1px; VERTICAL-ALIGN: middle; COLOR: #ffffff; =
PADDING-TOP: 1px; FONT-STYLE: italic; FONT-FAMILY: "Trebuchet =
MS",Verdana,Arial,Helvetica,sans-serif; BACKGROUND-COLOR: #333366; =
TEXT-ALIGN: center
}
TD.content_box_title {
	PADDING-RIGHT: 1px; PADDING-LEFT: 1px; FONT-WEIGHT: bold; FONT-SIZE: =
120%; PADDING-BOTTOM: 1px; VERTICAL-ALIGN: middle; COLOR: #ffffff; =
PADDING-TOP: 1px; FONT-STYLE: italic; FONT-FAMILY: "Trebuchet =
MS",Verdana,Arial,Helvetica,sans-serif; BACKGROUND-COLOR: #828282; =
TEXT-ALIGN: center
}
TD.content_box_space_between_sections {
	PADDING-TOP: 2px
}
TD.content_box_arrow {
	PADDING-RIGHT: 0px; PADDING-LEFT: 5px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 0px; TEXT-ALIGN: right
}
TD.content_box_item {
	PADDING-RIGHT: 5px; PADDING-LEFT: 3px; PADDING-BOTTOM: 3px; =
VERTICAL-ALIGN: top; PADDING-TOP: 0px; TEXT-ALIGN: left
}
TD.content_box_pdfinframes_citation_cell {
	BORDER-RIGHT: #000000 1px solid; PADDING-RIGHT: 3px; BORDER-TOP: =
#000000 1px solid; PADDING-LEFT: 3px; FONT-SIZE: 65%; PADDING-BOTTOM: =
3px; BORDER-LEFT: #000000 1px solid; PADDING-TOP: 3px; BORDER-BOTTOM: =
#000000 1px solid; FONT-FAMILY: Verdana,Arial,Helvetica,sans-serif; =
BACKGROUND-COLOR: #ffffff; TEXT-ALIGN: left
}
FONT.openaccess {
	PADDING-RIGHT: 3px; PADDING-LEFT: 3px; FONT-WEIGHT: bold; =
BACKGROUND-COLOR: #ffffff
}
FONT.openaccess_open {
	COLOR: #000000
}
FONT.openaccess_access {
	COLOR: #cc0000
}
FONT.openaccess_oa {
=09
}
.content_box_openaccess_title {
	WHITE-SPACE: nowrap; BACKGROUND-COLOR: #bababa; TEXT-ALIGN: center
}
DIV.referrer-based-search-line {
	PADDING-RIGHT: 25px; PADDING-LEFT: 25px; FONT-SIZE: 0.75em; =
PADDING-BOTTOM: 3px; MARGIN: 0px 4px 5px 0px; PADDING-TOP: 3px; =
FONT-FAMILY: arial,sans-serif; BACKGROUND-COLOR: #009918
}
DIV.referrer-based-search-line .search-terms {
	FONT-WEIGHT: bold
}
DIV.referrer-based-search-line .collection-name {
	FONT-STYLE: italic
}
</STYLE>

<SCRIPT language=3Djavascript>=0A=
		<!-- =0A=
	function popwin(url,wid,hei,fromtop,fromleft) {=0A=
		var winPref =3D =
"channelmode=3Dno,toolbar=3Dno,location=3Dno,directories=3Dno,status=3Dno=
,menubar=3Dno,scrollbars=3Dauto,resizable=3Dno,width=3D" + wid + =
",height=3D" + hei + ",top=3D" + fromtop + ",left=3D" + fromleft;=0A=
		window.open(url, "popwin", winPref);=0A=
	}=0A=
	// -->=0A=
	</SCRIPT>

<SCRIPT=20
src=3D"http://theoncologist.alphamedpress.org/javascript/ajax/xmlhttprequ=
est.js"=20
type=3Dtext/javascript></SCRIPT>

<SCRIPT =
src=3D"http://theoncologist.alphamedpress.org/javascript/ajax/utility.js"=
=20
type=3Dtext/javascript></SCRIPT>

<SCRIPT=20
src=3D"http://theoncologist.alphamedpress.org/javascript/entrez/callback.=
js"=20
type=3Dtext/javascript></SCRIPT>

<META content=3Dnofollow name=3Drobots>
<META content=3D"The Oncologist" name=3Dcitation_journal_title>
<META content=3D"Grier, Jeanine T.; Batchelor, Tracy" =
name=3Dcitation_authors>
<META content=3D"Low-Grade Gliomas in Adults" name=3Dcitation_title>
<META content=3D06/01/2006 name=3Dcitation_date>
<META content=3D11 name=3Dcitation_volume>
<META content=3D6 name=3Dcitation_issue>
<META content=3D681 name=3Dcitation_firstpage>
<META content=3D10.1634/theoncologist.11-6-681 name=3Dcitation_doi>
<META =
content=3Dhttp://theoncologist.alphamedpress.org/cgi/reprint/11/6/681.pdf=
=20
name=3Dcitation_pdf_url>
<META=20
content=3Dhttp://theoncologist.alphamedpress.org/cgi/content/abstract/11/=
6/681=20
name=3Dcitation_abstract_html_url>
<META =
content=3Dhttp://theoncologist.alphamedpress.org/cgi/content/full/11/6/68=
1=20
name=3Dcitation_fulltext_html_url>
<META content=3D"Grier, Jeanine T." name=3Ddc.Contributor>
<META content=3D"Batchelor, Tracy" name=3Ddc.Contributor>
<META content=3D"Low-Grade Gliomas in Adults" name=3Ddc.Title>
<META content=3D10.1634/theoncologist.11-6-681 name=3Ddc.Identifier>
<META content=3D06/01/2006 name=3Ddc.Date>
<META content=3D"AlphaMed Press" name=3Dcitation_publisher>
<META content=3DNOARCHIVE name=3DROBOTS>
<META content=3D"MSHTML 6.00.2900.2912" name=3DGENERATOR></HEAD>
<BODY bgColor=3D#ffffff><A name=3Dtop><!-- null --></A><NOBR><MAP=20
  name=3Dhome_button><AREA shape=3DRECT coords=3D57,22,110,40=20
  href=3D"http://theoncologist.alphamedpress.org/help/"><AREA =
shape=3DRECT=20
  coords=3D0,0,110,40 =
href=3D"http://theoncologist.alphamedpress.org/"></MAP><A=20
style=3D"TEXT-DECORATION: none" =
href=3D"http://theoncologist.alphamedpress.org/"=20
target=3D_top><IMG height=3D44 alt=3D"The Oncologist"=20
src=3D"http://theoncologist.alphamedpress.org/icons/banner/title.gif" =
width=3D220=20
border=3D0></A> <A=20
href=3D"http://ad.doubleclick.net/jump/N1471.TheOncologist/B1852285;dcadv=
=3D421173;sz=3D468x60;ord=3D[timestamp]?"><IMG=20
height=3D60 alt=3D"Click Here"=20
src=3D"http://ad.doubleclick.net/ad/N1471.TheOncologist/B1852285;dcadv=3D=
421173;sz=3D468x60;ord=3D[timestamp]?"=20
width=3D468 border=3D0></A> <IMG height=3D2=20
src=3D"http://171.66.124.80/RealMedia/ads/adstream_lx.ads/theoncologist.a=
lphamedpress.org/cgi/content/full/11/6/2132010894/Top/alphamedpress/GTO_L=
illy2006/GTO_Lilly2006.html/39373261623235323434396239323830?_RM_EMPTY_&a=
mp;tw_country_code=3DIT"=20
width=3D2 border=3D0> </NOBR><BR><NOBR>
<TABLE cellSpacing=3D2 cellPadding=3D2 width=3D450>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>HOME</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/help/" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>HELP</FONT></A></FONT></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/cgi/feedback"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>CONTACT=20
      US</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/subscriptions/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff=20
      size=3D-2>SUBSCRIPTIONS</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      =
href=3D"http://theoncologist.alphamedpress.org/contents-by-date.0.shtml" =

      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff=20
      size=3D-2>ARCHIVE</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/search.dtl" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>SEARCH</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      =
href=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>TABLE OF=20
      CONTENTS</FONT></A></TD></TR></TBODY></TABLE></NOBR>
<HR align=3Dleft width=3D450 noShade SIZE=3D1>
<FONT size=3D-1>The Oncologist, Vol. 11, No. 6, 681-693, June 2006;=20
doi:10.1634/theoncologist.11-6-681 <BR>=A9 2006 <A=20
href=3D"http://theoncologist.alphamedpress.org/misc/terms.shtml">AlphaMed=
=20
Press</A> </FONT>
<P>
<TABLE class=3Dcontent_box_outer_table align=3Dright>
  <TBODY>
  <TR>
    <TD><!-- beginning of inner table -->
      <TABLE class=3Dcontent_box_inner_table><!-- citation -->
        <TBODY>
        <TR>
          <TD class=3Dcontent_box_title_highlight colSpan=3D2>This =
Article</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/abstract/11/6/=
681">Abstract</A></STRONG>=20
            <IMG height=3D7 alt=3D"Freely available"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/toc/free.gif" =

            width=3D32 border=3D0> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/reprint/11/6/681"><STR=
ONG>Full=20
            Text</STRONG> (PDF)</A> </STRONG></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG>CME: Take the course for =
this=20
            article:<BR></STRONG><A=20
            =
href=3D"http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;ONC-11-6=
-681">Low-Grade=20
            Gliomas in Adults</A><BR></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/ctalert?alertTy=
pe=3Dcitedby&amp;addAlert=3Dcited_by&amp;saveAlert=3Dno&amp;cited_by_crit=
eria_resid=3Dtheoncologist;11/6/681&amp;return_type=3Darticle&amp;return_=
url=3Dhttp%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull=
%2F11%2F6%2F681">Alert=20
            me when this article is cited</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/ctalert?alertTy=
pe=3Dcorrection&amp;addAlert=3Dcorrection&amp;saveAlert=3Dno&amp;correcti=
on_criteria_value=3D11/6/681&amp;return_type=3Darticle&amp;return_url=3Dh=
ttp%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull%2F11%2=
F6%2F681">Alert=20
            me if a correction is posted</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/citemap?id=3Dtheoncolo=
gist;11/6/681"=20
            rel=3Dnofollow>Citation Map</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>Services</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/mailafriend?url=3Dhttp=
%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull%2F11%2F6%=
2F681&amp;title=3DLow-Grade+Gliomas+in+Adults">E-mail=20
            this article link to a friend</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/search?qbe=3Dtheoncolo=
gist;11/6/681&amp;journalcode=3Dtheoncologist&amp;minscore=3D5000">Simila=
r=20
            articles in this journal</A> </STRONG></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/etoc">Alert=20
            me to new issues of the journal</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/citmgr?gca=3Dtheoncolo=
gist;11/6/681">Download=20
            to citation manager</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/misc/reprints.shtml">Repri=
nts/Permissions</A></STRONG>=20
          </TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>Google =
Scholar</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            href=3D"http://scholar.google.com/scholar?q=3D%22author%3AJ. =
T.+author%3AGrier%22"=20
            target=3D_blank>Articles by Grier, J. T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://scholar.google.com/scholar?q=3D%22author%3AT.+author%3ABat=
chelor%22"=20
            target=3D_blank>Articles by Batchelor, T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>PubMed</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3DGrier+JT&amp;link_type=3DAUTHORSEARCH"=20
            target=3D_blank>Articles by Grier, J. T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3DBatchelor+T&amp;link_type=3DAUTHORSEARCH"=20
            target=3D_blank>Articles by Batchelor, T.</A></STRONG>=20
        </TD></TR></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
<TABLE cellSpacing=3D0 cellPadding=3D0>
  <TBODY>
  <TR>
    <TD>
      <HR noShade SIZE=3D1>

      <H3>Neuro-Oncology</H3></TD></TR></TBODY></TABLE>
<H2>Low-Grade Gliomas in Adults </H2><STRONG></NOBR><NOBR>Jeanine T.=20
Grier<SUP></SUP></NOBR>, <NOBR>Tracy Batchelor<SUP></SUP></NOBR> =
</STRONG>
<P><FONT size=3D-1>Division of Neuro-Oncology, Department of Neurology,=20
Massachusetts General Hospital and Harvard Medical School, Boston,=20
Massachusetts, USA </FONT>
<P><STRONG>Key Words. </STRONG>Low-grade glioma =95 Astrocytoma =95=20
Oligodendroglioma
<P>
<P>Correspondence: Tracy Batchelor, M.D., M.P.H., Stephen E. and =
Catherine=20
Pappas Center for Neuro-Oncology, Yawkey 9E, Massachusetts General =
Hospital, 55=20
Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617-643-1938; =
Fax:=20
617-643-2591; e-mail: <SPAN id=3Dem0>tbatchelor{at}partners.org</SPAN>
<SCRIPT type=3Dtext/javascript><!--=0A=
 var u =3D "tbatchelor", d =3D "partners.org"; =
document.getElementById("em0").innerHTML =3D '<a href=3D"mailto:' + u + =
'@' + d + '">' + u + '@' + d + '<\/a>'//--></SCRIPT>
</FONT>
<P>Received January 4, 2006; accepted for publication April 18, 2006.
<P><A name=3DSEC1><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; L<FONT=20
      size=3D-2>EARNING</FONT> O<FONT size=3D-2>BJECTIVES</FONT>=20
  </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Learning Objectives</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>A=
fter=20
completing this course, the reader will be able to:
<OL type=3D1>
  <LI>Discuss<SUP> </SUP>the incidence of low-grade gliomas and list the =

  various<SUP> </SUP>diagnostic<SUP> </SUP>methods employed for this =
group of=20
  tumors.<SUP> </SUP><BR>
  <LI>Identify the factors<SUP> </SUP>that influence treatment decisions =

  and<SUP> </SUP>the various treatment<SUP> </SUP>options available for=20
  low-grade gliomas.<SUP> </SUP><BR>
  <LI>Outline the evidence<SUP> </SUP>regarding resection, radiation, =
and=20
  chemotherapy<SUP> </SUP>for the treatment<SUP> </SUP>of low-grade=20
  gliomas.<SUP> </SUP><BR>
  <LI>List the specific subsets of low-grade<SUP> </SUP>glioma and the=20
  unique<SUP> </SUP>diagnostic, prognostic, and treatment<SUP> =
</SUP>factors=20
  associated with<SUP> </SUP>each subset.<SUP> </SUP><BR>
  <LI>Describe the different<SUP> </SUP>treatment-related complications=20
  that<SUP> </SUP>are relevant for the low-grade<SUP> </SUP>glioma =
patient=20
  population.<SUP> </SUP><BR></LI></OL><SUP></SUP>
<P>Access and take the CME test online and receive 1 AMA PRA =
category<SUP>=20
</SUP>1 credit at <A=20
href=3D"http://cme.theoncologist.com/">CME.TheOncologist.com</A><SUP> =
</SUP>
<P>
<P><A name=3DABS><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; A<FONT=20
      size=3D-1>BSTRACT</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><IMG height=3D9 alt=3D" " =
hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Abstract</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR><=
STRONG>Low-grade=20
gliomas are a heterogeneous group of neoplasms usually<SUP> =
</SUP>encountered in=20
younger patient populations. These tumors represent<SUP> </SUP>a unique=20
challenge because most patients will survive a decade<SUP> </SUP>or more =
and may=20
be at a higher risk for treatment-related complications.<SUP> =
</SUP>Clinical=20
observations over the years have identified a subset<SUP> </SUP>of =
low-grade=20
gliomas that tends to manifest more aggressive<SUP> </SUP>clinical =
behavior and=20
require earlier, more aggressive intervention.<SUP> </SUP>Clinical and =
molecular=20
parameters may allow better assessment<SUP> </SUP>of prognosis and =
application=20
of risk-adjusted management strategies<SUP> </SUP>that may include =
resection,=20
radiation, or chemotherapy. Improved<SUP> </SUP>methods of long-term =
cognitive=20
and functional assessment are<SUP> </SUP>desperately needed in this =
patient=20
population.<SUP> </SUP>
<P></STRONG><A name=3DSEC2><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; I<FONT=20
      size=3D-2>NTRODUCTION</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Introduction</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>T=
umors of=20
the central nervous system (CNS) are grouped according<SUP> </SUP>to =
their cell=20
of origin and are graded based on standard histopathological<SUP>=20
</SUP>features. Gliomas comprise a heterogeneous group of =
neuroectodermal<SUP>=20
</SUP>tumors that arise from the glia, the supporting cells of the<SUP>=20
</SUP>CNS. Astrocytes, oligodendrocytes, and ependymal cells are =
types<SUP>=20
</SUP>of glial cells that may give rise to astrocytomas,=20
oligodendrogliomas,<SUP> </SUP>and ependymomas, respectively.<SUP> =
</SUP>
<P>According to the World Health Organization (WHO) classification,<SUP> =

</SUP>the most commonly accepted grading system for brain tumors,<SUP> =
</SUP>the=20
surgical specimen should be assessed for atypical cells,<SUP> =
</SUP>mitoses,=20
endothelial proliferation, and necrosis. Tumors with<SUP> </SUP>none of =
these=20
characteristics are classified as grade 1. The<SUP> </SUP>more common =
gliomas in=20
this class are pilocytic astrocytoma<SUP> </SUP>(PA), dysembryoplastic=20
neuroepithelial tumor (DNET), pleomorphic<SUP> </SUP>xanthoastrocytoma =
(PXA),=20
and ganglioglioma. Gliomas that possess<SUP> </SUP>only one feature, =
usually=20
atypical cells, are grade 2. Astrocytoma,<SUP> </SUP>oligodendroglioma, =
and=20
oligoastrocytoma fall into the grade<SUP> </SUP>2 category. These tumors =
are=20
also termed low-grade astrocytoma,<SUP> </SUP>low-grade =
oligodendroglioma, and=20
low-grade oligoastrocytoma,<SUP> </SUP>respectively. A subset of gliomas =
may=20
have both endothelial<SUP> </SUP>proliferation and atypia but are well=20
circumscribed and slow-growing.<SUP> </SUP>These tumors are considered =
to be=20
low-grade gliomas (LGGs) despite<SUP> </SUP>their departure from the =
typical=20
classification scheme. LGG<SUP> </SUP>refers to tumors in either the =
grade 1 or=20
grade 2 categories.<SUP> </SUP>Tumors with two or more features are =
considered=20
malignant and<SUP> </SUP>are termed grade 3 or grade 4 gliomas.<SUP> =
</SUP>
<P>LGGs include a diverse group of tumors within the brain, =
brainstem,<SUP>=20
</SUP>and spinal cord, with distinct characteristics, patterns of<SUP>=20
</SUP>occurrence, response to treatment, and survival. Patients =
with<SUP>=20
</SUP>LGG tend to be young, otherwise healthy individuals, and =
management<SUP>=20
</SUP>decisions, such as timing of intervention, extent of surgical<SUP> =

</SUP>resection, timing of radiotherapy, and long-term benefits and<SUP> =

</SUP>risks of chemotherapy, have been controversial. In this =
review,<SUP>=20
</SUP>we outline the key issues of LGG management. For the purpose<SUP> =
</SUP>of=20
this review, LGG refers only to supratentorial nonpilocytic<SUP>=20
</SUP>astrocytoma, oligodendroglioma, and mixed oligoastrocytoma.<SUP>=20
</SUP>Other subtypes=97such as pilocytic astrocytoma, subependymal<SUP>=20
</SUP>giant cell astrocytoma, brainstem glioma, and optic nerve =
glioma=97have<SUP>=20
</SUP>different clinical presentations, diagnostic algorithms, and<SUP>=20
</SUP>treatments. These four subtypes are briefly discussed at the<SUP>=20
</SUP>end of this review.<SUP> </SUP>
<P><A name=3DSEC3><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; I<FONT=20
      size=3D-2>NCIDENCE</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><IMG height=3D9 alt=3D" " =
hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Incidence</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>A=
n=20
estimated 43,800 new cases of primary CNS tumors were diagnosed<SUP> =
</SUP>in=20
2005 [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].=20
Gliomas accounted for 40% of all these primary<SUP> </SUP>CNS tumors [<A =

href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].=20
Astrocytomas represent 75% of all gliomas, while<SUP> </SUP>ependymomas, =

oligodendrogliomas, and other glioma subtypes comprise<SUP> </SUP>the =
remaining=20
25%. The International Classification of Diseases<SUP> </SUP>for =
Oncology=20
(ICDO)-3 does not identify separate histology codes<SUP> </SUP>for =
low-grade=20
gliomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R2">2</A>].=20
Since no ICDO-3 codes exist for LGG,<SUP> </SUP>specific incidence rates =
for=20
low-grade oligodendroglioma and<SUP> </SUP>low-grade astrocytoma are =
difficult=20
to determine. From a compilation<SUP> </SUP>of citations, the American=20
Association of Neurological Surgeons<SUP> </SUP>(AANS) estimated that =
the annual=20
number of pediatric and adult<SUP> </SUP>LGG cases diagnosed in the =
U.S.,=20
including pilocytic astrocytoma,<SUP> </SUP>diffuse fibrillary =
astrocytoma,=20
oligodendroglioma, and oligoastrocytoma,<SUP> </SUP>is 1,800 [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R3">3</A>].<SUP>=20
</SUP>
<P>In adults aged 20=9634, gliomas account for 45% of all CNS<SUP> =
</SUP>tumors.=20
Astrocytomas as a group account for 18% and glioblastoma<SUP> =
</SUP>accounts for=20
6% of young adult tumors [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].=20
Incidence rates for<SUP> </SUP>glioblastoma, ependymoma, mixed glioma, =
and=20
oligodendroglioma<SUP> </SUP>are over two times greater in whites than =
in blacks=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].=20
Currently,<SUP> </SUP>there is no compelling evidence for a strong =
association=20
between<SUP> </SUP>environmental exposures and glioma development [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R4">4</A>].<SUP>=20
</SUP>
<P><A name=3DSEC4><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; P<FONT=20
      size=3D-2>RESENTATION</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Presentation</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>M=
ost=20
patients with LGG present between the second and fourth<SUP> =
</SUP>decades of=20
life, and a seizure is the presenting symptom in<SUP> </SUP>72%=9689% of =
patients=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R5">5</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R12">12</A>].=20
Mental status changes<SUP> </SUP>are present in 3%=9630% of patients at =
the time=20
of presentation<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R6">6</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R10">10</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R12">12</A>].=20
Ten percent to 44% have signs of increased intracranial<SUP> =
</SUP>pressure,=20
such as headache and nausea, when first diagnosed<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R6">6</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R10">10</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R11">11</A>].=20
Focal neurological deficits are present in 2%=9630%<SUP> </SUP>of =
patients [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R6">6</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R7">7</A>].=20
However, patients may have normal neurological<SUP> =
</SUP>examinations.<SUP>=20
</SUP>
<P><A name=3DSEC5><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; D<FONT=20
      size=3D-2>IAGNOSIS</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><IMG height=3D9 alt=3D" " =
hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Diagnosis</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>D=
iagnosis=20
is made through radiological imaging and histopathology.<SUP> </SUP>On=20
contrast-enhanced computerized tomography (CT) scans, an<SUP> </SUP>LGG =
usually=20
appears as a heterogeneous region of low attenuation<SUP> </SUP>that may =
or may=20
not enhance. There may be mass effect on adjacent<SUP> </SUP>structures, =
and=20
calcifications occur in up to 20% of oligodendrogliomas<SUP> </SUP>but =
are less=20
common in astrocytomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R13">13</A>].=20
On magnetic resonance<SUP> </SUP>imaging (MRI), LGGs are usually =
nonenhancing=20
with low signal<SUP> </SUP>intensity on T1-weighted (Fig. 1A<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F1"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>) and high signal intensity<SUP> </SUP>on =
T2-weighted MRI=20
sequences. Calcifications may appear as foci<SUP> </SUP>of high T1 and =
low T2=20
signals. Fluid-attenuated inversion recovery<SUP> </SUP>(FLAIR) =
sequences show=20
the best contrast between presumed infiltrating<SUP> </SUP>tumor margins =
and=20
normal brain (Fig. 1B<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F1"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>).<SUP> </SUP>
<P><A name=3DF1><!-- null --></A><BR clear=3Dall>
<CENTER>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"95%">
  <TBODY>
  <TR bgColor=3D#e1e1e1>
    <TD>
      <TABLE cellSpacing=3D2 cellPadding=3D2>
        <TBODY>
        <TR bgColor=3D#e1e1e1>
          <TD vAlign=3Dtop align=3Dmiddle bgColor=3D#ffffff><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F1"><IMG=20
            height=3D110 alt=3D"Figure 1" hspace=3D10=20
            =
src=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/images=
/small/681fig1.gif"=20
            width=3D200 vspace=3D5 border=3D2></A><BR><STRONG>View =
larger=20
            version</STRONG> (73K):<BR><NOBR><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F1">[in=20
            this window]</A><BR><A=20
            onmouseover=3D"window.status=3D'View figure in a separate =
window'; return true"=20
            onclick=3D"startTarget('F1', 590, 443); =
this.href=3D'/cgi/content-nw/full/11/6/681/F1'"=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content-nw/full/11/6/6=
81/F1"=20
            target=3DF1>[in a new window]</A><BR>&nbsp;</NOBR> </TD>
          <TD vAlign=3Dtop align=3Dleft><B>Figure 1.</B> Low-grade =
astrocytoma.=20
            <B>(A):</B> T1-weighted, postcontrast, axial magnetic =
resonance=20
            image of a patient with a right temporal low-grade =
astrocytoma. The=20
            tumor is dark without evidence of enhancement. <B>(B):</B> =
Axial=20
            fluid-attenuated inversion recovery image of the same =
patient as in=20
            <B>(A)</B> showing a bright signal abnormality in the right=20
            hemisphere.
            =
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>&nbsp=
;<BR>LGGs=20
may enhance on neuroimaging studies. Conversely, the absence<SUP> =
</SUP>of=20
enhancement does not always signify low-grade histopathology<SUP> =
</SUP>since up=20
to one third of nonenhancing diffuse gliomas in adults<SUP> </SUP>are =
high grade=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R14">14</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R15">15</A>].=20
These tumors are also highly infiltrative,<SUP> </SUP>and one must =
assume that=20
tumor cells extend beyond the radiographic<SUP> </SUP>border of the =
lesion [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R14">14</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R16">16</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R17">17</A>].=20
Pirzkall et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R13">13</A>]=20
demonstrated<SUP> </SUP>that metabolically active tumor is restricted =
mainly to=20
the<SUP> </SUP>T2 hyperintensity in LGG, but can extend beyond the T2=20
border<SUP> </SUP>for up to 2 cm. LGG are characteristically located in=20
white<SUP> </SUP>matter, but these tumors may also infiltrate into gray=20
matter.<SUP> </SUP>
<P><STRONG>Histopathology</STRONG><BR>Histopathological evaluation of =
tumor=20
tissue remains the standard<SUP> </SUP>method for diagnosis and =
classification=20
of glioma (Fig. 2<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F2"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>),<SUP> </SUP>but diagnostic challenges are =
well=20
recognized, including subjective<SUP> </SUP>criteria, tissue sampling =
error, and=20
lack of specific tumor<SUP> </SUP>markers [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R16">16</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R18">18</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R24">24</A>].=20
In general, lesions detected on CT<SUP> </SUP>or MRI scans that could be =

consistent with a brain tumor should<SUP> </SUP>prompt neurosurgical=20
consultation with a goal of achieving a<SUP> </SUP>tissue diagnosis. =
Exceptions=20
might include lesions in critical<SUP> </SUP>locations, such as the =
brainstem,=20
in which case a biopsy or<SUP> </SUP>resection is not possible. A =
stereotactic=20
biopsy is often performed<SUP> </SUP>on an awake patient positioned in a =

stereotactic frame, over<SUP> </SUP>which an MRI or CT scan is obtained =
to=20
compute the exact coordinates<SUP> </SUP>of the lesion. A small burr =
hole is=20
made in the skull, through<SUP> </SUP>which several small tissue core =
samples=20
are collected. In contrast,<SUP> </SUP>a craniotomy is performed under =
general=20
anesthesia and allows<SUP> </SUP>the surgeon to obtain a specimen for =
diagnostic=20
purposes as<SUP> </SUP>well as to resect the tumor and relieve mass =
effects,=20
thereby<SUP> </SUP>gaining some therapeutic benefit.<SUP> </SUP>
<P><A name=3DF2><!-- null --></A><BR clear=3Dall>
<CENTER>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"95%">
  <TBODY>
  <TR bgColor=3D#e1e1e1>
    <TD>
      <TABLE cellSpacing=3D2 cellPadding=3D2>
        <TBODY>
        <TR bgColor=3D#e1e1e1>
          <TD vAlign=3Dtop align=3Dmiddle bgColor=3D#ffffff><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F2"><IMG=20
            height=3D75 alt=3D"Figure 2" hspace=3D10=20
            =
src=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/images=
/small/681fig2.gif"=20
            width=3D200 vspace=3D5 border=3D2></A><BR><STRONG>View =
larger=20
            version</STRONG> (80K):<BR><NOBR><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F2">[in=20
            this window]</A><BR><A=20
            onmouseover=3D"window.status=3D'View figure in a separate =
window'; return true"=20
            onclick=3D"startTarget('F2', 590, 365); =
this.href=3D'/cgi/content-nw/full/11/6/681/F2'"=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content-nw/full/11/6/6=
81/F2"=20
            target=3DF2>[in a new window]</A><BR>&nbsp;</NOBR> </TD>
          <TD vAlign=3Dtop align=3Dleft><B>Figure 2.</B> Histopathology =
of=20
            low-grade gliomas. <B>(A):</B> A hematoxylineosin stain of a =
typical=20
            World Health Organization grade 2 astrocytoma with increased =

            cellularity and pleomorphism. This two-stage stain consists =
of=20
            hematoxylin followed by a counterstain of red eosin so that =
the=20
            nuclei stain a deep blue-black and the cytoplasm stains =
pink.=20
            Magnification, 400<FONT face=3Darial,helvetica>x</FONT>. =
Courtesy of=20
            David N. Louis, M.D., Department of Pathology, Massachusetts =
General=20
            Hospital. <B>(B):</B> Oligodendroglioma. High-power imaging=20
            demonstrates the classic appearance of a low-grade =
oligodendroglioma=20
            in hematoxylineosin stain. Note the well-defined cell walls, =
clear=20
            cytoplasm, and prominent nuclei. Magnification, 400<FONT=20
            face=3Darial,helvetica>x</FONT>. Courtesy of David N.Louis, =
M.D.,=20
            Department of Pathology, Massachusetts General Hospital.
            =
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>&nbsp=
;<BR>A=20
number of factors are considered when choosing between a =
stereotactic<SUP>=20
</SUP>biopsy and craniotomy for resection [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R25">25</A>].=20
Indications for stereotactic<SUP> </SUP>biopsy include: a deep-seated =
location=20
not amenable to resection,<SUP> </SUP>ambiguous radiological and =
clinical=20
information (i.e., the lesion<SUP> </SUP>might not be a tumor), a change =
in=20
appearance of a previously<SUP> </SUP>diagnosed and treated tumor, =
multiple or=20
diffuse lesions, an<SUP> </SUP>appearance that suggests lymphoma (which =
would=20
not require resection),<SUP> </SUP>and finally, if the patient is not =
clinically=20
stable enough<SUP> </SUP>to tolerate a craniotomy [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R26">26</A>].=20
As mentioned above, because of<SUP> </SUP>the morphological =
heterogeneity of=20
gliomas, stereotactic biopsy<SUP> </SUP>is limited by sampling error and =
may=20
miss a higher grade component<SUP> </SUP>of a mixed lesion [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R16">16</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R17">17</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R27">27</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R29">29</A>].=20
Perfusion-weighted<SUP> </SUP>imaging may provide a useful guide as to =
which=20
area of the LGG<SUP> </SUP>should be targeted for biopsy in an effort to =
reduce=20
sampling<SUP> </SUP>error [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R30">30</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R31">31</A>].=20
Even with improved selection of a biopsy zone,<SUP> </SUP>the =
reproducibility of=20
grading between two observers is lower<SUP> </SUP>for low-grade than for =

high-grade astrocytomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R32">32</A>].=20
The benefits<SUP> </SUP>of a craniotomy include more accurate diagnosis =
based on=20
full<SUP> </SUP>tissue evaluation, alleviation of mass effects, and=20
possible<SUP> </SUP>treatment, all in one operation.<SUP> </SUP>
<P><STRONG>Molecular Markers</STRONG><BR>Genetic testing should be =
strongly=20
considered for all low-grade<SUP> </SUP>oligodendrogliomas (LGOs) and=20
oligoastrocytomas (LGOAs). Over<SUP> </SUP>the past decade, it has been =
shown=20
that specific genetic markers<SUP> </SUP>are helpful in dividing gliomas =
into=20
subgroups with respect<SUP> </SUP>to prognosis and response to =
chemotherapy.=20
Oligodendroglial<SUP> </SUP>tumors frequently show loss of =
heterozygosity (LOH)=20
on chromosomes<SUP> </SUP>1p and 19q, reported in 50%=9670% of both =
low-grade=20
and<SUP> </SUP>anaplastic tumors [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R33">33</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R34">34</A>].=20
LOH for 1p or LOH for both 1p and<SUP> </SUP>19q is predictive of=20
chemosensitivity and longer survival in<SUP> </SUP>patients with =
anaplastic=20
oligodendrogliomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R35">35</A>].=20
Loss of 1p<SUP> </SUP>and 19q has also been shown to be a favorable =
prognostic=20
marker<SUP> </SUP>in LGO and LGOA [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R36">36</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R37">37</A>].=20
In a study of LGOs treated with temozolomide,<SUP> </SUP>there was a =
higher=20
likelihood of responding to temozolomide,<SUP> </SUP>an oral methylating =
drug,=20
if there was LOH for 1p [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R38">38</A>].=20
Smith<SUP> </SUP>et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R24">24</A>]=20
showed that combined loss of 1p and 19q is a statistically<SUP>=20
</SUP>significant predictor of prolonged survival in patients with<SUP>=20
</SUP>oligodendroglioma, independent of tumor grade.<SUP> </SUP>
<P><STRONG>Immunohistochemical Markers</STRONG><BR>Another proposed =
prognostic=20
indicator is an immunohistochemical<SUP> </SUP>stain for =
proliferation-related=20
nuclear markers, the Ki-67 antigen,<SUP> </SUP>or the MIB-1 antibody, =
both=20
reactive against the Ki-67 nuclear<SUP> </SUP>antigen [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R39">39</A>].=20
Immunohistochemistry for the Ki-67 antigen provides<SUP> =
</SUP>prognostic=20
information that is independent of histopathologic<SUP> </SUP>grading =
and tumor=20
localization [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R40">40</A>].=20
Diffuse grade 2 astrocytoma<SUP> </SUP>typically has a Ki-67/MIB-1 of =
1%=962%,=20
whereas WHO grade<SUP> </SUP>4 astrocytoma often has a labeling index of =
15%=9620%=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R41">41</A>].<SUP>=20
</SUP>Age at diagnosis, extent of resection, postoperative =
performance<SUP>=20
</SUP>status, and MIB-1 were all associated with survival in one =
study<SUP>=20
</SUP>of oligodendrogliomas and oligoastrocytomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R42">42</A>].=20
Significant<SUP> </SUP>differences in survival were found when patients =
with=20
oligodendroglioma<SUP> </SUP>and oligoastrocytoma were separated into =
two groups=20
based on<SUP> </SUP>whether their Ki-67/MIB-1 is <IMG alt=3D&#8804;=20
src=3D"http://theoncologist.alphamedpress.org/math/le.gif" border=3D0>5% =
or &gt;5%=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R43">43</A>].=20
Despite this<SUP> </SUP>evidence, there are still conflicting opinions =
on the=20
prognostic<SUP> </SUP>relevance of Ki-67/MIB-1 in LGG.<SUP> </SUP>
<P><A name=3DSEC6><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; T<FONT=20
      size=3D-2>REATMENT</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Treatment</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>M=
anagement=20
of LGG is controversial because these patients are<SUP> </SUP>typically =
younger,=20
with few, if any, neurological symptoms.<SUP> </SUP>Historically, when =
LGG was=20
diagnosed in a young, healthy adult,<SUP> </SUP>a commonly accepted =
strategy was=20
a "watch and wait" approach<SUP> </SUP>because of the indolent nature =
and=20
variable behavior of these<SUP> </SUP>tumors. The support for this =
practice came=20
from several retrospective<SUP> </SUP>studies showing that, when therapy =
was=20
deferred, patients had<SUP> </SUP>no difference in outcome (survival, =
quality of=20
life [QoL]) from<SUP> </SUP>time of radiologic diagnosis [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R7">7</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R11">11</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R44">44</A>].=20
There was also a belief<SUP> </SUP>that LGGs did not necessarily =
transform into=20
malignant tumors<SUP> </SUP>over time. However, the latter notion has =
been=20
refuted. In retrospective<SUP> </SUP>studies of the kinetics of glioma =
growth,=20
continuous growth<SUP> </SUP>was seen in the premalignant phase before=20
anaplastic transformation<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R45">45</A>].=20
The majority of LGGs are now known to progress to malignant<SUP> =
</SUP>gliomas=20
with time. A better understanding of the natural history<SUP> </SUP>of =
LGGs has=20
led to an interest in earlier treatment.<SUP> </SUP>
<P>The decision as to whether a patient with LGG should receive<SUP>=20
</SUP>resection, radiation therapy (RT), or chemotherapy is based<SUP> =
</SUP>on=20
a number of factors including age, performance status, location<SUP> =
</SUP>of=20
tumor, and patient preference. Since LGGs are such a heterogeneous<SUP>=20
</SUP>group of tumors with variable natural histories, the risks =
and<SUP>=20
</SUP>benefits of each of the three therapies must be carefully =
balanced<SUP>=20
</SUP>with the data available from limited prospective studies.<SUP> =
</SUP>
<P><STRONG>Surgery</STRONG><BR>Tumor location determines resectability =
of LGGs.=20
Tumors located<SUP> </SUP>in critical areas of the brain are typically=20
nonresectable.<SUP> </SUP>For those LGGs that can be resected, the =
important=20
question<SUP> </SUP>becomes how much tissue to resect in order to =
prolong=20
survival,<SUP> </SUP>alleviate symptoms, and minimize the risk for =
neurological=20
injury.<SUP> </SUP>Because there have been no randomized trials to =
determine=20
the<SUP> </SUP>benefit of extensive resection of LGGs, current surgical=20
management<SUP> </SUP>of these tumors is based on retrospective studies, =
expert=20
opinion,<SUP> </SUP>or case reports [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R9">9</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R46">46</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R49">49</A>].=20
In the early 1990s Berger<SUP> </SUP>et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R48">48</A>]=20
analyzed preoperative and postoperative radiographic<SUP> </SUP>tumor =
volumes in=20
53 patients to evaluate whether the percentage<SUP> </SUP>of resection =
and=20
volume of postoperative residual disease influenced<SUP> </SUP>the =
incidence of=20
recurrence, time to tumor progression, or histology<SUP> </SUP>of the =
recurrent=20
tumor. This retrospective study found that,<SUP> </SUP>in patients with=20
preoperative tumor volumes &lt;10 cm<SUP>3</SUP>, no recurrence<SUP> =
</SUP>was=20
detected over a 3- to 4-year span, regardless of percent<SUP> </SUP>of =
resection=20
and volume of residual disease [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R48">48</A>].=20
All patients<SUP> </SUP>with a complete gross resection were recurrence =
free at=20
a mean<SUP> </SUP>follow-up period of 54 months. In the remaining 40=20
patients,<SUP> </SUP>the percentage of resection was found to be =
inversely=20
correlated<SUP> </SUP>with the incidence of recurrence, and there was =
also a=20
shorter<SUP> </SUP>time to tumor progression in those with a larger =
volume of=20
residual<SUP> </SUP>tumor [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R48">48</A>].<SUP>=20
</SUP>
<P>Leighton and coworkers [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R50">50</A>]=20
retrospectively reviewed the records<SUP> </SUP>of 167 adults with LGGs =
and=20
found that minimal residual tumor<SUP> </SUP>after surgery was =
associated with a=20
significantly longer survival<SUP> </SUP>time in both univariate and=20
multivariate analyses. In 2001,<SUP> </SUP>Keles et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R47">47</A>]=20
conducted a comprehensive literature review<SUP> </SUP>to evaluate the=20
prognostic effect of extent of resection and<SUP> </SUP>to determine if=20
treatment-related guidelines could be established<SUP> </SUP>for the =
management=20
of LGG. Of 30 studies that included statistical<SUP> </SUP>analyses and =
were=20
published over a 30-year period (1970=962000),<SUP> </SUP>only five =
satisfied=20
methodological criteria outlined by the<SUP> </SUP>authors. In all five =
studies=20
the prognostic effect of extent<SUP> </SUP>of resection was found to be=20
statistically significant by univariate<SUP> </SUP>analysis. In =
addition, the=20
extent of resection was a significant<SUP> </SUP>prognostic factor by=20
multivariate analysis in four studies [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R47">47</A>].<SUP>=20
</SUP>It is not possible to quantify or eliminate the strong =
possibility<SUP>=20
</SUP>of confounding and selection bias in these retrospective =
studies.<SUP>=20
</SUP>Nevertheless, these observations represent the best =
information<SUP>=20
</SUP>available at the present time regarding this topic.<SUP> </SUP>
<P>Currently, the standard approach is to perform a gross total<SUP>=20
</SUP>resection if technically possible[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R20">20</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R49">49</A>].=20
The risks and benefits<SUP> </SUP>must be weighed carefully because the =
surgical=20
intervention<SUP> </SUP>itself may result in a transient or permanent =
decline in=20
neurological<SUP> </SUP>function [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R51">51</A>].=20
Surgical debulking is often recommended for any<SUP> </SUP>patient with=20
increased intracranial pressure, neurological deficits<SUP> =
</SUP>related to=20
mass effects, or uncontrollable seizures. It is important<SUP> </SUP>for =
the=20
patient to understand that gross total resection does<SUP> </SUP>not =
mean the=20
tumor has been completely removed [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R52">52</A>].=20
LGGs are<SUP> </SUP>infiltrative tumors with indistinct borders and=20
microscopic<SUP> </SUP>invasion beyond the radiographic margins. In the =
majority=20
of<SUP> </SUP>cases, the area of tumor resection may be stable for years =

until<SUP> </SUP>a recurrence is detected by symptoms or imaging [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R5">5</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R52">52</A>].=20
The<SUP> </SUP>recurrence may occur in the same area as the prior tumor =
or<SUP>=20
</SUP>in a separate location. Regular clinical and radiographic =
monitoring<SUP>=20
</SUP>are essential in postoperative management.<SUP> </SUP>
<P><STRONG>Radiation</STRONG><BR>The critical questions regarding RT for =

patients with LGG are:<SUP> </SUP>timing, effective dose, and how to =
weigh the=20
benefit of tumor<SUP> </SUP>control against potential toxicity [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R10">10</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R50">50</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R53">53</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R56">56</A>].=20
Three<SUP> </SUP>prospective randomized clinical trials have been =
conducted=20
to<SUP> </SUP>address these questions.<SUP> </SUP>
<P>The first randomized trial was conducted by the European =
Organization<SUP>=20
</SUP>for Research and Treatment of Cancer (EORTC, trial 22844) to<SUP>=20
</SUP>determine if a radiation dose response exists for LGG. In =
that<SUP>=20
</SUP>study, 379 adults with LGG were randomized to receive =
different<SUP>=20
</SUP>doses and schedules of RT after biopsy or resection, 45 Gy in<SUP> =
</SUP>5=20
weeks versus 59.4 Gy in 6.6 weeks. There were no significant<SUP>=20
</SUP>differences in progression-free or overall survival times =
between<SUP>=20
</SUP>the two groups. Other findings of the EORTC 22844 trial =
included<SUP>=20
</SUP>age as a significant prognostic factor for overall survival,<SUP>=20
</SUP>but not progression-free survival, while the size of tumor,<SUP> =
</SUP>or=20
"T" of the TNM classifications, appeared to be one of the<SUP> =
</SUP>most=20
important prognostic factors on multivariate analysis [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R57">57</A>,<SUP>=20
</SUP><A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R58">58</A>].<SUP>=20
</SUP>
<P>A second randomized trial, EORTC 22845, compared immediate RT<SUP> =
</SUP>for=20
cerebral LGG in adults with RT after recurrence. In that<SUP> =
</SUP>study, 311=20
adult patients from 24 European centers were randomized<SUP> </SUP>after =
surgery=20
to receive either 54 Gy in 1.8-Gy fractions over<SUP> </SUP>6 weeks or =
no=20
radiation until evidence of tumor progression<SUP> </SUP>was identified =
on=20
imaging or suggested by neurological deterioration<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R59">59</A>].=20
Postoperative CT scans were not routinely performed in<SUP> </SUP>that =
study,=20
thus the residual amount of tumor could not be assessed.<SUP> =
</SUP>Twenty-two=20
percent of the 232 tumors that were submitted for<SUP> </SUP>central=20
pathological review in EORTC 22845 were reclassified<SUP> </SUP>as =
high-grade=20
gliomas after being reviewed, and 3.4% were reclassified<SUP> </SUP>as=20
ineligible tumors based on study protocol. Overall survival<SUP> =
</SUP>and time=20
to progression were primary end points. Although overall<SUP> =
</SUP>survival at=20
5 years did not differ between the two groups, the<SUP> </SUP>median=20
progression-free survival time was 5.3 years for the<SUP> </SUP>group =
receiving=20
immediate RT versus 3.4 years for those with<SUP> </SUP>RT deferred [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R60">60</A>].=20
In addition, seizures were better controlled<SUP> </SUP>in the early RT =
group.=20
This study represents the first randomized<SUP> </SUP>trial to compare =
an active=20
treatment with the "watch and wait"<SUP> </SUP>approach. Although =
immediate=20
postoperative irradiation increased<SUP> </SUP>the median =
progression-free=20
survival time by nearly 2 years,<SUP> </SUP>it is not clear whether =
longer=20
progression-free survival represents<SUP> </SUP>better QoL.<SUP> </SUP>
<P>The results of EORTC 22844 were partially confirmed in a =
randomized<SUP>=20
</SUP>trial by the North Central Cancer Treatment Group =
(NCCTG)/Radiation<SUP>=20
</SUP>Therapy Oncology Group/Eastern Cooperative Oncology Group [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R61">61</A>].<SUP>=20
</SUP>In that study, 203 patients were randomized to receive either<SUP> =

</SUP>low-dose RT (50.4 Gy in 28 fractions) or high-dose RT (64.8<SUP> =
</SUP>Gy=20
in 36 fractions). These low and high doses differed from<SUP> =
</SUP>those used=20
in the EORTC study. Of these 203 patients, 103 had<SUP> </SUP>undergone =
biopsy,=20
71 had subtotal resections, and 29 had gross<SUP> </SUP>total resections =
before=20
starting RT. In addition, 139 patients<SUP> </SUP>had oligodendroglioma =
or mixed=20
oligoastrocytoma (mainly oligodendrocytic),<SUP> </SUP>while 64 patients =
had=20
astrocytoma or mixed oligoastrocytoma<SUP> </SUP>(mainly astrocytic).=20
Interpretation of these results is limited<SUP> </SUP>by this tumor=20
heterogeneity. However, this study did not find<SUP> </SUP>an advantage =
for=20
high-dose over low-dose RT in adults with supratentorial<SUP> </SUP>LGG =
in terms=20
of overall survival or time to progression [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R61">61</A>].<SUP>=20
</SUP>The currently accepted treatment for LGG includes a radiation<SUP> =

</SUP>dose of 50=9654 Gy in fractions of 1.8 Gy to the tumor bed<SUP> =
</SUP>as=20
well as a 1- to 2-cm surrounding margin.<SUP> </SUP>
<P>In a small prospective study of whether RT was needed =
postoperatively,<SUP>=20
</SUP>18 patients with resected LGOs were managed with follow-up =
alone<SUP>=20
</SUP>if full resection was achieved or chemotherapy if the tumor<SUP> =
</SUP>was=20
incompletely resected [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R54">54</A>].=20
In that study, all patients<SUP> </SUP>were alive and 94% were =
progression free=20
after a median follow-up<SUP> </SUP>of 4.7 years, with no use of RT. =
Similar=20
findings in other studies<SUP> </SUP>have led some to recommend RT for =
young=20
patients only if there<SUP> </SUP>is recurrence of tumor and not in the=20
immediate postoperative<SUP> </SUP>stage [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R62">62</A>]=20
because of the possible neurotoxic effects in long-term<SUP> =
</SUP>survivors [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R56">56</A>].=20
However, there has not been a randomized trial<SUP> </SUP>using =
percentage of=20
surgical resection to clarify this treatment<SUP> =
</SUP>recommendation.<SUP>=20
</SUP>
<P>Since the time of these original prospective studies, there<SUP> =
</SUP>have=20
been major technical advances in the delivery of radiation.<SUP> =
</SUP>There is=20
now computer optimization and intensity-modulated radiotherapy<SUP>=20
</SUP>(IMRT), which allow different levels of intensity across a =
lesion<SUP>=20
</SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R63">63</A>].=20
In addition, functional imaging such as positron- emission<SUP> =
</SUP>tomography=20
(PET) and single-photon-emission CT (SPECT), as well<SUP> </SUP>as =
dose-volume=20
histograms allow physicians to more accurately<SUP> </SUP>plan target =
volumes=20
and shape radiation beams [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R63">63</A>].=20
With these<SUP> </SUP>technical improvements, it is hoped that RT will =
be more=20
effective<SUP> </SUP>and long-term side effects of RT will be =
minimized.<SUP>=20
</SUP>
<P>Although stereotactic radiosurgery has been proposed to control<SUP>=20
</SUP>small areas of recurrent malignant glioma, there are =
insufficient<SUP>=20
</SUP>data to recommend radiosurgery as an effective treatment for<SUP>=20
</SUP>LGG.<SUP> </SUP>
<P>At this time, it is our practice to defer RT after complete<SUP>=20
</SUP>surgical resection of an LGG with a low mitotic labeling =
index.<SUP>=20
</SUP>In the case of incomplete resection, RT is recommended if =
there<SUP>=20
</SUP>is an elevated mitotic labeling index or recurrence of tumor<SUP> =
</SUP>on=20
follow-up imaging.<SUP> </SUP>
<P><STRONG>Chemotherapy</STRONG><BR>Most chemotherapeutic agents that =
are active=20
against anaplastic<SUP> </SUP>glioma also have activity against LGG. A =
major=20
advance relevant<SUP> </SUP>to the chemotherapeutic treatment for LGG =
was the=20
discovery<SUP> </SUP>of the chemosensitivity of anaplastic =
oligodendroglioma=20
based<SUP> </SUP>on chromosomal markers. Cairncross et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R35">35</A>]=20
observed that<SUP> </SUP>100% of tumors with chromosome 1p loss (24 =
patients)=20
were chemosensitive<SUP> </SUP>and that 100% of those with loss of both =
1p and=20
19q (22 patients)<SUP> </SUP>also responded to chemotherapy. The =
patients with=20
the chromosomal<SUP> </SUP>losses also had significantly longer =
progression-free=20
and overall<SUP> </SUP>survival times.<SUP> </SUP>
<P>Several phase II studies have investigated the role of =
chemotherapy<SUP>=20
</SUP>or the combination of chemotherapy and RT in LGG. One problem<SUP> =

</SUP>with assessing tumor response in these studies is that change<SUP> =

</SUP>in area-of-contrast enhancement has traditionally been used<SUP>=20
</SUP>with studies of higher-grade glioma, yet as discussed =
earlier,<SUP>=20
</SUP>LGGs do not typically enhance, thus complicating the =
measurement<SUP>=20
</SUP>of response to chemotherapy [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R64">64</A>].=20
FLAIR and T2 signal changes<SUP> </SUP>often reflect the combined effect =
of=20
underlying tumor and gliosis,<SUP> </SUP>making response assessment more =

difficult.<SUP> </SUP>
<P>Nine patients with LGO were treated with PCV (procarbazine,<SUP> =
</SUP>CCNU,=20
vincristine) at presentation, except for one patient who<SUP> </SUP>was =
treated=20
at the time of recurrence after failed RT [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R65">65</A>].<SUP>=20
</SUP>Evaluation of response was based on clinical and radiological<SUP> =

</SUP>factors, including volumetric tumor measurements on =
T2-weighted<SUP>=20
</SUP>MRI scans. Six patients had partial responses and three had<SUP>=20
</SUP>stable disease, while no patient deteriorated during =
treatment.<SUP>=20
</SUP>There were also notable improvements in seizure frequency and<SUP> =

</SUP>other neurologic symptoms [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R65">65</A>].<SUP>=20
</SUP>
<P>A retrospective study by Stege et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R66">66</A>]=20
of PCV chemotherapy<SUP> </SUP>in 16 patients with newly diagnosed LGO =
and LGOA=20
along with<SUP> </SUP>five patients with recurrent disease showed =
"clinical"=20
response<SUP> </SUP>regardless of 1p or 19q status. Nine of these =
patients had=20
gliomatosis<SUP> </SUP>cerebri. These authors recommended chemotherapy =
for LGO=20
patients<SUP> </SUP>with large tumors not amenable to RT.<SUP> </SUP>
<P>Several studies have addressed the use of temozolomide in the<SUP>=20
</SUP>treatment of recurrent or progressive LGG [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R38">38</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R67">67</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R70">70</A>].<SUP>=20
</SUP>Temozolomide is approved for the treatment of recurrent =
anaplastic<SUP>=20
</SUP>astrocytoma and newly diagnosed glioblastoma. Phase II =
studies<SUP>=20
</SUP>have provided evidence of excellent patient tolerance and =
potential<SUP>=20
</SUP>efficacy in LGG, but comparison studies versus other =
chemotherapeutic<SUP>=20
</SUP>agents or RT have not been done. In a phase II study by Brada<SUP> =

</SUP>et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R69">69</A>],=20
temozolomide resulted in a modest improvement in<SUP> </SUP>QoL and =
improvement=20
in seizure control.<SUP> </SUP>
<P>Another issue in the treatment of patients with LGG is whether<SUP> =
</SUP>a=20
combination of chemotherapy and RT is superior to RT alone<SUP> =
</SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R71">71</A>].=20
A prospective trial by the Southwest Oncology Group addressed<SUP> =
</SUP>this=20
question in 60 adult patients with incompletely resected<SUP> =
</SUP>LGGs.=20
Patients were randomly divided into two treatment groups.<SUP> =
</SUP>Patients=20
received either 55 Gy of RT alone or 55 Gy of RT-plus-lomustine.<SUP>=20
</SUP>There was a reduction in tumor size in 79% of patients in the<SUP> =

</SUP>RT group versus 54% of the RT plus lomustine group, based on<SUP> =
</SUP>CT=20
scan measurements. However, there was no difference in median<SUP>=20
</SUP>survival between the two treatment groups [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R72">72</A>].=20
This study did<SUP> </SUP>not separate different histologic subtypes for =

analysis, and<SUP> </SUP>anaplastic astrocytoma was included as an =
eligible=20
tumor, which<SUP> </SUP>complicates interpretation of the results. The =
study was=20
closed<SUP> </SUP>early because of slow accrual and a rejection of the=20
hypothesis<SUP> </SUP>of a 50% longer survival time for patients =
receiving=20
chemotherapy<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R72">72</A>].<SUP>=20
</SUP>
<P>Newer agents, such as signal transduction inhibitors, =
angiogenesis<SUP>=20
</SUP>inhibitors, monoclonal antibodies, immunotoxins, and gene =
transfer<SUP>=20
</SUP>therapies, as well as new approaches to drug delivery, such<SUP> =
</SUP>as=20
drug-impregnated sustained-release polymers and convection-enhanced<SUP> =

</SUP>delivery, remain to be investigated in LGGs.<SUP> </SUP>
<P><A name=3DSEC7><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; P<FONT=20
      size=3D-2>ROGNOSIS</FONT><FONT size=3D-1> </FONT><FONT =
size=3D-2>IN</FONT>=20
      L<FONT size=3D-2>OW</FONT>-G<FONT size=3D-2>RADE</FONT> G<FONT=20
      size=3D-2>LIOMAS</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Prognosis in Low-Grade =
Gliomas</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>T=
he=20
prognosis for patients with LGG is more favorable than that<SUP> =
</SUP>for=20
higher-grade gliomas because of the more indolent course<SUP> </SUP>and =
younger=20
age at which most patients are diagnosed. The three<SUP> </SUP>largest=20
randomized trials mentioned previously all included<SUP> </SUP>overall =
survival=20
as a primary end point. EORTC 22844, EORTC<SUP> </SUP>22845, and the =
NCCTG trial=20
together studied 836 patients with<SUP> </SUP>LGG, and 58%=9672% of =
patients were=20
alive at 5 years from<SUP> </SUP>the time of diagnosis. The EORTC =
conducted a=20
detailed analysis<SUP> </SUP>of prognostic factors for overall survival =
based on=20
the 22844<SUP> </SUP>and 22845 studies. That analysis excluded patients =
with=20
WHO<SUP> </SUP>grade 1 astrocytomas and was conducted over a longer=20
follow-up<SUP> </SUP>than either of the two original studies. Factors =
that=20
negatively<SUP> </SUP>affected survival were: age &gt;40 years, =
astrocytoma=20
histology,<SUP> </SUP>maximum tumor diameter <IMG alt=3D&#8805;=20
src=3D"http://theoncologist.alphamedpress.org/math/ge.gif" border=3D0>6 =
cm, tumor=20
crossing the corpus callosum,<SUP> </SUP>and the presence of a =
neurological=20
deficit before surgery. Based<SUP> </SUP>on these factors, the EORTC =
proposed a=20
multivariate prognostic<SUP> </SUP>score that would separate patients =
into risk=20
categories. Patients<SUP> </SUP>with two or fewer prognostic factors =
were deemed=20
low risk, and<SUP> </SUP>their median overall survival time was 7.7 =
years.=20
Patients with<SUP> </SUP>three or more prognostic factors were judged to =
be high=20
risk,<SUP> </SUP>and their median overall survival time was 3.2 years =
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R73">73</A>].=20
The<SUP> </SUP>NCCTG identified tumor size, histologic subtype, and age =
as<SUP>=20
</SUP>substantial prognostic factors in their group of patients. =
The<SUP>=20
</SUP>median survival time for their entire cohort of 203 patients<SUP>=20
</SUP>was 9.25 years [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R61">61</A>].<SUP>=20
</SUP>
<P><A name=3DSEC8><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; S<FONT=20
      size=3D-2>PECIAL</FONT> T<FONT size=3D-2>OPICS</FONT>=20
</FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><IMG height=3D9 =
alt=3D" "=20
      hspace=3D5 =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif"=20
      width=3D11 border=3D0><FONT color=3D#464c53>Special =
Topics</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR><=
STRONG>Pilocytic=20
Astrocytomas</STRONG><BR>Pilocytic astrocytomas (PAs) are =
well-circumscribed=20
solid tumors<SUP> </SUP>that occur most frequently in children and young =
adults=20
but<SUP> </SUP>rarely in those over the age of 30 years (Fig. 3<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F3"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>). These tumors<SUP> </SUP>have also been =
termed juvenile=20
pilocytic astrocytomas or cystic<SUP> </SUP>astrocytomas, or have been =
named=20
according to location (e.g.,<SUP> </SUP>optic nerve gliomas, cerebellar=20
astrocytomas, etc.). PAs represent<SUP> </SUP>1.9% of all reported brain =
tumors=20
and 5.7% of all gliomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].<SUP>=20
</SUP>PAs may also be associated with neurofibromatosis-1 (NF-1),<SUP> =
</SUP>an=20
autosomal dominant genetic disorder in which patients are<SUP> </SUP>at =
high=20
risk for cranial and peripheral nerve sheath tumors.<SUP> </SUP>The mean =
age at=20
diagnosis of PA is 17 years, and the survival<SUP> </SUP>rate is very =
good, with=20
84.3% of patients alive 10 years after<SUP> </SUP>diagnosis [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].=20
Supratentorial PAs are characteristically located<SUP> </SUP>in the =
region of=20
the optic nerves or chiasm as well as in periventricular<SUP> =
</SUP>regions such=20
as the hypothalamus and thalamus. PAs may also<SUP> </SUP>occur in the =
spinal=20
cord either as a primary site or as a site<SUP> </SUP>of metastatic =
spread.<SUP>=20
</SUP>
<P><A name=3DF3><!-- null --></A><BR clear=3Dall>
<CENTER>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"95%">
  <TBODY>
  <TR bgColor=3D#e1e1e1>
    <TD>
      <TABLE cellSpacing=3D2 cellPadding=3D2>
        <TBODY>
        <TR bgColor=3D#e1e1e1>
          <TD vAlign=3Dtop align=3Dmiddle bgColor=3D#ffffff><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F3"><IMG=20
            height=3D200 alt=3D"Figure 3" hspace=3D10=20
            =
src=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/images=
/small/681fig3.gif"=20
            width=3D180 vspace=3D5 border=3D2></A><BR><STRONG>View =
larger=20
            version</STRONG> (125K):<BR><NOBR><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F3">[in=20
            this window]</A><BR><A=20
            onmouseover=3D"window.status=3D'View figure in a separate =
window'; return true"=20
            onclick=3D"startTarget('F3', 547, 640); =
this.href=3D'/cgi/content-nw/full/11/6/681/F3'"=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content-nw/full/11/6/6=
81/F3"=20
            target=3DF3>[in a new window]</A><BR>&nbsp;</NOBR> </TD>
          <TD vAlign=3Dtop align=3Dleft><B>Figure 3.</B> Juvenile =
pilocytic=20
            astrocytoma. Axial <B>(A, B)</B> and sagittal <B>(C)</B> =
T1-weighted=20
            images before and after gadolinium administration show a=20
            well-circumscribed mass lesion with irregular ring =
enhancement in=20
            the left cerebellar hemisphere. Thin, smooth enhancement of =
the=20
            margins of the cystic structures is seen (arrow). Courtesy =
of John=20
            W. Henson, M.D., Department of Radiology, Massachusetts =
General=20
            Hospital.
            =
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>&nbsp=
;<BR>Although=20
macroscopically PAs appear well demarcated, these tumors<SUP> </SUP>may=20
infiltrate surrounding tissue on the microscopic level.<SUP> =
</SUP>Microscopic=20
infiltration is seen in adult forms of PA but is<SUP> </SUP>rarely seen =
in=20
juvenile PA [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R74">74</A>].=20
Multicentric spread is well<SUP> </SUP>documented, and patients with=20
hypothalamic region tumors are<SUP> </SUP>up to 23 times more likely to =
develop=20
multicentric spread than<SUP> </SUP>those with PAs elsewhere [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R75">75</A>].=20
One third of tumors form a large<SUP> </SUP>cyst with clear fluid and =
sometimes=20
a mural nodule [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R76">76</A>].=20
PAs<SUP> </SUP>frequently enhance on MRI because of their vascularity, =
but<SUP>=20
</SUP>there is usually minimal associated edema. Malignant =
transformation<SUP>=20
</SUP>and metastatic spread are rare.<SUP> </SUP>
<P>
<P><STRONG><EM>Clinical Features</EM></STRONG><BR>Most patients present =
within=20
the first three decades of life.<SUP> </SUP>Because PAs have a tendency =
to=20
develop in midline peri-ventricular<SUP> </SUP>zones, patients may =
present with=20
evidence of obstructive hydrocephalus.<SUP> </SUP>If the tumor occurs in =
an=20
infratentorial location, the patient<SUP> </SUP>may present with =
symptoms of=20
increased intracranial pressure<SUP> </SUP>or cerebellar dysfunction.=20
Association with NF-1 should be excluded<SUP> </SUP>in all cases. =
Seizures,=20
headaches, cranial nerve deficits, and<SUP> </SUP>rarely, hemorrhage, =
may also=20
be part of the patient=92s<SUP> </SUP>initial clinical =
presentation.<SUP> </SUP>
<P>
<P><STRONG><EM>Treatment</EM></STRONG><BR>The majority of PAs are =
amenable to=20
gross total resection and<SUP> </SUP>cure. The best predictor of outcome =
is=20
extent of resection,<SUP> </SUP>with &gt;90% 10-year survival rates in =
patients=20
with gross total<SUP> </SUP>resection of cerebellar PAs. Chemotherapy or =
RT may=20
be recommended<SUP> </SUP>if there is residual tumor after resection. =
Focal=20
irradiation<SUP> </SUP>at a total dose of 54=9656 Gy is recommended in =
adults=20
and<SUP> </SUP>children over the age of 5 years [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R75">75</A>].=20
In patients with subtotally<SUP> </SUP>resected PAs, the incidence of =
recurrence=20
in a site different<SUP> </SUP>from the primary site is approximately =
12% [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R75">75</A>].=20
MRI of the<SUP> </SUP>craniospinal axis and cerebrospinal fluid (CSF)=20
examination<SUP> </SUP>should be routinely performed in patients with =
PAs.<SUP>=20
</SUP>
<P><STRONG>Subependymal Giant Cell Astrocytoma</STRONG><BR>Subependymal =
giant=20
cell astrocytomas (SGCAs) are almost always<SUP> </SUP>associated with =
tuberous=20
sclerosis. Tuberous sclerosis is an<SUP> </SUP>autosomal dominant =
neurocutaneous=20
disorder characterized by<SUP> </SUP>mental retardation, seizures, =
facial=20
angiofibromas and SGCAs.<SUP> </SUP>SGCAs are firm, slow-growing,=20
well-circumscribed tumors typically<SUP> </SUP>located in the walls of =
the=20
lateral ventricles near the foramen<SUP> </SUP>of Monro (Fig. 4<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F4"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>). There may be associated cyst formation, =
hemorrhage,<SUP>=20
</SUP>necrosis, or calcification. On MR images, the tumors usually<SUP>=20
</SUP>appear as intraventricular enhancing masses. On histological<SUP>=20
</SUP>examination, the tumors consist of giant astrocytes without<SUP>=20
</SUP>significant anaplasia.<SUP> </SUP>
<P><A name=3DF4><!-- null --></A><BR clear=3Dall>
<CENTER>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"95%">
  <TBODY>
  <TR bgColor=3D#e1e1e1>
    <TD>
      <TABLE cellSpacing=3D2 cellPadding=3D2>
        <TBODY>
        <TR bgColor=3D#e1e1e1>
          <TD vAlign=3Dtop align=3Dmiddle bgColor=3D#ffffff><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F4"><IMG=20
            height=3D200 alt=3D"Figure 4" hspace=3D10=20
            =
src=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/images=
/small/681fig4.gif"=20
            width=3D177 vspace=3D5 border=3D2></A><BR><STRONG>View =
larger=20
            version</STRONG> (147K):<BR><NOBR><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F4">[in=20
            this window]</A><BR><A=20
            onmouseover=3D"window.status=3D'View figure in a separate =
window'; return true"=20
            onclick=3D"startTarget('F4', 539, 640); =
this.href=3D'/cgi/content-nw/full/11/6/681/F4'"=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content-nw/full/11/6/6=
81/F4"=20
            target=3DF4>[in a new window]</A><BR>&nbsp;</NOBR> </TD>
          <TD vAlign=3Dtop align=3Dleft><B>Figure 4.</B> Subependymal =
giant cell=20
            astrocytoma. This axial, postcontrast, fat-saturated =
T1-weighted=20
            image shows the tumor as an enhancing, mass lesion at the =
foramen of=20
            Monro (arrow). Progressive enlargement may be the only way =
to=20
            distinguish the tumor from subependymal nodules seen in =
tuberous=20
            sclerosis. Courtesy of John W. Henson, M.D., Department of=20
            Radiology, Massachusetts General Hospital.
            =
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>&nbsp=
;<BR>
<P><STRONG><EM>Clinical Symptoms</EM></STRONG><BR>Because these tumors =
typically=20
obstruct CSF flow, patients usually<SUP> </SUP>become symptomatic with=20
hydrocephalus or increased intracranial<SUP> </SUP>pressure during the =
first and=20
second decades of life. Diagnosis<SUP> </SUP>of an SGCA is occasionally =
the=20
presenting feature of tuberous<SUP> </SUP>sclerosis.<SUP> </SUP>
<P>
<P><STRONG><EM>Treatment</EM></STRONG><BR>Treatment for SGCA depends =
upon=20
symptoms. Surgical resection<SUP> </SUP>is performed if symptoms are =
severe and=20
resection is possible<SUP> </SUP>based on location. These tumors rarely =
display=20
malignant degeneration.<SUP> </SUP>Fatal cases are usually secondary to =
surgical=20
complications.<SUP> </SUP>The favorable prognosis distinguishes SGCAs =
from other=20
intraventricular<SUP> </SUP>tumors, such as intraventricular ependymomas =
and=20
astrocytomas,<SUP> </SUP>which typically have worse prognoses.<SUP> =
</SUP>
<P><STRONG>Brainstem Gliomas</STRONG><BR>Approximately 4% of all gliomas =
occur=20
in the brainstem [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R1">1</A>].<SUP>=20
</SUP>Brainstem gliomas tend to affect children and young adults =
and<SUP>=20
</SUP>comprise a heterogeneous group of neoplasms. Brainstem =
gliomas<SUP>=20
</SUP>have the worst prognosis of any childhood brain tumor, but =
subsets<SUP>=20
</SUP>of brainstem gliomas=97including NF-1-associated gliomas,<SUP> =
</SUP>tectal=20
gliomas, and cervicomedullary gliomas=97have better<SUP> </SUP>prognoses =
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R77">77</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R78">78</A>].=20
Approximately 4% of patients with NF-1 have<SUP> </SUP>brainstem =
astrocytomas=20
[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R79">79</A>].=20
In contrast to other patients,<SUP> </SUP>NF-1-associated tumors are =
usually=20
centered in the medulla,<SUP> </SUP>not in the pons [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R79">79</A>].=20
Brainstem gliomas are diffusely infiltrative<SUP> </SUP>tumors and, in =
some=20
instances, may display malignant transformation<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R80">80</A>].=20
These tumors may also have a cystic component, which has<SUP> </SUP>not =
been=20
shown to affect survival [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R80">80</A>].<SUP>=20
</SUP>
<P>
<P><STRONG><EM>Clinical Features</EM></STRONG><BR>Because of the =
indolent nature=20
of these tumors, symptoms may<SUP> </SUP>be vague and include failure to =
thrive,=20
persistent vomiting,<SUP> </SUP>and abnormal breathing. Patients with =
NF-1=20
appear to have a<SUP> </SUP>higher rate of hydrocephalus requiring early =

intervention [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R79">79</A>].<SUP>=20
</SUP>Cervicomedullary tumors may cause symptoms ranging from a =
mild<SUP>=20
</SUP>motor deficit to quadriparesis with varying involvement of =
cranial<SUP>=20
</SUP>nerves, and some patients may become tracheostomy dependent<SUP> =
</SUP>or=20
require ventilation. Although tumor infiltration along cranial<SUP> =
</SUP>nerves=20
is rare, it has been described without evidence of leptomeningeal<SUP>=20
</SUP>dissemination [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R81">81</A>].=20
With pontine gliomas, symptom duration is<SUP> </SUP>relatively short, =
2=964=20
months, whereas the duration of<SUP> </SUP>symptoms before diagnosis of =
patients=20
with cervicomedullary<SUP> </SUP>gliomas may range up to 2 years because =
of the=20
indolent nature<SUP> </SUP>of these typically lower-grade lesions [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R82">82</A>].=20
Other clinical<SUP> </SUP>features seen in patients with brainstem =
gliomas=20
include headache,<SUP> </SUP>gross motor incoordination, head tilt, and=20
developmental delay.<SUP> </SUP>
<P>
<P><STRONG><EM>Treatment</EM></STRONG><BR>For most brainstem gliomas, =
total=20
resection is not possible.<SUP> </SUP>Accurate histopathological =
diagnosis is=20
often difficult because<SUP> </SUP>obtaining tumor tissue can be risky =
and is=20
limited by sampling<SUP> </SUP>error. Cystic tumors may be aspirated and =
tumor=20
volume debulked<SUP> </SUP>for palliative reasons [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R80">80</A>].=20
In a series of patients with cervicomedullary<SUP> </SUP>gliomas, =
Robertson et=20
al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R82">82</A>]=20
confirmed that these tumors were<SUP> </SUP>distinct, with generally =
indolent=20
courses and low-grade pathology.<SUP> </SUP>Four-year progression-free =
and=20
overall survival rates are as<SUP> </SUP>high as 70% and 100%,=20
respectively.<SUP> </SUP>
<P>The role of RT is controversial, and some authorities advocate<SUP>=20
</SUP>chemotherapy in place of RT, especially in young patients or<SUP>=20
</SUP>patients who have received prior radiation [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R83">83</A>].=20
Broniscer et<SUP> </SUP>al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R84">84</A>]=20
found that administration of temozolomide after RT<SUP> </SUP>in =
children with=20
newly diagnosed diffuse brainstem gliomas did<SUP> </SUP>not alter the =
poor=20
prognosis. All patients in their study died<SUP> </SUP>within a median =
of 12=20
months.<SUP> </SUP>
<P>Because NF-1-associated brainstem gliomas are less aggressive<SUP> =
</SUP>than=20
their non-NF-1 counterparts, Molloy et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R79">79</A>]=20
recommend<SUP> </SUP>conservative management, including close clinical=20
observation<SUP> </SUP>and radiographic follow-up.<SUP> </SUP>
<P><STRONG>Optic Nerve Gliomas</STRONG><BR>Optic nerve gliomas are =
generally=20
considered to be low-grade<SUP> </SUP>astrocytomas with occasional=20
oligodendrocytic components, but<SUP> </SUP>these tumors may display a =
wide=20
variation in growth rate and<SUP> </SUP>clinical behavior [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>].=20
Optic nerve gliomas are most commonly<SUP> </SUP>found in children with =
NF-1,=20
and only rarely in adults. When<SUP> </SUP>optic nerve gliomas present =
in=20
adulthood, the tumors are usually<SUP> </SUP>bilateral and malignant, =
and may=20
mimic optic neuritis in initial<SUP> </SUP>presentation [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R86">86</A>].<SUP>=20
</SUP>
<P>Optic nerve gliomas typically involve the hypothalamus and optic<SUP> =

</SUP>chiasm more frequently than the intraorbital optic nerve [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>]<SUP>=20
</SUP>(Fig. 5<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
F5"><IMG=20
height=3D7 alt=3DGo =
src=3D"http://theoncologist.alphamedpress.org/icons/fig-down.gif"=20
width=3D8 border=3D1></A>). Tumors involving the hypothalamus may be =
considered<SUP>=20
</SUP>as a separate subset of optic pathway gliomas in terms of =
management<SUP>=20
</SUP>and prognosis. Histology is typically low-grade astrocytoma<SUP>=20
</SUP>with a higher frequency of malignant variants seen in older<SUP>=20
</SUP>patients and in patients with tumors located near the optic<SUP>=20
</SUP>chiasm. Among children who are long-term survivors of CNS =
tumors,<SUP>=20
</SUP>cases of optic glioma have developed in later years as =
secondary<SUP>=20
</SUP>tumors [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R87">87</A>].=20
In patients with NF-1, these tumors most commonly<SUP> </SUP>occur in =
the=20
optic=96hypothalamic region [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R83">83</A>].<SUP>=20
</SUP>
<P><A name=3DF5><!-- null --></A><BR clear=3Dall>
<CENTER>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"95%">
  <TBODY>
  <TR bgColor=3D#e1e1e1>
    <TD>
      <TABLE cellSpacing=3D2 cellPadding=3D2>
        <TBODY>
        <TR bgColor=3D#e1e1e1>
          <TD vAlign=3Dtop align=3Dmiddle bgColor=3D#ffffff><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F5"><IMG=20
            height=3D101 alt=3D"Figure 5" hspace=3D10=20
            =
src=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/images=
/small/681fig5.gif"=20
            width=3D200 vspace=3D5 border=3D2></A><BR><STRONG>View =
larger=20
            version</STRONG> (97K):<BR><NOBR><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681/=
F5">[in=20
            this window]</A><BR><A=20
            onmouseover=3D"window.status=3D'View figure in a separate =
window'; return true"=20
            onclick=3D"startTarget('F5', 590, 423); =
this.href=3D'/cgi/content-nw/full/11/6/681/F5'"=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content-nw/full/11/6/6=
81/F5"=20
            target=3DF5>[in a new window]</A><BR>&nbsp;</NOBR> </TD>
          <TD vAlign=3Dtop align=3Dleft><B>Figure 5.</B> Optic nerve =
glioma.=20
            <B>(A):</B> T1-weighted, gadolinium-enhanced, fat-saturated =
image=20
            reveals enlargement and abnormal enhancement of the orbital=20
            component of the right optic nerve (white arrow) and of the =
optic=20
            chiasm (black arrow). <B>(B):</B> T2-weighted image shows =
the=20
            enlarged right optic nerve compared to the normal left optic =
nerve.=20
            Courtesy of John W. Henson, M.D., Department of Radiology,=20
            Massachusetts General Hospital.
            =
<P></P></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>&nbsp=
;<BR>
<P><STRONG><EM>Clinical Features</EM></STRONG><BR>Visual loss, endocrine =

disturbances, and proptosis may be the<SUP> </SUP>initial complaints [<A =

href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>]=20
When tumors are located in the optic<SUP> </SUP>chiasm=96hypothalamic =
region, the=20
majority of patients present<SUP> </SUP>with signs of increased =
intracranial=20
pressure and may require<SUP> </SUP>CSF shunting [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R83">83</A>].=20
In adults, optic nerve gliomas can mimic<SUP> </SUP>optic neuritis in =
their=20
clinical presentation [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R86">86</A>].<SUP>=20
</SUP>
<P>
<P><STRONG><EM>Treatment</EM></STRONG><BR>Location and patient age =
determine=20
optimum treatment. Surgery<SUP> </SUP>is generally recommended for =
tumors of the=20
optic nerve, and<SUP> </SUP>RT is recommended for tumors of the optic =
chiasm [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>].=20
Optic<SUP> </SUP>chiasmal gliomas appear to respond to radiation with =
doses=20
above<SUP> </SUP>45 Gy [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>].=20
An estimated 25% of optic nerve gliomas have already<SUP> </SUP>invaded =
the=20
optic chiasm by the time of diagnosis, and another<SUP> </SUP>5% recur =
in the=20
chiasm following a complete intraorbital resection<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>].=20
Patients with NF-1 have twice the rate of recurrence,<SUP> </SUP>but =
their=20
prognosis does not differ from other patients after<SUP> =
</SUP>irradiation of=20
chiasmal gliomas [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R85">85</A>].=20
In adults, although RT<SUP> </SUP>appears to prolong life expectancy, =
neither=20
surgery, RT, nor<SUP> </SUP>chemotherapy has been able to prevent visual =
loss=20
and death<SUP> </SUP>for most patients within 12=9624 months of =
diagnosis [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R86">86</A>].<SUP>=20
</SUP>
<P><A name=3DSEC9><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; T<FONT=20
      size=3D-2>REATMENT</FONT>-R<FONT size=3D-2>ELATED</FONT> C<FONT=20
      size=3D-2>OMPLICATIONS</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><IMG height=3D9 alt=3D" " =
hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Treatment-Related =
Complications</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>I=
n=20
addition to the symptoms caused directly by the brain tumor,<SUP> =
</SUP>patients=20
with LGGs often experience significant adverse effects<SUP> </SUP>from =
various=20
treatment modalities administered for the tumor.<SUP> </SUP>This is an =
important=20
issue to consider when contemplating treatment<SUP> </SUP>of a patient =
with LGG=20
because this population is generally young<SUP> </SUP>and these tumors =
are slow=20
growing and may not even be causing<SUP> </SUP>symptoms at the time of=20
diagnosis. RT may have neurotoxic effects<SUP> </SUP>and can produce=20
neurological and cognitive symptoms. Because<SUP> </SUP>RT is often =
included in=20
the treatment of patients with LGG,<SUP> </SUP>there is concern about =
possible=20
adverse effects in this population.<SUP> </SUP>Because of the long =
survival=20
times of these patients and the<SUP> </SUP>concern regarding RT effects, =
both=20
the EORTC and the NCCTG have<SUP> </SUP>conducted studies to address =
this issue.=20
In 1985, when the EORTC<SUP> </SUP>Radiotherapy Cooperative Group began =
the=20
phase III trial on<SUP> </SUP>dose response of LGG to RT, a QoL =
questionnaire=20
was also included<SUP> </SUP>to assess physical, social, sexual, =
cognitive, and=20
emotional<SUP> </SUP>factors overtime. In this QoL portion of EORTC =
22844, 379=20
patients<SUP> </SUP>were randomized to receive either high-dose (59.4 =
Gy) or=20
low-dose<SUP> </SUP>(45 Gy) RT, and 22%=9643% of these patients =
completed and<SUP>=20
</SUP>returned the QoL forms [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R88">88</A>].=20
Analysis of responses suggested<SUP> </SUP>that patients who received =
high-dose=20
RT had lower levels of<SUP> </SUP>daily functioning and more negative =
symptoms=20
in the first 6<SUP> </SUP>months after RT [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R88">88</A>].=20
Emotional health and quality of leisure<SUP> </SUP>time were =
significantly=20
different between the high-dose and<SUP> </SUP>lower-dose RT groups even =
7=9615=20
months after radiotherapy<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R88">88</A>].<SUP>=20
</SUP>
<P>The NCCTG likewise analyzed cognitive performance data using<SUP> =
</SUP>the=20
Folstein Mini-Mental State Examination (MMSE) and neurologic<SUP> =
</SUP>function=20
score (NFS), collected in a prospective clinical trial<SUP> </SUP>of 203 =

patients. NFS was calculated based on the number of neurological<SUP>=20
</SUP>symptoms the patient experienced as well as functional =
status.<SUP>=20
</SUP>The investigators found that after focal RT, most patients =
with<SUP>=20
</SUP>LGG had a stable neurocognitive status, and if a change was<SUP>=20
</SUP>noted, it was more often an improvement in status following<SUP> =
</SUP>RT=20
treatment [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R89">89</A>].=20
In that study, patients received either a<SUP> </SUP>total RT dose of =
50.4 Gy in=20
28 fractions or a higher total dose<SUP> </SUP>of 64.8 Gy [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R88">88</A>].=20
A fundamental weakness of the study was the<SUP> </SUP>lack of a more=20
discriminating neurocognitive assessment tool.<SUP> </SUP>Although the =
MMSE is=20
easy for clinicians to use and may be sufficient<SUP> </SUP>for =
assessing=20
dementia, it relies mainly on verbal skills and<SUP> </SUP>is not =
sufficiently=20
sensitive to detect subtle intellectual<SUP> </SUP>changes that may =
occur in=20
young, otherwise healthy LGG patients.<SUP> </SUP>
<P>Klein et al. [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R90">90</A>]=20
compared cognitive function in a group of<SUP> </SUP>195 patients with =
LGG, of=20
whom, over half had received prior<SUP> </SUP>RT. The comparison groups=20
consisted of patients with hematological<SUP> </SUP>disease and a group =
of=20
healthy controls. Results from a comprehensive<SUP> </SUP>battery of=20
neuropsychological tests suggested that it was the<SUP> </SUP>tumor =
itself that=20
had the greatest deleterious effect on cognitive<SUP> </SUP>health, as =
both=20
irradiated and nonirradiated LGG patients had<SUP> </SUP>significantly =
worse=20
scores than either of the other two groups.<SUP> </SUP>Their results =
agreed with=20
previous studies that the radiation<SUP> </SUP>dose, treatment volume, =
and size=20
of fraction are responsible<SUP> </SUP>for the late neurotoxicity =
associated=20
with RT. Their study did<SUP> </SUP>not include pretreatment tests of =
cognition.=20
This is a shortcoming<SUP> </SUP>of most studies and complicates the=20
determination of how much<SUP> </SUP>cognitive decline is a result of =
the tumor=20
itself, versus an<SUP> </SUP>iatrogenic cause.<SUP> </SUP>
<P>Antiepileptic drugs and chemotherapeutic agents are also capable<SUP> =

</SUP>of deleterious effects on cognitive functioning as well as on<SUP> =

</SUP>the emotional and physical health of LGG patients. Other =
agents<SUP>=20
</SUP>that may affect QoL include corticosteroids and =
anticoagulants<SUP>=20
</SUP>used to treat other major medical problems accompanying brain<SUP> =

</SUP>tumors.<SUP> </SUP>
<P>Although treatment-related secondary malignancies have been<SUP> =
</SUP>the=20
subject of much debate in childhood cancer patients as well<SUP> =
</SUP>as=20
non-Hodgkin=92s lymphoma patients [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R87">87</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R91">91</A>=96<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R93">93</A>],<SUP>=20
</SUP>the advances in treatment strategies make this a new area of<SUP>=20
</SUP>concern in the glioma population. There is compelling =
evidence<SUP>=20
</SUP>that alkylating agents can cause chromosomal damage that may<SUP>=20
</SUP>lead to secondary malignancies, including treatment-related<SUP>=20
</SUP>myelodysplastic syndrome (tMDS), acute myelogenous leukemia,<SUP> =
</SUP>or=20
bone sarcoma in later years [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R87">87</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R92">92</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R94">94</A>].<SUP>=20
</SUP>
<P>Temozolomide and procarbazine, two drugs commonly used in =
patients<SUP>=20
</SUP>with malignant gliomas, exert their anticancer activity =
through<SUP>=20
</SUP>the methylation of DNA at the O<SUP>6</SUP> position of guanine=20
residues<SUP> </SUP>[<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R95">95</A>,=20
<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R96">96</A>].=20
Prolonged administration of temozolomide is associated<SUP> </SUP>with =
side=20
effects, including prolonged lymphopenia even after<SUP> </SUP>drug=20
discontinuation and susceptibility to clinically significant<SUP>=20
</SUP>opportunistic infections including <I>Pneumocystis carinii</I>=20
pneumonia,<SUP> </SUP>herpes simplex virus, and Kaposi=92s sarcoma [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R97">97</A>].=20
There<SUP> </SUP>is one published report and other clinical reports of =
tMDS=20
after<SUP> </SUP>temozolomide treatment [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R98">98</A>].=20
The prognosis of tMDS is generally<SUP> </SUP>poor, with rapid evolution =
into=20
acute leukemia. Ongoing studies<SUP> </SUP>of prolonged temozolomide =
schedules=20
should monitor for and report<SUP> </SUP>second malignancies so this =
issue can=20
be further clarified [<A=20
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
R95">95</A>].<SUP>=20
</SUP>
<P><A name=3DSEC10><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; C<FONT=20
      size=3D-2>ONCLUSION</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><IMG height=3D9 =
alt=3D" "=20
      hspace=3D5 =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif"=20
      width=3D11 border=3D0><FONT =
color=3D#464c53>Conclusion</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>L=
GGs are a=20
heterogeneous group of CNS neoplasms that pose unique<SUP> =
</SUP>management=20
challenges. The tumors typically occur in younger,<SUP> </SUP>healthier =
patient=20
populations, and life expectancy is often<SUP> </SUP>a decade or more. =
Thus,=20
both the short-term and long-term risks<SUP> </SUP>of therapy must be =
carefully=20
weighed in this patient population.<SUP> </SUP>There have been no =
randomized=20
trials of resection versus biopsy<SUP> </SUP>or observation. However,=20
retrospective data suggest that maximal<SUP> </SUP>surgical resection =
does=20
provide a survival benefit for patients<SUP> </SUP>with LGGs. RT does =
prolong=20
progression-free survival but not<SUP> </SUP>overall survival, as =
demonstrated=20
in three randomized trials.<SUP> </SUP>Although significant cognitive =
decline=20
over time has not been<SUP> </SUP>reported in these prospective RT =
trials, the=20
assessment tools<SUP> </SUP>for such detection are insensitive. =
Chemotherapy may=20
be associated<SUP> </SUP>with a reduction in tumor size in LGG subsets,=20
including those<SUP> </SUP>tumors with oligodendroglial elements or =
those tumors=20
with loss<SUP> </SUP>of chromosome 1p. LOH for chromosome 1p does seem =
to=20
correlate<SUP> </SUP>with a better prognosis in LGOs. Future =
developments of=20
importance<SUP> </SUP>for patients with LGGs will include better =
intraoperative=20
mapping<SUP> </SUP>and imaging to allow for more aggressive resections; =
the=20
development<SUP> </SUP>of safer radiation techniques that will "spare" =
adjacent=20
normal<SUP> </SUP>brain tissue; incorporation of molecular markers of=20
prognosis,<SUP> </SUP>especially for LGOs; and the development of=20
chemotherapeutic<SUP> </SUP>strategies for chemosensitive LGGs. Future =
trials=20
need more<SUP> </SUP>sensitive measures of long-term cognitive, =
functional, and=20
QoL<SUP> </SUP>outcomes.<SUP> </SUP>
<P><A name=3DSEC11><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; D<FONT=20
      size=3D-2>ISCLOSURE</FONT><FONT size=3D-1> </FONT><FONT =
size=3D-2>OF</FONT>=20
      P<FONT size=3D-2>OTENTIAL</FONT> C<FONT =
size=3D-2>ONFLICTS</FONT><FONT=20
      size=3D-1> </FONT><FONT size=3D-2>OF</FONT> I<FONT =
size=3D-2>NTEREST</FONT>=20
      </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><IMG height=3D9 alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT color=3D#464c53>Disclosure of =
Potential...</FONT><BR><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
BIBL"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/darrow.gif" =
width=3D11=20
      =
border=3D0>References<BR></A></FONT></TH></TR></TBODY></TABLE>&nbsp;<BR>T=
he=20
authors indicate no potential conflicts of interest.<SUP> </SUP>
<P><SUP></SUP>
<P><A name=3DBIBL><!-- null --></A><BR clear=3Dright>
<TABLE cellSpacing=3D0 cellPadding=3D0 width=3D"100%" bgColor=3D#e1e1e1>
  <TBODY>
  <TR>
    <TD vAlign=3Dcenter align=3Dleft width=3D"5%" bgColor=3D#ffffff><IMG =
height=3D21=20
      alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif"=20
    width=3D10></TD>
    <TH vAlign=3Dcenter align=3Dleft width=3D"95%"><FONT =
size=3D+2>&nbsp;&nbsp; R<FONT=20
      size=3D-2>EFERENCES</FONT> </FONT></TH></TR></TBODY></TABLE>
<TABLE cellPadding=3D5 align=3Dright border=3D1>
  <TBODY>
  <TR>
    <TH align=3Dleft><FONT size=3D-1><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
top"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Top<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC1"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Learning Objectives<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
ABS"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Abstract<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC2"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Introduction<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC3"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Incidence<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC4"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Presentation<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC5"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Diagnosis<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC6"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC7"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Prognosis in Low-Grade Gliomas<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC8"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Special Topics<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC9"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Treatment-Related Complications<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC10"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Conclusion<BR></A><A=20
      =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/full/11/6/681#=
SEC11"><IMG=20
      height=3D9 alt=3D" " hspace=3D5=20
      =
src=3D"http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif" =
width=3D11=20
      border=3D0>Disclosure of Potential...<BR></A><IMG height=3D9 =
alt=3D" " hspace=3D5=20
      src=3D"http://theoncologist.alphamedpress.org/icons/toc/dot.gif" =
width=3D11=20
      border=3D0><FONT=20
color=3D#464c53>References</FONT><BR></FONT></TH></TR></TBODY></TABLE>&nb=
sp;<BR>
<OL compact><A name=3DR1><!-- null --></A>
  <LI value=3D1>Central Brain Tumor Registry of the United States. =
Statistical=20
  Report: Primary Brain Tumors in the United States, 1997=962001. =
Chicago: CBTRUS,=20
  2004:1=9651.<!-- HIGHWIRE ID=3D"11:6:681:1" --><!-- /HIGHWIRE --><A =
name=3DR2><!-- null --></A>
  <LI value=3D2>Fritz AG, Percy C, Jack A et al., eds. International=20
  Classification of Diseases for Oncology, 3rd Ed. T.E. Geneva, =
Switzerland:=20
  World Health Organization, 2000:1=96240.<!-- HIGHWIRE =
ID=3D"11:6:681:2" --><!-- /HIGHWIRE --><A name=3DR3><!-- null --></A>
  <LI value=3D3>Shaw E, Bernstein M, Recht L et al. Practice parameters =
in adults=20
  with suspected or known supratentorial nonoptic pathway low-grade =
glioma.=20
  Neurosurg Focus=20
  1998;4:10.<!-- HIGHWIRE ID=3D"11:6:681:3" --><!-- /HIGHWIRE --><A =
name=3DR4><!-- null --></A>
  <LI value=3D4>Schlehofer B, Hettinger I, Ryan P et al. Occupational =
risk factors=20
  for low grade and high grade glioma: results from an international =
case=20
  control study of adult brain tumours. Int J Cancer =
2005;113:116=96125.<!-- HIGHWIRE ID=3D"11:6:681:4" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/ijc.20504&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15386358&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR5><!-- null --></A>
  <LI value=3D5>Whittle IR. The dilemma of low-grade glioma. J Neurol =
Neurosurg=20
  Psychiatry 2004;75(suppl 2):ii31=96ii36.<!-- HIGHWIRE =
ID=3D"11:6:681:5" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DFULL=
&amp;journalCode=3Djnnp&amp;resid=3D75/suppl_2/ii31"><NOBR>[<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR6><!-- null --></A>
  <LI value=3D6>Yeh SA, Lee TC, Chen HJ et al. Treatment outcomes and =
prognostic=20
  factors of patients with supratentorial low-grade oligodendroglioma. =
Int J=20
  Radiat Oncol Biol Phys 2002;54:1405=961409.<!-- HIGHWIRE =
ID=3D"11:6:681:6" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(02)03053-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12459363&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR7><!-- null --></A>
  <LI value=3D7>Recht LD, Lew R, Smith TW. Suspected low-grade glioma: =
is=20
  deferring treatment safe? Ann Neurol 1992;31:431=96436.<!-- HIGHWIRE =
ID=3D"11:6:681:7" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/ana.410310413&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D1586143&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR8><!-- null --></A>
  <LI value=3D8>Shafqat S, Hedley-Whyte ET, Henson JW. Age-dependent =
rate of=20
  anaplastic transformation in low-grade astrocytoma. Neurology 1999;52: =

867=96869.<!-- HIGHWIRE ID=3D"11:6:681:8" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D52/4/867"><NOBR>[Abstract/<FONT =

  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR9><!-- null --></A>
  <LI value=3D9>Shaw EG, Scheithauer BW, O=92Fallon JR et al. Mixed=20
  oligoastrocytomas: a survival and prognostic factor analysis. =
Neurosurgery=20
  1994;34:577=96582; discussion 582.<!-- HIGHWIRE ID=3D"11:6:681:9" =
--><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8008153&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR10><!-- null --></A>
  <LI value=3D10>Wessels PH, Weber WE, Raven G et al. Supratentorial =
grade II=20
  astrocytoma: biological features and clinical course. Lancet Neurol =
2003;2:=20
  395=96403.<!-- HIGHWIRE ID=3D"11:6:681:10" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S1474-4422(03)00434-4&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12849117&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR11><!-- null --></A>
  <LI value=3D11>Olson JD, Riedel E, DeAngelis LM. Long-term outcome of =
low-grade=20
  oligodendroglioma and mixed glioma. Neurology 2000;54:1442=961448.<!-- =
HIGHWIRE ID=3D"11:6:681:11" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D54/7/1442"><NOBR>[Abstract/<FONT=
=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR12><!-- null --></A>
  <LI value=3D12>Lebrun C, Fontaine D, Ramaioli A et al. Long-term =
outcome of=20
  oligodengrogliomas. Neurology 2004;62:1783=961787.<!-- HIGHWIRE =
ID=3D"11:6:681:12" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D62/10/1783"><NOBR>[Abstract/<FON=
T=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR13><!-- null --></A>
  <LI value=3D13>Pirzkall A, Nelson SJ, McKnight TR et al. Metabolic =
imaging of=20
  low-grade gliomas with three-dimensional magnetic resonance =
spectroscopy. Int=20
  J Radiat Oncol Biol Phys=20
  2002;53:1254=961264.<!-- HIGHWIRE ID=3D"11:6:681:13" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(02)02869-9&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12128127&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR14><!-- null --></A>
  <LI value=3D14>Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of =
adult=20
  gliomas. Lancet Oncol 2005;6:167=96175.<!-- HIGHWIRE =
ID=3D"11:6:681:14" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S1470-2045(05)01767-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15737833&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR15><!-- null --></A>
  <LI value=3D15>Recht LD, Bernstein M. Low-grade gliomas. Neurol Clin =
1995;13:=20
  847=96859.<!-- HIGHWIRE ID=3D"11:6:681:15" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8584000&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR16><!-- null --></A>
  <LI value=3D16>McKnight TR, von dem Bussche MH, Vigneron DB et al.=20
  Histopathological validation of a three-dimensional magnetic resonance =

  spectroscopy index as a predictor of tumor presence. J Neurosurg=20
  2002;97:794=96802.<!-- HIGHWIRE ID=3D"11:6:681:16" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12405365&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR17><!-- null --></A>
  <LI value=3D17>Nuutinen J, Sonninen P, Lehikoinen P et al. =
Radiotherapy=20
  treatment planning and long-term follow-up with [(11)C]methionine PET =
in=20
  patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys =
2000;48:=20
  43=9652.<!-- HIGHWIRE ID=3D"11:6:681:17" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(00)00604-0&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10924970&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR18><!-- null --></A>
  <LI value=3D18>Galanaud D, Chinot O, Nicoli F et al. Use of proton =
magnetic=20
  resonance spectroscopy of the brain to differentiate gliomatosis =
cerebri from=20
  low-grade glioma. J Neurosurg 2003;98:269=96276.<!-- HIGHWIRE =
ID=3D"11:6:681:18" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12593610&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR19><!-- null --></A>
  <LI value=3D19>Pirotte B, Goldman S, Massager N et al. Combined use of =

  18F-fluorode-oxyglucose and 11C-methionine in 45 positron emission=20
  tomography-guided stereotactic brain biopsies. J Neurosurg =
2004;101:476=96483.<!-- HIGHWIRE ID=3D"11:6:681:19" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15352606&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR20><!-- null --></A>
  <LI value=3D20>Lopes MB, Laws ER. Low-grade central nervous system =
tumors.=20
  Neurol Focus=20
  2002;12:1=964.<!-- HIGHWIRE ID=3D"11:6:681:20" --><!-- /HIGHWIRE --><A =
name=3DR21><!-- null --></A>
  <LI value=3D21>Afra D, MW. Recurrent low-grade gliomas: =
dedifferentiation and=20
  prospects of reoperation. In: Karim ABMF, Karim ER, eds. GLIOMA: =
Principles=20
  and Practice in Neuro-Oncology. Berlin-Heidelberg, Germany: =
Springer-Verlag,=20
  1991:189=96203.<!-- HIGHWIRE ID=3D"11:6:681:21" --><!-- /HIGHWIRE =
--><A name=3DR22><!-- null --></A>
  <LI value=3D22>Cha S, Tihan T, Crawford F et al. Differentiation of =
low-grade=20
  oligodendrogliomas from low-grade astrocytomas by using quantitative=20
  blood-volume measurements derived from dynamic susceptibility=20
  contrast-enhanced MR imaging. AJNR Am J Neuroradiol =
2005;26:266=96273.<!-- HIGHWIRE ID=3D"11:6:681:22" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dajnr&amp;resid=3D26/2/266"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR23><!-- null --></A>
  <LI value=3D23>Jeuken JW, von Deimling A, Wesseling P. Molecular =
pathogenesis of=20
  oligodendroglial tumors. J Neurooncol 2004;70:161=96181.<!-- HIGHWIRE =
ID=3D"11:6:681:23" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1007/s11060-004-2748-1&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15674476&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR24><!-- null --></A>
  <LI value=3D24>Smith JS, Perry A, Borell TJ et al. Alterations of =
chromosome=20
  arms 1p and 19q as predictors of survival in oligodendrogliomas, =
astrocytomas,=20
  and mixed oligoastrocytomas. J Clin Oncol 2000;18:636=96645.<!-- =
HIGHWIRE ID=3D"11:6:681:24" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D18/3/636"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR25><!-- null --></A>
  <LI value=3D25>Eskandar EN, Loeffler JS, O=92Neill AM et al. Case =
records of the=20
  Massachusetts General Hospital. Weekly clinicopathological exercises. =
Case=20
  33-2004. A 34-year-old man with a seizure and a frontal-lobe brain =
lesion. N=20
  Engl J Med 2004;351:1875=961882.<!-- HIGHWIRE ID=3D"11:6:681:25" --><A =

  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DFULL=
&amp;journalCode=3Dnejm&amp;resid=3D351/18/1875"><NOBR>[<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR26><!-- null --></A>
  <LI value=3D26>Lunsford LD, Somaza S, Kondziolka D et al. Survival =
after=20
  stereotactic biopsy and irradiation of cerebral nonanaplastic, =
nonpilocytic=20
  astrocytoma. J Neurosurg 1995;82:523=96529.<!-- HIGHWIRE =
ID=3D"11:6:681:26" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D7897510&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR27><!-- null --></A>
  <LI value=3D27>Revesz T, Scaravilli F, Coutinho L et al. Reliability =
of=20
  histological diagnosis including grading in gliomas biopsied by =
image-guided=20
  stereotactic technique. Brain 1993;116:781=96793.<!-- HIGHWIRE =
ID=3D"11:6:681:27" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dbrain&amp;resid=3D116/4/781"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR28><!-- null --></A>
  <LI value=3D28>Muller W, Afra D, Schroder R. Supratentorial =
recurrences of=20
  gliomas. Morphological studies in relation to time intervals with=20
  astrocytomas. Acta Neurochir (Wien) 1977;37:75=9691.<!-- HIGHWIRE =
ID=3D"11:6:681:28" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1007/BF01401927&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D195444&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR29><!-- null --></A>
  <LI value=3D29>Chandrasoma PT, Smith MM, Apuzzo ML. Stereotactic =
biopsy in the=20
  diagnosis of brain masses: comparison of results of biopsy and =
resected=20
  surgical specimen. Neurosurgery 1989;24:160=96165.<!-- HIGHWIRE =
ID=3D"11:6:681:29" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D2537475&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR30><!-- null --></A>
  <LI value=3D30>Maia AC, Malheiros SM, da Rocha AJ et al. Stereotactic =
biopsy=20
  guidance in adults with supratentorial nonenhancing gliomas: role of=20
  perfusion-weighted magnetic resonance imaging. J Neurosurg =
2004;101:970=96976.<!-- HIGHWIRE ID=3D"11:6:681:30" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15597757&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR31><!-- null --></A>
  <LI value=3D31>Hakyemez B, Erdogan C, Ercan I et al. High-grade and =
low-grade=20
  gliomas: differentiation by using perfusion MR imaging. Clin Radiol=20
  2005;60:493=96502.<!-- HIGHWIRE ID=3D"11:6:681:31" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/j.crad.2004.09.009&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15767107&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR32><!-- null --></A>
  <LI value=3D32>Daumas-Duport C, Scheithauer B, O=92Fallon J et al. =
Grading of=20
  astrocytomas. A simple and reproducible method. Cancer =
1988;62:2152=962165.<!-- HIGHWIRE ID=3D"11:6:681:32" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D3179928&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR33><!-- null --></A>
  <LI value=3D33>Reifenberger J, Reifenberger G, Liu L et al. Molecular =
genetic=20
  analysis of oligodendroglial tumors shows preferential allelic =
deletions on=20
  19q and 1p. Am J Pathol=20
  1994;145:1175=961190.<!-- HIGHWIRE ID=3D"11:6:681:33" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Damjpathol&amp;resid=3D145/5/1175">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR34><!-- null --></A>
  <LI value=3D34>von Deimling A, Louis DN, von Ammon K et al. Evidence =
for a tumor=20
  suppressor gene on chromosome 19q associated with human astrocytomas,=20
  oligodendrogliomas, and mixed gliomas. Cancer Res =
1992;52:4227=964279.<!-- HIGHWIRE ID=3D"11:6:681:34" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dcanres&amp;resid=3D52/15/4227">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR35><!-- null --></A>
  <LI value=3D35>Cairncross JG, Ueki K, Zlatescu MC et al. Specific =
genetic=20
  predictors of chemotherapeutic response and survival in patients with=20
  anaplastic oligodendrogliomas. J Natl Cancer Inst =
1998;90:1473=961479.<!-- HIGHWIRE ID=3D"11:6:681:35" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djnci&amp;resid=3D90/19/1473"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR36><!-- null --></A>
  <LI value=3D36>Buckner JC, Ballman KV, Scheithauer BW et al. =
Diagnostic and=20
  prognostic significance of 1p and 19q deletions in patients with =
low-grade=20
  oligodendroglioma and astrocytoma. Proc Am Soc Clin Oncol =
2005;23:114S.<!-- HIGHWIRE ID=3D"11:6:681:36" --><!-- /HIGHWIRE --><A =
name=3DR37><!-- null --></A>
  <LI value=3D37>Ashby LS, Pueschel JK, Scheck AC et al. Prognostic =
factors for=20
  patients with newly diagnosed low-grade oligodendroglial tumors: =
molecular=20
  genetics, histopathology, and neuroimaging. Proc Am Soc Clin Oncol=20
  2005;23:114S.<!-- HIGHWIRE ID=3D"11:6:681:37" --><!-- /HIGHWIRE --><A =
name=3DR38><!-- null --></A>
  <LI value=3D38>Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as =
initial=20
  treatment for adults with low-grade oligodendrogliomas or =
oligoastrocytomas=20
  and correlation with chromosome 1p deletions. J Clin Oncol =
2004;22:3133=963138.<!-- HIGHWIRE ID=3D"11:6:681:38" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D22/15/3133"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR39><!-- null --></A>
  <LI value=3D39>DeGirolami U, Smith TW. Neuropathology of central =
nervous system=20
  tumors. In: Black PM, Loeffler JS, eds. Cancer of the Nervous System, =
Second=20
  Edition. Philadelphia: Lippincott, Williams &amp; Wilkins: =
2005:18;15=9645.<!-- HIGHWIRE ID=3D"11:6:681:39" --><!-- /HIGHWIRE --><A =
name=3DR40><!-- null --></A>
  <LI value=3D40>Kros JM, Hop WC, Godschalk JJ et al. Prognostic value =
of the=20
  proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer =
1996;78:=20
  1107=961113.<!-- HIGHWIRE ID=3D"11:6:681:40" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5&amp=
;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8780550&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR41><!-- null --></A>
  <LI value=3D41>Burger PC, Scheithauer B, Vogel FS. Surgical Pathology =
of the=20
  Nervous System and Its Coverings, Fourth Edition. New York: Churchill=20
  Livingstone, 2002:1=96657.<!-- HIGHWIRE ID=3D"11:6:681:41" --><!-- =
/HIGHWIRE --><A=20
  name=3DR42><!-- null --></A>
  <LI value=3D42>Schiffer D, Dutto A, Cavalla P et al. Prognostic =
factors in=20
  oligodendroglioma. Can J Neurol Sci 1997;24:313=96319.<!-- HIGHWIRE =
ID=3D"11:6:681:42" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D9398978&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR43><!-- null --></A>
  <LI value=3D43>Coons SW, Johnson PC, Pearl DK. The prognostic =
significance of=20
  Ki-67 labeling indices for oligodendrogliomas. Neurosurgery =
1997;41:878=96884;=20
  discussion 884=96885.<!-- HIGHWIRE ID=3D"11:6:681:43" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1097/00006123-199710000-00021&amp;link_type=3DDOI">[CrossRef]</A><=
A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D9316050&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR44><!-- null --></A>
  <LI value=3D44>Cairncross JG, Laperriere NJ. Low-grade glioma. To =
treat or not=20
  to treat? Arch Neurol 1989;46:1238=961239.<!-- HIGHWIRE =
ID=3D"11:6:681:44" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1001/archneur.46.11.1238&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D2818260&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR45><!-- null --></A>
  <LI value=3D45>Mandonnet E, Delattre JY, Tanguy ML et al. Continuous =
growth of=20
  mean tumor diameter in a subset of grade II gliomas. Ann Neurol=20
  2003;53:524=96528.<!-- HIGHWIRE ID=3D"11:6:681:45" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/ana.10528&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12666121&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR46><!-- null --></A>
  <LI value=3D46>Ashby LS, Shapiro WR. Low-grade glioma: supratentorial=20
  astrocytoma, oligodendroglioma, and oligoastrocytoma in adults. Curr =
Neurol=20
  Neurosci Rep 2004;4:211=96217.<!-- HIGHWIRE ID=3D"11:6:681:46" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15102347&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR47><!-- null --></A>
  <LI value=3D47>Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric =
gliomas in=20
  adults: a critical review of extent of resection as a factor =
influencing=20
  outcome. J Neurosurg 2001;95:735=96745.<!-- HIGHWIRE =
ID=3D"11:6:681:47" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D11702861&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR48><!-- null --></A>
  <LI value=3D48>Berger MS, Deliganis AV, Dobbins J et al. The effect of =
extent of=20
  resection on recurrence in patients with low grade cerebral hemisphere =

  gliomas. Cancer 1994;74:1784=961791.<!-- HIGHWIRE ID=3D"11:6:681:48" =
--><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8082081&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR49><!-- null --></A>
  <LI value=3D49>van Veelen ML, Avezaat CJ, Kros JM et al. =
Supratentorial low=20
  grade astrocytoma: prognostic factors, dedifferentiation, and the =
issue of=20
  early versus late surgery. J Neurol Neurosurg Psychiatry =
1998;64:581=96587.<!-- HIGHWIRE ID=3D"11:6:681:49" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djnnp&amp;resid=3D64/5/581"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR50><!-- null --></A>
  <LI value=3D50>Leighton C, Fisher B, Bauman G et al. Supratentorial =
low-grade=20
  glioma in adults: an analysis of prognostic factors and timing of =
radiation. J=20
  Clin Oncol 1997;15:1294=961301.<!-- HIGHWIRE ID=3D"11:6:681:50" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D15/4/1294"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR51><!-- null --></A>
  <LI value=3D51>Packer RJ, Mehta M. Neurocognitive sequelae of cancer =
treatment.=20
  Neurology 2002;59:8=9610.<!-- HIGHWIRE ID=3D"11:6:681:51" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DFULL=
&amp;journalCode=3Dneurology&amp;resid=3D59/1/8"><NOBR>[<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR52><!-- null --></A>
  <LI value=3D52>Surma-aho O, Niemela M, Vilkki J et al. Adverse =
long-term effects=20
  of brain radiotherapy in adult low-grade glioma patients. Neurology=20
  2001;56:1285=961290.<!-- HIGHWIRE ID=3D"11:6:681:52" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D56/10/1285"><NOBR>[Abstract/<FON=
T=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR53><!-- null --></A>
  <LI value=3D53>Fazekas JT. Treatment of grades I and II brain =
astrocytomas. The=20
  role of radiotherapy. Int J Radiat Oncol Biol Phys =
1977;2:661=96666.<!-- HIGHWIRE ID=3D"11:6:681:53" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D893171&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR54><!-- null --></A>
  <LI value=3D54>Higuchi Y, Iwadate Y, Yamaura A. Treatment of low-grade =

  oligodendroglial tumors without radiotherapy. Neurology =
2004;63:2384=962386.<!-- HIGHWIRE ID=3D"11:6:681:54" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D63/12/2384"><NOBR>[Abstract/<FON=
T=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR55><!-- null --></A>
  <LI value=3D55>Garcia DM, Fulling KH, Marks JE. The value of radiation =
therapy=20
  in addition to surgery for astrocytomas of the adult cerebrum. Cancer=20
  1985;55:919=96927.<!-- HIGHWIRE ID=3D"11:6:681:55" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D3967199&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR56><!-- null --></A>
  <LI value=3D56>Schultheiss TE, Kun LE, Ang KK et al. Radiation =
response of the=20
  central nervous system. Int J Radiat Oncol Biol Phys =
1995;31:1093=961112.<!-- HIGHWIRE ID=3D"11:6:681:56" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/0360-3016(94)00655-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D7677836&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR57><!-- null --></A>
  <LI value=3D57>Karim A. Cure and quality of life after treatment for =
glioma. In:=20
  Karim ABMF, Laws ER, eds. GLIOMA: Principles and Practice in =
Neuro-Oncology.=20
  Berlin: Springer-Verlag, 1991:1=96289.<!-- HIGHWIRE ID=3D"11:6:681:57" =
--><!-- /HIGHWIRE --><A name=3DR58><!-- null --></A>
  <LI value=3D58>Karim AB, Maat B, Hatlevoll R et al. A randomized trial =
on=20
  dose-response in radiation therapy of low-grade cerebral glioma: =
European=20
  Organization for Research and Treatment of Cancer (EORTC) Study 22844. =
Int J=20
  Radiat Oncol Biol Phys 1996;36:549=96556.<!-- HIGHWIRE =
ID=3D"11:6:681:58" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(96)00352-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8948338&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR59><!-- null --></A>
  <LI value=3D59>Karim AB, Afra D, Cornu P et al. Randomized trial on =
the efficacy=20
  of radiotherapy for cerebral low-grade glioma in the adult: European=20
  Organization for Research and Treatment of Cancer Study 22845 with the =
Medical=20
  Research Council study BRO4: an interim analysis. Int J Radiat Oncol =
Biol Phys=20
  2002;52:316=96324.<!-- HIGHWIRE ID=3D"11:6:681:59" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(01)02692-X&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D11872276&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR60><!-- null --></A>
  <LI value=3D60>van den Bent MJ, Afra D, de WitteO et al. Long-term =
efficacy of=20
  early versus delayed radiotherapy for low-grade astrocytoma and=20
  oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet=20
  2005;366:985=96990.<!-- HIGHWIRE ID=3D"11:6:681:60" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0140-6736(05)67070-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D16168780&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR61><!-- null --></A>
  <LI value=3D61>Shaw E, Arusell R, Scheithauer B et al. Prospective =
randomized=20
  trial of low- versus high-dose radiation therapy in adults with =
supratentorial=20
  low-grade glioma: initial report of a North Central Cancer Treatment=20
  Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology =
Group=20
  study. J Clin Oncol 2002;20:2267=962276.<!-- HIGHWIRE =
ID=3D"11:6:681:61" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D20/9/2267"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR62><!-- null --></A>
  <LI value=3D62>Shaw EG, Wisoff JH. Prospective clinical trials of =
intracranial=20
  low-grade glioma in adults and children. Neurooncol =
2003;5:153=96160.<!-- HIGHWIRE ID=3D"11:6:681:62" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dddno&amp;resid=3D5/3/153"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR63><!-- null --></A>
  <LI value=3D63>Moran JM, Elshaikh MA, Lawrence TS. Radiotherapy: what =
can be=20
  achieved by technical improvements in dose delivery? Lancet Oncol=20
  2005;6):51=9658.<!-- HIGHWIRE ID=3D"11:6:681:63" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15629276&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR64><!-- null --></A>
  <LI value=3D64>Van den Bent MJ. Can chemotherapy replace radiotherapy =
in=20
  low-grade gliomas? Time for randomized studies. Semin Oncol =
2003;30(suppl=20
  19):39=9644.<!-- HIGHWIRE ID=3D"11:6:681:64" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12644983&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR65><!-- null --></A>
  <LI value=3D65>Mason WP, Krol GS, DeAngelis LM. Low-grade =
oligodendroglioma=20
  responds to chemotherapy. Neurology 1996;46:203=96207.<!-- HIGHWIRE =
ID=3D"11:6:681:65" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D46/1/203">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR66><!-- null --></A>
  <LI value=3D66>Stege EM, Kros JM, de Bruin HG et al. Successful =
treatment of=20
  low-grade oligodendroglial tumors with a chemotherapy regimen of =
procarbazine,=20
  lomustine, and vincristine. Cancer 2005;103:802=96809.<!-- HIGHWIRE =
ID=3D"11:6:681:66" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/cncr.20828&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15637687&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR67><!-- null --></A>
  <LI value=3D67>Quinn JA, Reardon DA, Friedman AH et al. Phase II trial =
of=20
  temozolomide in patients with progressive low-grade glioma. J Clin =
Oncol=20
  2003;21:646=96651.<!-- HIGHWIRE ID=3D"11:6:681:67" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D21/4/646"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR68><!-- null --></A>
  <LI value=3D68>Murphy PS Viviers L, Abson C et al. Monitoring =
temozolomide=20
  treatment of low-grade glioma with proton magnetic resonance =
spectroscopy. Br=20
  J Cancer 2004;90:781=96786.<!-- HIGHWIRE ID=3D"11:6:681:68" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1038/sj.bjc.6601593&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D14970853&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR69><!-- null --></A>
  <LI value=3D69>Brada M, Viviers L, Abson C et al. Phase II study of =
primary=20
  temozolomide chemotherapy in patients with WHO grade II gliomas. Ann =
Oncol=20
  2003;14:1715=961721.<!-- HIGHWIRE ID=3D"11:6:681:69" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dannonc&amp;resid=3D14/12/1715"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR70><!-- null --></A>
  <LI value=3D70>Pace A, Vidiri A, Galie E et al. Temozolomide =
chemotherapy for=20
  progressive low-grade glioma: clinical benefits and radiological =
response. Ann=20
  Oncol 2003;14:1722=961726.<!-- HIGHWIRE ID=3D"11:6:681:70" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dannonc&amp;resid=3D14/12/1722"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR71><!-- null --></A>
  <LI value=3D71>Allison RR, Schulsinger A, Vongtama V et al. Radiation =
and=20
  chemotherapy improve outcome in oligodendroglioma. Int J Radiat Oncol =
Biol=20
  Phys 1997;37:399=96403.<!-- HIGHWIRE ID=3D"11:6:681:71" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0360-3016(96)00452-X&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D9069313&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR72><!-- null --></A>
  <LI value=3D72>Eyre HJ, Crowley JJ, Townsend JJ et al. A randomized =
trial of=20
  radiotherapy versus radiotherapy plus CCNU for incompletely resected =
low-grade=20
  gliomas: a Southwest Oncology Group study. J Neurosurg =
1993;78:909=96914.<!-- HIGHWIRE ID=3D"11:6:681:72" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8487073&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR73><!-- null --></A>
  <LI value=3D73>Pignatti F, van den Bent M, Curran D et al. Prognostic =
factors=20
  for survival in adult patients with cerebral low-grade glioma. J Clin =
Oncol=20
  2002;20:2076=962084.<!-- HIGHWIRE ID=3D"11:6:681:73" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D20/8/2076"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR74><!-- null --></A>
  <LI value=3D74>Enam SA, Rock JP. Uncommon low-grade primary brain =
tumors. In:=20
  Rock JP, Rosenblum ML, Shaw EG et al., eds. The Practical Management =
of=20
  Low-Grade Primary Brain Tumors. Philadelphia: Lippincott, Williams and =

  Wilkins, 1999:111=96131.<!-- HIGHWIRE ID=3D"11:6:681:74" --><!-- =
/HIGHWIRE --><A=20
  name=3DR75><!-- null --></A>
  <LI value=3D75>Mamelak AN, Prados MD, Obana WG et al. Treatment =
options and=20
  prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg =

  1994;81:24=9630.<!-- HIGHWIRE ID=3D"11:6:681:75" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8207524&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR76><!-- null --></A>
  <LI value=3D76>Gutierrez J. Classification and pathobiology of =
low-grade glial=20
  and glioneuronal neoplasms. In: Rock JP, Rosenblum ML, Shaw EG et al., =
eds.=20
  The Practical Management of Low-Grade Primary Brain Tumors. =
Philadelphia:=20
  Lippincott, Williams &amp; Wilkins, 1999:33=9667.<!-- HIGHWIRE =
ID=3D"11:6:681:76" --><!-- /HIGHWIRE --><A name=3DR77><!-- null --></A>
  <LI value=3D77>Stark AM, Fritsch MJ, Claviez A et al. Management of =
tectal=20
  glioma in childhood. Pediatr Neurol 2005;33:33=9638.<!-- HIGHWIRE =
ID=3D"11:6:681:77" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/j.pediatrneurol.2004.12.014&amp;link_type=3DDOI">[CrossRef]</=
A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15876519&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR78><!-- null --></A>
  <LI value=3D78>Cohen ME, Duffner PK, Heffner RR et al. Prognostic =
factors in=20
  brainstem gliomas. Neurology 1986;36:602=96605.<!-- HIGHWIRE =
ID=3D"11:6:681:78" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D36/5/602">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR79><!-- null --></A>
  <LI value=3D79>Molloy PT, Bilaniuk LT, Vaughan SN et al. Brainstem =
tumors in=20
  patients with neurofibromatosis type 1: a distinct clinical entity. =
Neurology=20
  1995;45:1897=961902.<!-- HIGHWIRE ID=3D"11:6:681:79" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D45/10/1897">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR80><!-- null --></A>
  <LI value=3D80>Berger MS, Edwards MS, LaMasters D et al. Pediatric =
brain stem=20
  tumors: radiographic, pathological, and clinical correlations. =
Neurosurgery=20
  1983;12:298=96302.<!-- HIGHWIRE ID=3D"11:6:681:80" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D6302553&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR81><!-- null --></A>
  <LI value=3D81>Ree A, Jain R, Rock J et al. Direct infiltration of =
brainstem=20
  glioma along the cranial nerves. J Neuroimaging 2005;15:197=96199.<!-- =
HIGHWIRE ID=3D"11:6:681:81" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dspjon&amp;resid=3D15/2/197"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR82><!-- null --></A>
  <LI value=3D82>Robertson PL, Allen JC, Abbott IR et al. =
Cervicomedullary tumors=20
  in children: a distinct subset of brainstem gliomas. Neurology =
1994;44:=20
  1798=961803.<!-- HIGHWIRE ID=3D"11:6:681:82" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Dneurology&amp;resid=3D44/10/1798">[Abstract]</A><!-- =
/HIGHWIRE --><A=20
  name=3DR83><!-- null --></A>
  <LI value=3D83>Hoffman HJ, Soloniuk DS, Humphreys RP et al. Management =
and=20
  outcome of low-grade astrocytomas of the midline in children: a =
retrospective=20
  review. Neurosurgery 1993;33:964=96971.<!-- HIGHWIRE =
ID=3D"11:6:681:83" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D8134009&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR84><!-- null --></A>
  <LI value=3D84>Broniscer A, Iacono L, Chintagumpala M et al. Role of=20
  temozolomide after radiotherapy for newly diagnosed diffuse brainstem =
glioma=20
  in children: results of a multiinstitutional study (SJHG-98). Cancer =
2005;103:=20
  133=96139.<!-- HIGHWIRE ID=3D"11:6:681:84" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1002/cncr.20741&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15565574&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR85><!-- null --></A>
  <LI value=3D85>Alvord EC Jr, Lofton S. Gliomas of the optic nerve or =
chiasm.=20
  Outcome by patients=91 age, tumor site, and treatment. J Neurosurg=20
1988;68:85=9698.<!-- HIGHWIRE ID=3D"11:6:681:85" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D3275755&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR86><!-- null --></A>
  <LI value=3D86>Wabbels B, Demmler A, Seitz J et al. Unilateral adult =
malignant=20
  optic nerve glioma. Graefes Arch Clin Exp Ophthalmol =
2004;242:741=96748.<!-- HIGHWIRE ID=3D"11:6:681:86" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1007/s00417-004-0905-z&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15085353&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR87><!-- null --></A>
  <LI value=3D87>Kingston JE, Hawkins MM, Draper GJ et al. Patterns of =
multiple=20
  primary tumours in patients treated for cancer during childhood. Br J =
Cancer=20
  1987;56:331=96338.<!-- HIGHWIRE ID=3D"11:6:681:87" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D3478072&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR88><!-- null --></A>
  <LI value=3D88>Kiebert GM, Curran D, Aaronson NK et al. Quality of =
life after=20
  radiation therapy of cerebral low-grade gliomas of the adult: results =
of a=20
  randomised phase III trial on dose response (EORTC trial 22844). EORTC =

  Radiotherapy Co-operative Group. Eur J Cancer 1998;34:1902=961909.<!-- =
HIGHWIRE ID=3D"11:6:681:88" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0959-8049(98)00268-8&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10023313&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR89><!-- null --></A>
  <LI value=3D89>Brown PD, Buckner JC, O=91Fallon JRet al. Effects of =
radiotherapy=20
  on cognitive function in patients with low-grade glioma measured by =
the=20
  Folstein mini-mental state examination. J Clin Oncol =
2003;21:2519=962524.<!-- HIGHWIRE ID=3D"11:6:681:89" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D21/13/2519"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR90><!-- null --></A>
  <LI value=3D90>Klein M, Heimans JJ, Aaronson NKet al. Effect of =
radiotherapy and=20
  other treatment-related factors on mid-term to long-term cognitive =
sequelae in=20
  low-grade gliomas: a comparative study. Lancet =
2002;360:1361=961368.<!-- HIGHWIRE ID=3D"11:6:681:90" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1016/S0140-6736(02)11398-5&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D12423981&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR91><!-- null --></A>
  <LI value=3D91>Bhatia S, Yasui Y, Robison LL et al. High risk of =
subsequent=20
  neoplasms continues with extended follow-up of childhood Hodgkin=91s =
disease:=20
  report from the Late Effects Study Group. J Clin Oncol =
2003;21:4386=964394.<!-- HIGHWIRE ID=3D"11:6:681:91" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D21/23/4386"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR92><!-- null --></A>
  <LI value=3D92>Armitage JO, Carbone PP, Connors JM et al. =
Treatment-related=20
  myelo-dysplasia and acute leukemia in non-Hodgkin=91s lymphoma =
patients. J Clin=20
  Oncol 2003;21:897=96906.<!-- HIGHWIRE ID=3D"11:6:681:92" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D21/5/897"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR93><!-- null --></A>
  <LI value=3D93>Hawkins MM, Draper GJ, Kingston JE. Incidence of second =
primary=20
  tumours among childhood cancer survivors. Br J Cancer 1987;56: =
339=96347.<!-- HIGHWIRE ID=3D"11:6:681:93" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D2822073&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE --><A=20
  name=3DR94><!-- null --></A>
  <LI value=3D94>Bielack SS, Kempf-Bielack B, Heise U et al. Combined =
modality=20
  treatment for osteosarcoma occurring as a second malignant disease.=20
  Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin =
Oncol=20
  1999;17:1164.<!-- HIGHWIRE ID=3D"11:6:681:94" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D17/4/1164"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR95><!-- null --></A>
  <LI value=3D95>Gajewski TF. Temozolomide for melanoma: new toxicities =
and new=20
  opportunities. J Clin Oncol=20
  2004;22:580=96581.<!-- HIGHWIRE ID=3D"11:6:681:95" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DFULL=
&amp;journalCode=3Djco&amp;resid=3D22/4/580"><NOBR>[<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR96><!-- null --></A>
  <LI value=3D96>Gerson SL. Clinical relevance of MGMT in the treatment =
of cancer.=20
  J Clin Oncol 2002;20:2388=962399.<!-- HIGHWIRE ID=3D"11:6:681:96" =
--><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D20/9/2388"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR97><!-- null --></A>
  <LI value=3D97>Su YB, Sohn S, Krown SE et al. Selective CD4+ =
lymphopenia in=20
  melanoma patients treated with temozolomide: a toxicity with =
therapeutic=20
  implications. J Clin Oncol=20
  2004;22:610=96616.<!-- HIGHWIRE ID=3D"11:6:681:97" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/ijlink?linkType=3DABST=
&amp;journalCode=3Djco&amp;resid=3D22/4/610"><NOBR>[Abstract/<FONT=20
  color=3D#cc0000>Free</FONT> Full&nbsp;Text]</NOBR></A><!-- /HIGHWIRE =
--><A=20
  name=3DR98><!-- null --></A>
  <LI value=3D98>Su YW, Chang MC, Chiang MF et al. Treatment-related=20
  myelodysplastic syndrome after temozolomide for recurrent high-grade =
glioma. J=20
  Neurooncol 2005;71:315=96318.<!-- HIGHWIRE ID=3D"11:6:681:98" --><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D10.1007/s11060-004-2028-0&amp;link_type=3DDOI">[CrossRef]</A><A=20
  =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3D15735923&amp;link_type=3DMED">[Medline]</A><!-- /HIGHWIRE =
--></LI></OL><BR=20
clear=3Dall><FONT face=3D""></FONT><BR clear=3Dall><BR clear=3Dall><BR =
clear=3Dall>
<TABLE class=3Dcontent_box_outer_table>
  <TBODY>
  <TR>
    <TD><!-- beginning of inner table -->
      <TABLE class=3Dcontent_box_inner_table><!-- citation -->
        <TBODY>
        <TR>
          <TD class=3Dcontent_box_title_highlight colSpan=3D2>This =
Article</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/content/abstract/11/6/=
681">Abstract</A></STRONG>=20
            <IMG height=3D7 alt=3D"Freely available"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/toc/free.gif" =

            width=3D32 border=3D0> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/reprint/11/6/681"><STR=
ONG>Full=20
            Text</STRONG> (PDF)</A> </STRONG></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG>CME: Take the course for =
this=20
            article:<BR></STRONG><A=20
            =
href=3D"http://cme.alphamedpress.org/cgi/hierarchy/ampcme_course;ONC-11-6=
-681">Low-Grade=20
            Gliomas in Adults</A><BR></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/ctalert?alertTy=
pe=3Dcitedby&amp;addAlert=3Dcited_by&amp;saveAlert=3Dno&amp;cited_by_crit=
eria_resid=3Dtheoncologist;11/6/681&amp;return_type=3Darticle&amp;return_=
url=3Dhttp%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull=
%2F11%2F6%2F681">Alert=20
            me when this article is cited</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/ctalert?alertTy=
pe=3Dcorrection&amp;addAlert=3Dcorrection&amp;saveAlert=3Dno&amp;correcti=
on_criteria_value=3D11/6/681&amp;return_type=3Darticle&amp;return_url=3Dh=
ttp%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull%2F11%2=
F6%2F681">Alert=20
            me if a correction is posted</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/citemap?id=3Dtheoncolo=
gist;11/6/681"=20
            rel=3Dnofollow>Citation Map</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>Services</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/mailafriend?url=3Dhttp=
%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull%2F11%2F6%=
2F681&amp;title=3DLow-Grade+Gliomas+in+Adults">E-mail=20
            this article link to a friend</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/search?qbe=3Dtheoncolo=
gist;11/6/681&amp;journalcode=3Dtheoncologist&amp;minscore=3D5000">Simila=
r=20
            articles in this journal</A> </STRONG></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/alerts/etoc">Alert=20
            me to new issues of the journal</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/citmgr?gca=3Dtheoncolo=
gist;11/6/681">Download=20
            to citation manager</A></STRONG> </TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/misc/reprints.shtml">Repri=
nts/Permissions</A></STRONG>=20
          </TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>Google =
Scholar</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            href=3D"http://scholar.google.com/scholar?q=3D%22author%3AJ. =
T.+author%3AGrier%22"=20
            target=3D_blank>Articles by Grier, J. T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://scholar.google.com/scholar?q=3D%22author%3AT.+author%3ABat=
chelor%22"=20
            target=3D_blank>Articles by Batchelor, T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_title colSpan=3D2>PubMed</TD></TR>
        <TR>
          <TD class=3Dcontent_box_space_between_sections =
colSpan=3D2><IMG height=3D1=20
            alt=3D" "=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/spacer.gif"=20
            width=3D200></TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3DGrier+JT&amp;link_type=3DAUTHORSEARCH"=20
            target=3D_blank>Articles by Grier, J. T.</A></STRONG> =
</TD></TR>
        <TR>
          <TD class=3Dcontent_box_arrow vAlign=3Dtop width=3D4><IMG =
height=3D11=20
            alt=3D"Right arrow"=20
            =
src=3D"http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtri=
m.gif"=20
            width=3D4 border=3D0></TD>
          <TD class=3Dcontent_box_item><STRONG><A=20
            =
href=3D"http://theoncologist.alphamedpress.org/cgi/external_ref?access_nu=
m=3DBatchelor+T&amp;link_type=3DAUTHORSEARCH"=20
            target=3D_blank>Articles by Batchelor, T.</A></STRONG>=20
        =
</TD></TR></TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE><BR =
clear=3Dall>
<P>
<HR align=3Dleft width=3D450 noShade SIZE=3D1>

<TABLE cellSpacing=3D2 cellPadding=3D2 width=3D450>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>HOME</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/help/" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>HELP</FONT></A></FONT></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/cgi/feedback"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>CONTACT=20
      US</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/subscriptions/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff=20
      size=3D-2>SUBSCRIPTIONS</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      =
href=3D"http://theoncologist.alphamedpress.org/contents-by-date.0.shtml" =

      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff=20
      size=3D-2>ARCHIVE</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      href=3D"http://theoncologist.alphamedpress.org/search.dtl" =
target=3D_top><FONT=20
      face=3Darial,helvetica color=3D#ffffff =
size=3D-2>SEARCH</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none"=20
      =
href=3D"http://theoncologist.alphamedpress.org/content/vol11/issue6/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>TABLE OF=20
      CONTENTS</FONT></A></TD></TR></TBODY></TABLE>
<TABLE cellSpacing=3D2 cellPadding=3D2 width=3D450>
  <TBODY>
  <TR>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#e1e1e1><FONT=20
      face=3Darial,helvetica color=3D#000000 size=3D-2>THE =
ONCOLOGIST</FONT></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none" =
href=3D"http://stemcells.alphamedpress.org/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>STEM=20
      CELLS</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none" =
href=3D"http://cme.alphamedpress.org/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff=20
    size=3D-2>CME</FONT></A></TD>
    <TD vAlign=3Dtop noWrap align=3Dmiddle bgColor=3D#333366><A=20
      style=3D"TEXT-DECORATION: none" =
href=3D"http://www.alphamedpress.org/"=20
      target=3D_top><FONT face=3Darial,helvetica color=3D#ffffff =
size=3D-2>ALPHAMED=20
      PRESS JOURNALS</FONT></A></TD></TR></TBODY></TABLE><A=20
href=3D"http://171.66.124.80/RealMedia/ads/click_lx.ads/theoncologist.alp=
hamedpress.org/cgi/content/full/11/6/916595736/Bottom/alphamedpress/Tarce=
va/tarceva_banner_animated.gif/39373261623235323434396239323830?tw_countr=
y_code=3DIT"=20
target=3Dnew><IMG height=3D60 alt=3D""=20
src=3D"http://171.66.124.80/RealMedia/ads/adstream_lx.ads/theoncologist.a=
lphamedpress.org/cgi/content/full/11/6/916595736/Bottom/alphamedpress/Tar=
ceva/tarceva_banner_animated.gif/39373261623235323434396239323830?tw_coun=
try_code=3DIT"=20
width=3D468 border=3D0></A> <BR></BODY></HTML>

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/banner/title.gif
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/N1471.TheOncologist/B1852285;dcadv=421173;sz=468x60;ord=[timestamp]?
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://171.66.124.80/RealMedia/ads/adstream_lx.ads/theoncologist.alphamedpress.org/cgi/content/full/11/6/2132010894/Top/alphamedpress/GTO_Lilly2006/GTO_Lilly2006.html/39373261623235323434396239323830?_RM_EMPTY_&tw_country_code=IT

R0lGODlhAQABAID/AMDAwAAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/spacer.gif

R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAQAICRAEAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/shared/misc/arrowTtrim.gif

R0lGODlhBAAJAIABAGZmZv///yH5BAEAAAEALAAAAAAEAAkAAAIKjAMHidsLm2HHFAA7

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/shared/toc/free.gif

R0lGODlhIAAHAIABANYTNP///yH5BAEAAAEALAAAAAAgAAcAQAIjjI+pqwDpTAzzVPjQ3Nl2Boah
Q0pkd2YpVq1mW2IypZ5vVQAAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/toc/rarrow.gif

R0lGODlhCgAVALMAAFhYgkxMeTs7bO/w81NTfvz9/VRUf/Hx9Tc3aUpKdzMzZv///wAAAAAAAAAA
AAAAACH5BAAAAAAALAAAAAAKABUAQAQ9cMlJk7oKmSNt3pXGUYuHZcQAjOSytt0lVqecmuhQFMkM
/wFQy+KbmIq4Dyd5EQCSiBQPE9XtiMJJkEWJAAA7

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/toc/uarrow.gif

R0lGODlhCwAJAKIAAOXl7J6etsvL2Do6azMzZv///wAAAAAAACH5BAAAAAAALAAAAAALAAkAQAMW
WLrczmIQEl4BLs5NrY1Vo23hyE1BAgA7

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/toc/dot.gif

R0lGODlhCwAJAIAAAP///0JCSiH5BAAAAAAALAAAAAALAAkAQAIMhI+pGb2PWoC0yooKADs=

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/toc/darrow.gif

R0lGODlhCwAJAKIAAOXl7J6etsvL2Do6azMzZv///wAAAAAAACH5BAAAAAAALAAAAAALAAkAQAMW
WLrcBU4MQmtwWEl6c9tV2IFcNHRKAgA7

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/icons/fig-down.gif

R0lGODlhCAAHAPf/AP///wAAAP//////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
////////////////////////////////////////////////////////////////////////////
/////////////////////////////////////////////////////ywAAAAACAAHAAAIGQABCBxI
EECAAAUNIhx4sOFChQcLRkxIMCAAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/content/vol11/issue6/images/small/681fig1.gif
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/content/vol11/issue6/images/small/681fig2.gif
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==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/math/le.gif

R0lGODlhBwAKAMIAAAAAACQkJElJSW1tbZKSkra2ttvb2////yH5BAEAAAcALAAAAAAHAAoAQAMa
eKoV+4YMAweh7xRR1h6HEGCQMGWKIQZsICQAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/math/ge.gif

R0lGODlhBwAKAMIAAAAAACQkJElJSW1tbZKSkra2ttvb2////yH5BAEAAAcALAAAAAAHAAoAQAMa
GHXc/mYQwwwZtIjlxn5MEQxHJFAlKAQsKyQAOw==

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/content/vol11/issue6/images/small/681fig3.gif
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/content/vol11/issue6/images/small/681fig4.gif
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://theoncologist.alphamedpress.org/content/vol11/issue6/images/small/681fig5.gif
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------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://171.66.124.80/RealMedia/ads/adstream_lx.ads/theoncologist.alphamedpress.org/cgi/content/full/11/6/916595736/Bottom/alphamedpress/Tarceva/tarceva_banner_animated.gif/39373261623235323434396239323830?tw_country_code=IT

R0lGODlh1AE8ANU7APXr1tqxuLJdda+qn8W/tfPm4+vU1MiKcYwqR+LDx9unkEcPFbpwhPjw5+S9
p718ZLBtV3YhOoSKktvVyYQwMjIDB8WElN+5wO5bjY5SRdCeqOjIs9ObgngqLeve22wjJ1AqJ+gK
W8qRnlRaYWA9O59sYY9EPb+LiKFdTHlFO+jMz/SfuFcYHWQeI6RCYD9DSWk1LpypwWhxfsamkHg1
Mt+xmoIlQfPnzJotTgAAAPv17////wAAAAAAAAAAAAAAACH/C05FVFNDQVBFMi4wAwEAAAAh+QQF
yAA7ACwAAAAA1AE8AAAG/8CccEgsGo/IpHLJbDqf0Kh0Sq1ar9isdsvteom4sHhMLpvP6LR6zW67
3/C4fE7HnW74vH7P7/v/gIGCg4SFhoeIiYqLeEJ1j5CRkpOUlZR3jJmam5ydnp+ejpajpKWmp6iY
oKusra6vsKKos7S1traqsLq7vL29shELwsIsxcbDCyzJxS0tH88fHdEd1B0U19jZ19QRHy0szeHh
3uHHwiQJ6err7O3u7/Dx8vP09fb3+OseDfz9/v8AAwocSLCgwYMIEypcyLChw4YA8gCrQLHigooY
KQ4z1gyax2rZrFEQWc2bsZMczV2sSEKHy5cwY8qcSbOmzZs4c+rcybOnz/+fQIMKHUq0qNGjNBtE
bJRDTISMFS6uxCh1mTNo0rJS08a1ZLOU38oVQ8YSqdmzaNOqXcu2rdu3Q5VKbBrmKdS7UYmBcAaj
ml+/2UxsCylNnDPDY4dhbAm3sePHkCNLnjx56Y2Jd6dGzbvs2d+Rnymg4AChqzSP056JVba5LOXX
sGPLnk2brVymTivkyIyMGIu906wBpiB4qwLSJkiCPh389FdlihfXnk69uvXrry1jzrgS2VhwnjvQ
ED6eAocHya0pUPAghUgKD0o3F65aZWuKjLHr38+/v/+at11GFw5P7cbdRidd9dd41JRQA3rGIScS
BOylwAJg1JCTWHQVpfD/34cghigiZdoNGMFuBm7mGzjggBDeX+JRcEANB2QQjXmkZSDSA+zBcOFy
GX6gkjD35TfikUgmqaRPAU6Uoka+GfZBX+JVyWAHJ9CIwjPmHQDhNRyc5yOMzikDHZHSLanmmmwu
WaJTKFJl1VVYbQUkNRwocMCWH8j4wJc4QgBDCxlq9cwxZ6JZgZFtNuroo9Q1aWJmzNA5HzbVjBfm
ARBsxYGXKFBjwqeCpiZcYd9sqNmikLbq6quSvVmXbnJWitWlmFJzgp6CdjDqeaHSMOoDKFBJjZcw
1HdSb67B6uyz0BolaW61gtPRiyDlqimND4xkwgGgWoOCnltWgwKNKRyG/2gyirIa7bvwxouTrATS
CiUz3tQ5XK4d5IksBRl4CQEK11C4Jwjb8PiAjyZ9x66ijMor8cTPTjsrVZVeO59yy63nZQrE/Tnw
NQecB0Gf1pS88GGpLgsxxTDH/Cq9dkFpVb63TmNann+69y2oJowKap8jgXtAsg0vC12zMjftdJIW
14txxh+FN9I21cwYrtB/CkaqjSJ9urBqLZuTJqwCiHGkCGIkcJMYAqzFdhhugzg3DnUXpUI6Bdi0
dzpC/Z23TjQ/GeU4qN1IWAclOGCyr5uWxrV74ob5AAiorsthxDWlfYZ/nuOwdttvhxG3WncP7l/q
nYdhQUyewySCC2S8Dv9TAgzQTkYAOiQghgg24a77GLzjFHXNGnGkMWpbnUpNBo7vmTKwFLhwHITW
5KkABIQmrerZOIVeRnUFJBBA8S6FbtbeGngAF+sueWD+4HDLTbrd988U+uCxu8SAGadzyd3KADzf
hQF4NBkgGRA4r7nkxkAIQlzi7ESBCICGAg4gFwzgQ71zkWaDwgoTB1DAMpQkimk3CZ0IVsjC6tSP
LfCLjAFxwEAdvDAtMfxPDmEnBhf0LX1hcIkK4BYA8zGAAS/RwBgYUMQEiEAABfwdTZQoBiam44k1
BBDNuEM1S2FrMNioAXtM0AIKQABcnTJBDUgDMjOSyj0aQgmHKuAhnaj/ryYFCMAKA/DDl6hDBTrI
o+peIjiX6BF9LimfBvbYx97BLQGA1EEhYZLHFUbSj+kAZAEWeUkP/C8MGkhAI524wgS4jybyA1z8
0nHK3plSB6kUZSCpiAMGvNKGppulCC5ZE/PtsZUw0aMGCsC6WALTladUgR5FoAFeSlIdhhQBIl/i
AWHK8nZ7nIkwiZk/mYjPdjro3w4TObxpBtKRB5xJAcopk0baZIvVMsxh6lTBq2HDcgPLwBlBhYKS
oQBkvzpY5sp2JhTa5I4zUaALNACTKqqAdll8iedc8FC4/XCIZUBfGU6HUB1oYHg4EEAfq5gAdupA
gXgzJEiDSJMAiOGH/547nQfCwDvWzVCKuKxlScVgTpistJaUDJ0LLEA6jIY0mGEA5CfHIFKJhsEF
BggdEl9SAKKSoW477eElCyBUq6aUJuLDQSTFWUV3erSKvcRpTGg51Z8c70DKE0e+zEgwClIABxxY
o8lG8ymBDWyDavxUBlgAjXI8Z3M76ajsejg8BorBqxEFYkjDOlUDCkB8p9yoZEUnQMa67iWPJYML
OntVHRhgeJdlqTpJV4AxGDIMfbMpAV0S2jGMtiamE4BJw4mGug3vkv+7bdpcoFu0Sja1YwCuGdw2
QxfoLoBhHcMgncpUyQrRtqrbX1rT6c1u+gSeFlmRPKOxgQ0coDhgzP/rcUymvb7GBwUmGJeekEY2
cdjHXTnZ3x/j18MCrFMMmWUqFME6BgtgVpLoMypDaZtL6nJ2pul0KWwZ/NTZ3S+GtERfT1+iO+BJ
OKk6+N/p4DfDGtrWwnSryTDJGYapGtWHXL0fLW3XWhoaspWfvC1vH6vC1z7VbR7YpQ6eG0ieSrK/
MU4xgUMqxf6FmAwCaOXwgqdWn6otKG+V0zIS9AEBPOAACtgAB0yQAcFcw2s1SLOeHqBevZ6HWBD4
EwpchBrELA0/iQWgS2iJwLstmHgpNPKQBR0Ttd5wx5ylZYC/mtyTXjh/dxPAdGXyybh5FQcMpZ3t
SFzlRo9zySN+LGn/vwphHNxWwscctYMZWmL/Efq6NJUs8O62ae/CxHOnFYMKnJxkrVKYszRptUxc
KxTwhnfLxmjccQ7ggG7F+T14FaMYP5WnNKvZvQMDwYWCVFixoIlzS4ayq5U8w6keOtwvgaxLcDdb
CgcQ0eOm4QrF8OcGwy+Gpa6wWWFCxdGmzXMMgHDxOM1dd4960rDMnbifHGtHKxnRvBMxVVFMbHij
08aDVm0Sq7hC3SFxqQO3NXXPmluNe3SlDcgpsGci7EJfGShZtkhUzHSSDNAIXGOUXjbUqwA3r8cB
QF+PCIm1F+Y4J46swbMdX37r+83wdOfW38vv5uEzOLbBm91su194/+9ufhhuzoSJUQ1oQBdI+IcE
x7jBHf5VmVRUs4iuWww/zIAaL7jXZHDwunFa8ZegtH7aZTvC+xfddi4V03Hfrtqb/vCf0IsCUCEG
ssFxgm65YGBnzEAGCEayaa+n59Yur7SXDQESbJs59T2GQVtn8nhj1bhR765qvZpp0xXR0Fi3+FIZ
wMJSrr3rjU84Gdo6E7gd1fgBTLuJ7S1yhps9ATHdbMgfXmNTU/GUfGa3au8o7OG5k5ZQ7D3vQjf9
tss+fiulyVItLepgVznd7XersTkz+Qs9iAIfQMEZBbWne0o7r9UGdBuQQaDHKzCAOdGQgKlXUPgV
Pky3cdzlZ2t3UP8vtz9jR2FXd1R6x3YbxnWPFnyJdHgUKGriw0DK11DMB4Iu0WHH5RJeNVWBF28t
9hKVpmpZd3EItFQL5kfGFRMvuFmDp1oK5H65lG9ht3cFBxNGGBTzlzyT5yDd0gEUgh4ZgB4pIBhg
lmYzIm0OUF4DKEakNyap4RHPkXQNGGitB0tINjyL9m7hxjsfNlqtNmOg9VQGAFNXVmpmJ0QaUDwe
qGS0dk7nQ1U9ZBMDVFPS5XdOZ1E/9Ifmh4JHlVWn83UGlogv8XU4gD4TVQAeEDp4yFLCFofFEwDu
01h9U01Vx2OWKHUrJz7rZgF104n05oI9JAKnlAAWgETlxg6R5FX/LmCLr0h8WuRAF3NsJsQCedUt
AUMaMvJPEOAebRYmoOeFG6ACQCdGRIc5heIc5RAd4MaKK7dYT9VYdaiBI2gGCPRTOHV4nIVQlzYG
COSIdWNU6TQ3l0WONfF1SKhxMQRSUJeCj0iDaHA6K+VVqgNSfURLZnCDLRddKYWJL1SQzbdjYkds
N2VbP4R34naR1RVIDpl770SMUhNeZoJsaYYe+4QC8VGFW5IC63UcMFkD5dWFA+gAa/QAGVB0fkGG
h7US3yh74SiOPbSDOeWGrOgCh9dWX/dEOPV2LNVRfxePAJk3hzdr6HgT1Xc6WSmUefN1/6iBnyZJ
w3NEL0SPDEBL/6qze0EFNwPEkGpVAOz4VQHwU6djlmjJejFxN/vIVO5EcUt0cXAnQOoojEkxfwjC
LsWQJeRiNBBgAg9QAhQAAiXjeTCpADRZjV/oJRmwANq4k+TwFS+jE5NEE5UkTe60X2goOipgSTHh
AZwUSMLUSqU5j9BEScsUSn2EmrHUSCqwSKS4SotkmjmhDq1EnEqoDo2Eis20bpm0SnyDR4cUTUKW
SHoESLsZE+XDSjJxSH2zmtIkRLWZnbdETctURDFBSiIwnrApZNdJE38jE+HpS79UE725R9cknu0Q
dvUpTdeUE1tkOBuxZSWwATc5Gv2HAhkAAxDQXtpzHGlGkyqQmf8lQAILUCUlkS89uXqwoVhP06Ee
+hJvlSK9QXMscAIEKgKc8mV/Ai5sxnOfN215RY0boCcZQAIVYCzcpiHt8pOTwaEf+qNO04TesWWi
R23gwqB5ZZNq9nlhkmY1uUYHkAIgsAB3wo2JURE5wKOS4aNA2qUTE3PHtiIDOoDtVTI996LXaG09
J41dSIDbQwJTaix1dqXgMxuj6aV4SjFNSH/JAANe6HnnUTJsCnRKem3UVgNB9ykTWgEIQw305W2K
kqV5OqmU6hhgqhGcoQwc4IXHcQIccALPKEI1kAAbQKqEqqSHapPLNmeMChresBct0y5KV6m0Wqto
IaT0lwEROoD/enIAlZcuZlQybZoAAniN1HamayalFTANyUJQZEERu6Gltjqt1HoTl2ozySCTRXoC
vjqhW+GYYRIAQEesQCdCTRo5KbAAOUABSBOrDJgR0lqt8jqvLmGYNvMAXmiTA2A5xZItJSCoiIqq
/gJm/Eqh2/aqqiIVUBGv9NqwtXqtyDCmM6lXJ1ACOWlXJrCgHBAATGo5bMYeOAkCjCoNe3FCeDGr
DpuyDbunwuCn+aqv3IoCJKAzZxYyYeKpRrqi51ECytoBzWqyVAGvKju083qpw5AC2jqxUCoDUuoM
74ENGaui3Jqif/Jl/ySyzaptZhi0Qku0Xjut9go91HiNA1B5/zkJHu8hGILRT4LKKSVgtY+prISl
te+qZRr6tXj7o0abApc5kxl0HkzLEdNgZtdQAnlCKvHxJ5tnsSJbsnQatEQyFQybt5SrpyKJPBXQ
OG3qtzVQtowruDojGCkQA6QbAxIgATKQujLwAi9Qo1NaDNoWuZH3rGdYubbrNGDKt4Tqt3/7mKbH
ZdFAA2dWujEgA6i7uqybvDkwpVM6R2GqsLV7u9ILM/SCABFwvRFAXNqrW7rlXM5FAQhgAwgwvuQ7
vjiAAOfbvSbgvS6AAO1rvQhAAiQQAeNrAzSAAH5Bv9hrQfoLv5f1vwAcwAI8wARcwAZ8wAicwAq8
wAzcwAGsAW8AEMESPMEUXMEWfMEYnMEavMEc3MEe/MEgHMIiPMIirAeycAsonMIqvMJtkAu+8MIw
HMMyTAgnzMI2fMM4TAsuPMM83MM+vAs1nMNCPMRETAc7/MNInMRKvAhf0MRO/MRQHMVSPMVUXMVW
fMVfEAQAIfkEBQAAOwAsAQABANIBNwAABv9AhHBILBqPyKRyyWw6n9CodEqtInaTrHbL7Xq/4LB4
TC6bz+i0es3O7t7wuHxOr9vv+Lx+z+/7/4CBgoOEhYaHiImKi4yNjo+QkZKTlJWWl5iZmpucnZ6f
oKGUC6KlpqeoqaqeAIikq7CxsrO0sDq1uLm6u7y9vr/AwcLDxMV4BakFDcbMzXavtQ0G0wYefQkB
BpEFAQFz3cjY2jsq3QHIe9TVy40FF90JdQYB8c6G3N72l6QsghCb+Myp4CNuW7dv58glsNYAnDI+
5uA5KhfPGp159Sg1QNeJox58+nZ1uMQt3rx8cDx6LJiyjscdL1vGUQZSDjg5NWXeOYiPY0z/PA3Y
4dzBUh49OhuFAkW3cU7QNxiH0nkIU+nMlz/foMsJ56nWmQdDiiVUcoeHABd2YMQGExvacSzLdVOx
DJuKdxeWNXgXgOIbuQEs8uWLMFy2HRG1GeA70E7Ym4vhKUML82BDax4Gv7F7IcHJg1FDH5Xj9mi5
tGbPlZTrQa5iem61RYTKNwGyeXfRurs5k2/CyPSQ4Ts5sDSyuRcU1xYedqzzP9wueLCrFm3nHe/o
vrNWkGID6tgu5NZ2ene8ctrTnpUutzDRwyeVrW9QLivic6dT583/rkD8szs0dM5Z2oQn3l593XaU
aBm9sV6A1vREVFrRqeBWAtiYhFZuaZWn/x99lM0jHmPvjANHdgV4kCJaIFJoXXtnJXRfZ9WwmB9X
z21CAyoB9bWMiFqFhd572myn33vFHWZkVNlFVsCQON5nmDY1UWRAUQhJRk5fb4BTTmsl3lVdcn5R
t9lh1WmophwxLnRigoFV5qKLGqYloH+jDSklbtUNNI+JlQUglJ4OdbMRT811YxGhqjWXoyt97DjS
DgrcQQEmZcURVaBQHVXQTSAV9OlvR8GDoW0FRXlTqmGFd6pFdDhKZJcD9pWcrX6idWqSJrLEYJpz
ANZYjGJWFk9ZZW0KzqYsLQvfs4By1Wyj3oCUE2/TFhDlo6dMWscBdEAjSKZwbCrgMkMWZP/kg6Iq
6W482cXh10nusZqPX3Fg+JKsQ54bEHaKpobSmb2iGdW8o8kBoozmjIPsUclCDFqeXJ77Z3WvAXon
HP0aai2iKPHWsaDWYshtKf9oQm6nGWUY45RjZnZYu6/BcxSxV65ID2E2JWTvGwJ6poJsMsIhKz7T
cQlwh83hZYAKvMLBUowXvLNmHK3pzE5+QR4rsYbZWD0mlYpSd/HZaEr9lgrals3lx9XOtQxvSFMH
98mUeCvHjnQ8wIElBSTQGBzTDa5W1Wz/5aZZLitujYWLLrQpcLZtqcJ0DW5WOeRtZbQbPdxVnm/m
MN2V3NZuFt6VXOIpBCvnm4mnuupYJ2D/NaxnDR74QLu3lat4wQXI9ZNVG7DMdJilvri8WhJ/eufQ
k9MfUaKXXvwygR9rMt6AiJvHpXaMBO5Y2gZoJveBYGPVHZuinwcymJ8qf/Uh6X3HP+A3E2M3qLn/
B598aJ//6tCYz0TEHPaRhff0kL8HvCFlcYCgPfxTDUWIgAEY7EUAMMgAQM2hAALAoAj2sJEExoqD
HpzFBjGYQgJaxIAR0cAI14c1agzCAzb0hP12MD45mIBSmLggB4fIAFoIsYi8WGEH8cDBETpCiS2M
BRRTYiG8uMAFAtAA1OAgxPd4g4gMGJhaNABGBpiEg2KUgwHICEbSDWKB4csfHXbkQDtQ/2CHjDgi
GFEhDQvF4YiKwOEFTJiIKWrlSoBq4iMMiYspBq5qVbPdH/+YQWwIIIQYvKILyMEODWBRAJrEoAAs
kABPhhA/GLocTLSBSQZcEosM0GIqLeIBWE1CjnvApSOOeMA0gkKRgdCWMJEBO6OhMCXbU4S+5mAA
NMYBmI1gZC2gmJnOWFOSm3xDXt7QxVLuwAUYtIAILHBJFl0gmzsYpQYMYAFwBsCJseylipCIQQ3I
cJw7CGNEapkiQg7ijjsA6Bw+AApA2mFhCbAKNRjimTrgcBp/SRjQKKeUZoazgmbJYVfcAitsiOCj
GsBOEWFVADYy4HnDaZh9KGgiCnJkGv8ayAY19HIBDq4THYpEkC3lIRf6qS0vjqTGS6aBjqShZacP
HQe+cBIe46lRInMIT0M4CEnbJe4N7bxiPlHTzSKCczHJkVk2GJBNC+gKOBcY4SXDKB7AxEEA8DKU
XXDIP2lEMRQUqFQdd8lBx4Cxf/mspwcw6MsdHNEDFuCgBdgx2DbCAYxONKg2iSiCugTgkyKwKAbr
ocRjFsACgR2iHRLAQey9gQFOLEA4A2BSxYAxHzbVrBnvUMaQdiWxaDxmYxkAWqlh0BomVaxQjvhZ
m8ZhqkQcBzuHaAFYNQC3hBWlBqwZEyxqVQPx6Go6YwkTbcUosZsUQP/4opgQutMA2mr/jwDesF58
1GOYPPOfZG2iWOiiJLeErYMQP0pE21qUvxzEKWW52dcuNdGZtgNnLLMaQrgOJLyZFEHVcBBYADvP
YbZzpQtCWg8sboawrN2kC8ijVQUTZbBXvCAoC1yHcOoxI3pMLlY5CCsy9vaC4oSubQ0rwhjXuIyu
DSdue8vjMm7Ydla5AAYCu14XDKSbIQXnJUVwwHxuUgQW+ZdaMqjPA2bQsE8KGHAi4k+xHFEdWVZs
gKArYMVSWb9DfOcQ4ZeR3fYPmkVGomrzq4K+WpK5ODCvhGv6zSKWqLez1abbeNcNcuZzB7YFJ3B5
2w2y/mUvItBqEXFjaXCC9ph12Oaa/+vpoCEGBbrjqGl+A7Tq6pmUi3G274c9GyfcwnOzZjH1c10J
6UHKQQUruCJqyeqCtHQzACtGJz0OYmkZadmi+ewlspvNIYHBhi9lhsTfvmWJGItwsqtWImqG6EZK
4noH0HWjM0/7bVh/WdUMaPOVUCKA6ZDVlRKGgzu5ZFveKrViHuuGBpoMaXanJbH8e7SDWMtlFdFj
vZ1q7R72a+Bwg3rPvJ31T5To7pNuedUmNVyuzy1EbygxHxvc5ApEDuwVYOC30PXAsVf42A52A5yb
LBp51WLeMDrMGn2NSJLQ5JZsFwICutzDA3oICW+j9g0S/zh3Q+vEO0j25FAJ7qqpbv9uJJrUHFTF
xidBS1pBZwScMVUMuyldIlq1DS0Qf7SCNbBnt5CxXAy/d5GQ/c3qSBMnWn86pDnIWVDnOR427koA
oMtig2oWtiw+kU0bTWqTFv6bGrBlyxNAzmKvwM2V7MZiKJxOUN682S81R1pLr0+oZYeDLiDzlhIE
GKMP4gElgMV8O65cYOIZzl9GDILLGMaaC57AX3Y6YRP8bdJKWQRnj+dAEBvaDGrR7UiDuAHWK0RS
YlBAd494JpfIFk1WDdmgjOJuB5zncTCStPVsAAZRs+sydhwq6xYtfYk/wjMbeJM7Rg4rMIDBtgMh
YA3e5kVFEnfRZmVgli/mAE8xdUD/CSBEAkBllGFt/MMbkPAAezUJcKQHuwd1oKZZ/dZuVsdi4hZa
FjA068Z19zd49XRA84ZJI1R2ZAV9+nZSyMFawVVOIOI1SmNYpmeDTydwSBQg73RJ+fQj3sCEfcF3
alEHIbdcgndEhcdCXTFEqoYO8JYNr4Z8SPR4a8cASdZEFHh4XdJkO9ZyBIgBIZBNGNdXFrI42nBF
6xUPxGaGbGIhphRGTzJLwldJyxM/1bBM8hV5kmdx87d2VWcHkoVquzUOL4hnBqVEpCN2zXdvFxh9
kQE83tAAJlVsWrI09DR/sJRfSIg1O2Zb3BBYsXcW2tdiq0Zxgzh1qBYHWteK7cZx/2KIfyBHVWpk
XN9AjIkFdX9BgAQobMakf8ykSHO4U+XygjMxRNI4QMCXhNUYTsvAZo6YB1hIFKJFhl9ofPHGDgY1
h8NyHTCoRI2BddwxOPIXTjDxQbdoRqI4RCZiSM0UQpXFDsD0d8Y3QprVW/BHWHoEKAd5bnm2EdCF
jgVGhuLIQY1ROfaFPWyxkHLmVRpAHwMoHAMYeYzXKQ5zRKgxbYSFDvMQUiZIDUNjEZ1VNKwFNLZn
CB94CB1AUIkwghXHW7L2jXigfMVXfa9Fgvp3dcQHeYJnSOtXfCv0UT9ZBwsJjMF3iybCfgFpeHIQ
eL5HRH9HREIBb/aXZ1SJEk5XIP/8V4bRpXJDww4NMIAq0EWEo3+yxVxCQXzf1o9E5I9A43R8CRPX
GAv9kAchCI6KGAed1YgDaZi8FVxtGGvr1pS/2IxeCZSMFFwmV0aFtYXtNo/HZ5UcM0S3tpRaiTU6
ZlJOtH7TVZomFYANcERmdZQR+YL5KGMTyX6qWVM5pxQDqA1ySZkBQgCtJEraiAWd9UnctX1rxUF/
aRY7UAJ7OXUFMAG1RAl1hAKBsG2D6QhJdQffITdqNA2B2XUCs1O7wVC6sVGi5yAaBTRu8TxQIZ6H
NA1KITOi4x+1QUPMRFTlwp8pMVMzER4vJJ+rRJ93gC8cpZ4RAqDHJVTBQg/HA1X/3RkgDjoTPeVB
n4Fex4UNC6oCmScvK8eeKWRDE2AABOAbKkAAczABDnIBA4BdBOCWJqoO4wArLEqdtREgXWENLEoL
FUADeIQLPImNRLoIeyFyeFBLHlCfK3oVWCAHPUo4HnGjbDITPNqBRRqDWbqlyoSkQEGdVRqmhDMB
L6EiM8Gk5nlc1FmTfrBtNkkMQ8qlcvoHQzOnisABH8g3vTChvhClpdAA44k3T2OnhKoJS+ogjGUW
jJWoFgGoNJkSa2oWHkCmNDmdDhKpZkGpzkk4EEKdVpEUteSWoXqpVOE/T1KoqHoJ1dkAlOqoq9qq
PHo8E3A8JEWm8LMRswoTnqqr/0khqayKDJr6pDRRnTOxpmCKBSnSo5N6qAOkn3IqQanqCCmSqZgh
HJgBpmZanZMKrFC6otgTpbkKBz06rcTKrFrhp7rqINb6BuOKrtHKPZUyB0EaKe/qFCy6pFQaIPfK
qk+qr8h6pXEQpdqSBXoBrlBKnW6ABcsQpUqKrvwqqbqKsMjwsPU6QAeQe45QmHJKpjdKsRyrsOCa
IqxqpgELNJTaqgYbsDTBWCpiEWBKsSarrr5KFTBbsdzDdIDAAQcgQXpqs7qKGcT6s5KKOyebq1Sh
rC5bsFKqsjhBsOwas1XhrxBrqWrqs9wzAztwk3mgs3ywne86nfATrroatkIxqbSXyq4uqyIju6xS
+7OHOp1KKq422rDAyhDKig7UOapYYK5W+xxYywdLBwcPAK11oLF26hNSUY8zATTs4BFmOq2OqqM7
yqwbYa5eIbNv2xWMu6McAajO2rfNgLWE+wejC7qme7qwgLF9MLg89Aaqi7qwG7upYLhyIANwMAIj
ILu6u7u5IAESEAe5y7vCO7yKgAKgdLweBgc9qwfoBAc28AbLiwAdYANyZAPP+wbTe73Eu719GwQA
IfkEBQAAOwAsAQABANIBOgAABv9Am3BILBqPyKRyyWw6n9CodEqt2kqErHbL7Xq/4LB4TC6bz+i0
es3O7t7wuHxOr9vv+Lx+z+/7/4CBgjsWg4aHiImKi4yNjo+QkZKTjYWUl5iZmpucnZ6foG+WoaSl
pqALLKdvqauur7CxsrANfQulqnK3s7y9vr/AgbV8FZ0sLblvLXLFwc7P0NHSO7t1LCA7HYcfO9xv
3nO5FdXT5ebn6JjNmh3gutTphw0Gsh4F8fj5c+usb/xvIK4BSnHoH4w9BQIoDJCgjwgGASYZYMBg
DkV6DyPuCECRAb09CxkCgOTBAkURdTii1MdoYkWWkHIwI3dHGyaafFx21Kgno0T/ihY9bhTRsMBF
A/f2dKQ4qpEGBiIaNKSjUlMBD6Tm9XEJE9K/Bc2SxbG5gwadA93qUEDxxuxYPPwWHNQzESXHl3Cw
vmmg941POB/neBj2xgDhOIHf2OMq56IcxnkP0wHqMvDgPgWSysH6NyXUOkgR6r06J/ObqnEuC05q
r46HxDtUy+FbGGjpyIBtd5X0r482BYhaLEtUd0cCoCofxn5IUaPPBk8pavDLQINJBvcKXH+KEnrH
qdevB8UIccfSiHer3wHagCLW9CLsAfUA1GjDBOFrPbQuIn3FqgB+FkcDzH3GkSXHGVBXdAlEd8FG
UDH34FKndRQfhNa5d11fil0n/xR8WLl0QXM7FEhPc+WBuANku3niTQc0kPUGB5nMlcdEFuCn3l0W
RGVSANox0JBP3BXg00MWZBjRUxYYYBJKT2kAgEnGUZTAXeOVWN6IHhVwXCFPcdiYR0xWid2BhDDg
AZcGHNeAUWqO+CBzSQapAT0B2iUgHCNa8GZD9AklQiEuacCcCA/pWZ14TNJz3JkMFHJXANv9KIdJ
d17gwaMJRboiU9GZaZh5J13AKZostujLARD4IZwiOqkHoSWB1sLRdD5ZaaaWEeUqJIQoSUcpmeql
Sip5ETHGXQCdBXUSVk9F1J6aTzX4o3U79BkAd1pOR51GeQIrx6NEwYHpRA3h+P8poQZ6CqcBqEW7
w7QecITejuXlRZFm8tLL1b+66bpDv+4Zq+oiOPnBAY2nFBcHaoxV5Ss9XB1ZnmNVMYVofD4Z61jH
tiG58VST4fXtGxcdF+2i90bYH69w/BUuag935C2X2H6KUnHFoXYRan/9nOLQPH1qctAeAVwRZI7B
fKzBByfSWx9o7YCCjKA4DAdqcN4TJcwm3eepxRH92MCTaRbNLZdZgvwSmnEgKqZub3zddaAMtBe2
mYd1JvNn3NIcR6dCTZsvz5/1/Fmt8arXtb0Q3lv0u3DYva/SRsPRtOXYceUBolFD8sFwfTCch42S
aF3hSloS5R7MB+o4Z3k+wff/2aMaMNsmU+KNiWzmO8DZX+7HjvmYlfuh7Gl0w5hkgUK45us0lxag
LbhxAeyOXd0UDYP4zu1ChDaXySKPr+SRy8Hctq+ZPx3mgQJZvNEJJI956IssQ/pAO5hAyudFM87L
9jKsO52mXAKEylSY1RAGzstQVxLQBa5zoSjVj3Uxu5ADP8c6JzFlSBeKGwYLs6yRDOU+AwxedJJ0
wq0hkEAQucDL6hfA+p2EZCrLy8sAuJx7JSlSWAFAmVZUQgGi8IizWWGIisjB5azkLpwJIRGhEoCR
NLGJ+GvE6ARBgTxg7RyvCZ6lsqiIh2gmD9cjIx+wcsGNuVGK09CfO/hQNYU9/+AOYpnFo5giGTUG
YkTeAsme/AgSWy3lkEJJxxwDYbpBJCwWa2III66kkHLASyFnnIMBRJA7kuGhAAYQ040WkklgXFJ+
etDAAhFJEQEIIA+ZMY0gYllKQEzNEWyZQxfzkEdAUDIkCwnGLy1JSjwsxJONOGUtfaFMwAyLSoRo
EE8oqaWKXACYsCmACoCpEKwkRCGwkYM2uRkAUfpBJo6QUasyIAes9RIOvSTIHn7JTVlchUPDXERm
RnWJZu7lKmc8ZiT8+Yxmfq56CLWAC1zwBgEQhpoPcQFEtuXK02hGOq+caCEGJYD+KMhQnExX2RYS
nfKAVJXzSgAy7dCMYrxTEf8MrQNaFsmMQPxSQTgNpykEGojX5LSFiCmmYkDXCLmVZiGJ4ekjCOoM
ZeInoQh9w0JxMAqIZpRZrhTAQimiAwO8UqoCsIBeJPrV6SAyAR4oawBUIIKKukAAh1Rpm3SKh0ci
oosOgIP/ShAHb7wzj6jDQz7t4FNR0lIxyzxsbEJZGpyK6ZsMkaViU6MgzTwkq6+0wCs104BtgjMp
LgFlZfsIhzfJcl6ZIUxmKKKCWL6hqwtp7TAE2tXQfLKwpPXpiopp2gJIJrVvuIqCWjM41y7WnHyp
bGMZKxgF7XYhCV1BYFZgiYX6CXu9YihESsKAC6jgOhd4UEMj1Z+lZFYEEk3/Unr6oqY0YceCPCrA
NUkrB3TCgxJ13AGN8ktTQwxWk8C8QFIV0tpr0pWSF5CvUiEbkr5wcyr/NcA1eXpZRAFpwuUsDDfv
4VUc1NM1wYzNaabSAIXANSTZ4eZHYqvgbt4Bw7Ed10K8W0zIerJe8vNsSDyJ4AZgWAVy0LFQW6yQ
BMfhlzTeVqSqJyYMDKwib0WJVc2z1nkoaI8BeKULrkuq8mgnyyf+KFCaEqiVhFJB16GvM5bx0j78
N6hFxnBgYjvhAytEpcAEcvDuTM/ZAhPCIX5uAMJL4GoSmCOEoNQAXZA7joT1iQyhpAGYFIBacHBb
hChR5RSjEKC8UgAc1rIA/4hHFERrYEQCKPId+IzhvtATmEnBsGa2Kd4rmerHcKAknlEMByHXeMYT
xiE5J1S9TK4gBCHoNEOnM2WITAeuFNKIAKaCt+AqZKuIfF5D66Ur/3SErorIayIaCYlf0jIpJS5y
LTDs52MmwM6x7XPw+gJZB9/5yCFOd/ZisxAYTnTQFYEIA8Kq2R2kmlSI3giH3Gc0Ge4gpijTwD22
+aivas6VFXklIKV9AVcKlQ4G0AGfCr1nVWMXlaec875jQxjPivfka70pp4t8j3ncI9jzWog3Z/yG
K6G3erBZAQZC0J8ICsBRlYyo9LbMnIOb5yPVLjm2EYlogQNljz26Drhd9f8GFkSgVZL4YiJefW9B
fyTlp9G5YNWeLbbLAalbK3vPQ3zKdhsJL9hBr8DDShglTwdcRn7ydLrmErZuLe30uKYKhNXr5gRg
oWiN1HQYeoP/YHKeZT+lnv2pb/HimLSnzDXcIfsRHT+W7ZIW9Oaz7AIMrEAOQsfARPUNJIiCSqqD
JtVGMhqYncTmeRj3fAMxfZ5qipc5W3/LKfp7CLJLcgc6Tgpk9axUOwxWxx8ZJzbj/vy5VxL6SFUQ
Uiv8srbunXWpthT1i7zJfB3lIijBwcDSroJ0x48nB6rkwZnCUBeMyNx20FkP9gamp2GX530ZRnGI
AWPfd3LWBk5vgGEARmD/CjJhQFaAu6VdiRF7FkBdGCApfJZ0zREY1UMqTpdIEMIU5yVR1XEXjRYR
SwEt0jFp33YIvRRAjKAKNuENW9R8gYZvB2hjadd91hdoaIdjKsZ9PBZizgdO6yNJeudoGFRAxvFK
wDRw0lIw+2IJRmJwRYZjCMcT5PMg/qclBlcRQBcdicWAZQeAgqYZSAhkEIiAwCR630d6Q4iDpzSA
bggvD2cysYcBQxcC2QJzIkg7EHeGu2dwiVEgZdVlFmJrmsUUPcdKKBgICVM1uRQJNtECzOdmP9hr
QxZjGyF3RdiABRhs9gB3Q7iE36djKpBTSPGEQ3JiA4d+nSY+AydkCgUp/+wCETFVP+bxPAwhSY4H
B0bRUYUAahBCCHp3JyuxTC5nDzh3cnrBVDN2Sd6DVNo3TSGGh23XgM50Z7LIRmy3SQzlZG8QiIIY
Ajigjj5Wh8xSLiWWVShhF18lJg3CUR41aYiCUjoWITi0MQxhVPkTB/uzA3cUB8ChB8DBAZsIB/3V
ZmsnjuO4cmhXikRYB4NlbpCVFKyoka6oEackSrRYIhIlhQ/DXVZHgAuxFCEUHmkHVyUCd8eYay8B
cRNRiubxbtFYB3XmfVMBiwh4Rr6mZ+D3fKGHgA+4ctgnTqQYZKTYIA9nCezYjhjAE3uIg03ZEOl2
TYkVkgMyY8sUCF90C/+tEAg1oAdrCQckcAfgYFcVyZWdNy/s1op58EtYgYQPgocZqZEX8FD5NmOj
4QF6wVP+hHZAZpgPo2qyURiCVk5IeIBvGFwa0Ekih5eVSRX31mLUFhIqQE9nNJkZ5n0PIhWBlk/g
yJd6cRlythdhNJmheW07gAEFEHsr0ACBSABFQ0/B1Vp7IXPQdwLsNwzaBGTTF0uhlBQ6JmDDMAEq
oGekMQkRuQN8xUjwFAlvdpGENocimZfkNIdsyIq+xpQuSU4rlnmjGBIUw2piKRgh0ZRFQ1AwtkDq
SZlSGZ5TwYDRJwcwBmfhaZ7gaIiXR5o8xYB+KFEroCnBJYgrQE3IGJ//JcdNL6cDxKmfe3ahJNV9
ztdJijEBiNAKedSQc+A/iOAWcuCJPmiRAMp+jbmRdIBgQoaUkQROwklkGhFh6KmZBCVk7ZmExiR3
1UdQk2mfSvlx4vRjOjYVRBaLSJqUayVj5CihqimWvoZKNbpjwfVj8MIALjBCDopdjxFMBTAAGqoQ
JyABckAAEvaSEtAfyKkBEvCC24JSbzABZgpMuaNnHpAFIHoIqZCW+cUIKYANdvCJCGFchDVcpaGo
pxgRopVJVsYaCnIYPiV9jqoYOHVGitVb4jRcw/AmjpWovoWMwFVamZpcxNWpmTobr9GaypUXoeGp
jVqqm8FcojUaihpL/5KRXMv5qaN1qzUHSiazA0L3esFzWqZ6DwSAp+/GqJJBAMFlAASgKQMwOANw
bs2qGdJKAKIVStKaFyAarobAAoG6A4bKlYkgdj0IDNtJSPDqCdqBrHvQrBNwRuQKB/k6ARPQAPm6
A/86ARzSrXLwpx8KsH5wS5eSV+QmCOLWD7tUDu8arxSLCQQSSAiRBYdhsHDAsQ0wAQQgJiGbGmcE
ohwrYsiYBeZ0B/alCxTZByQ6ByTwArYUCxNbsTgbCSyqRmGRMBgbBzUQs3ywC2JnBy27CpNVDv96
CgVwsjh7AT+bs5DAMHJZU/4gtTtgsFqbtR3bsR/7BgDwp9MZGwMgsP9Zq7LBZZjhCrIje7Yg+rVe
27RZkJnIaA9zG1xZkBR+irX1krM4AWQOsJZowQElYAKDSgdC2wcJWQ1HS7HNGjwD4E3dCqJlKrk7
kK1ZOwAjwa95EQNmK7AegLmh661nC1BZK7Aj27b+GhuGCbKbMQAh+7gA6wGuC7DbKrVlSUa9sQFz
cLg70JZvsAEPKzVwoLCE1KdnK61mi7xsm7VYwbloSwCHca1rupfk2rZvMLLMu7YcgrypsbYg6r3S
GxtLi7XwihMKALhvgBYDAHZ/ILQVUAwoGgdVi7vXGrsAWwtlOrvdamnd2qerGwfUGxsgK7rkOsBv
EANb8AaYOwC18LH/WrAZ4Ju8BBC55Gu+hGQTuzAOerCQiNAMc/GyGKyvyIu/2VvC3tsAkeut9ioH
1Fu5sxs8B+zC9kBczSq+/VoA/6rDd2qy3rqq5TvCfmS8cJACMLBID+C7eHAQLYANIjzCzbu3d+oG
Umy7WEEAMXAPHmBC1Mu5AKvF1zuwYtKnpHu5ihGuW3zBp6vGeRHEQpxF9csHDWsH2mCoV/vGdOAB
MfC8Wdy5fKwZExADd0q9ZZu9IVsAnhvBPKwYZbu8nuvFtquvzYrFWFHIi+zFfnqv81LIeExIxjsA
D1ACb7kHg5sHdlxXb3wZtJEaD8whqyxLsrG8lPu2nArJp6sZyvq5pFr8wJgqrqrRtLnbyV3BwXZA
uH6AFiXQKh6cosQgzM78zNIAvHAgzaOMB1FrB6dcB3EMzdzczb0wx4Awyi8QFnAAFvvgzeiczr4g
zeiKB/KkBzTbB+NAxOpcz/bcCG+Vz1plcW+AAHiAA4lYxDiAAEJAAhQQAW9gAzsQARRgA2aB0HCg
DRCt0Pdc0RZ90RjdFBi90RwdDxrd0SAd0s/w0SLtR0EAACH5BAWQATsALAEAAQDSATcAAAb/wIhw
SCwaj8ikcslsOp/QqHRKrUZ2g6x2y+16v+CweEwum8/otHrNzu7e8Lh8Tq/b7/i8fs/v+/+AgYKD
hIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8
vbYdvpIJpyoewcfIuB4izCIBfQI4IpEJODhz1sPR0zsW1jjDe83Ojyou1gJ1IjjpyYXV1+7yhvDf
Fnzb1NbY4N0Czx6yJTC25xs6RwzY7XhGZ107Sh5UfAq3B968VDR2cLBDYVK1dOviwZE4Mk4+OBTl
kERZJ+WOYhblZJMTsySeffAortzjgaDK/x0n1SmkM5AnyYhzer5x+JNOsTdPnbrc2bRmHJ87rV7E
lDGPgj0dG31ciMPFDofRXkYry+1kQmsM3kRjEM2FMQ/ncCRs9xYHw7Vr+WmTtsPgNBF549rZVxiH
RMToipV9uS/gswB5BRQAqteFgJD7mIoeavJbOm9mySb4+DbAWw1n2a2FbXBp5sd666pYS9Xct2GQ
2UmEp8HavbX9jLs4fHuH1q2UMgJTVc1FgLmxXXjecc5CQL+cp+31EO14WW+E9yaIli5hXO1k/aIX
HH5HcXAeAkxOSDVOtoRm6YeDB96kc44K9yWg3w7fIYgDbIAxYMBcwCk02kNvFJdOfpT1I/+AWdXR
hQ572YlolnrxEWihcnCdww0c5zCQgAYqCKhiOvAI8FZ84ZimgY0FOscYdJdMR8dGodSj11KTdfiG
N3Hlc85lk5VX35SxGagXZAm4J6RIcMyUT0x7iRAUP5HtkNA9jamQkGsu0mUfW3txplh9WebJVBwC
/gMHheBVJySIK5r1XQJ7rvmGNSqsc886ca3zYoc+KdomPABYVJM1DFnK6HNEhtoSaUy2ExNT+cxk
UT6p9sPUiAIIsBthz4lJK2N1xepnHUPKRVhjCnYGqQuPlqWreS+edGGecqC35JwuMJDaWNSu2E42
e56ELWGSxjapVdqCoylOQ86Ep0C9iqr/7hxjxbHnd8Z4KSV4+pnFKmEucpaOlXDUeR99YzIWpEmy
ygSmmkvCq8I33HEanxxBKatQnXvKoWI/jf1aLY7WOplowtYsw+3Ikx7aL8gDjnvNphh7Ca9Fu2G4
riRGyoHkHR9A0i4cFbMnoET5rGPdORASFrRpCgnIgJnBspMXwLfG891nSwNrME2cYtdwe0Oes5wF
Uf6K530fdsynBU0TBCBKCm0cGw4WkFjccl9et2S3eIvt63IMqACP3XGp3KF3VteNneAzz7wbm3Bc
x/hZFD65q927xv2M5W/QFcCeGjTn3nUyA1Uw5jGjBNgzsVIVK7vS0i35ZQIw7sFbxPrD/5DtfxKr
QewL8c5n2buSdefiat1DvEMAGpA5Y11qx811sEc/h7TCOdc6N6WX3s2Boq/UvOvZr564JjXXEZYu
fu8wIdzjBxKNT3lU3L4dEoGu6/0Fz3+zPAJak9r8fSjOnfQgPwA2i0kGSaBLZnYA6CCIHInQgQR1
UIsJSvAOq/HABfXggQT0Bw8WpGAsQrgHBjAENAnchwjrYMFBtNCAdAghCVvxwlnM0A41ZMQNX3HD
BMStLOjQQAMYwLgJcuYaMlzhG5JoxB3OgYkbHEVX3oCCHVQRE1BUoihymENDdPERN+SiER3hRBq2
cDfa0c6H3mCW/+3AiGsRgQQJBJRuEP9kcyJwU+wk6JpYyUiCXfLjMxC1kAkuQwQa0EEfdcSQANxu
XVk0xRf54LfVrAZ3cbih9hSRuieKMYo6nOQqQoiZD2HABac0JYxECMdryLF/33BBA1aYGR30RWqw
5NTC3qBBHaAnLil0pIIWuInyVUKUS3RiC8foyQ0yM5k7TCI0tXhD5OwjLStk4pdkiENm1lCC2Xih
NN84xmeysIzklKYynblOdmpxmqBM5zvl2ULtnBIDCWjAGwwAocK0o5Vn0UEDtPOj2ejgWsYCzTkW
Ag9iOWtCGaJgXmanl835zwMamJS6kKlNOHS0mR2Foke5Kc9MSpNCqyGpNqtBz3nC8yX/yYRmOJs4
zkh2k6Tw5GY0aTrOln5SpT2Fojk+lD+TNGpR6QCoHCloyT6JkB2baRhhGhAAW1pDBKvZEUPMsrCh
eHA1gYlEBswYz5F+9KNyyCIrRerTaZqVm9uwoOUUGTvYvESCFtCOYmTYJXZgL1Y6KJ1i8jdBTsXF
AhScXeY0CJSqmqmqGmCAOdN6VpuG0Z04VetbSchWn0rwQ6hUXhwwkExuxEWpOqBoAt+YDvB0KB5G
TOFVC2AWx6DnGcExCDEVsb9UsFWta8UpZSMZxcuCUpzLtGBcJwgSHQgNPpJtTNxi+oa/Hc4aOhiG
K5fC2MIaKw7duYcsBSjC6Ep2sh7d/2xOgVrO9r51s+zlaUk5y0RtYOACcsBACHawgglaALHpPKIc
HxIrFbY2HF2F7QVlKw1fFiavk+lfrPKy20Vc0bchRW570WvSDZe1pG59Lz2nmZalHLTBQvuTL5cU
jjG6LGTwyG5hnAPNdKqwcWVZcAAWJgBjlAUAfkHmcIOLWSITOYbeTK6HqalhCs5Qgu8h7WhDEAIM
aDaOPpnl1J5KkbxMg6pWfRBUnjHHjLFvNr7CWB7Od4zfNvnIIEzykr/5zDfLEKXGiKv8TjyNFiv3
V+jCgYyrW5gkhpNn7PgsvsQcjeL08sPrLfJLXyrnzC45xB3W5pMpKID7TjkEAjDACv/qeNKr6vMN
jgzMQQtDEYUGqB5EjNEsT/wNibxFRn2pMCV6y4lJbtrDeaAzT4Na5zmHcLmcRjFpBHDiuCyIhOy7
FHYZImNBy/DQGUr0iYsWreemlhkuteyb4WvsSk/6i5rdNBs/TWU4jLrURgPTjVldGoYxKJfaVqRp
UJ1ACmuC157w9bhBfAdhX9CmBAexWpEdHueSSgf3gbC1J1ivG32piH+b9YLBscJDPWNAsWEoXAYd
bjdfOtJGNq6RJ01uJTtTG+xu937X649dmRZob4xbUVFNFx0lAJA9N2FJY3U7+zmjk+0T+MmFjGlx
F7fYkoZYgy+o52UL1GvzCSFo8lf/F25s/Oex5Tif/scQls6SUyQ/J2bP/VNzE3zg7fzwkw3Qxjfo
l8p4XyJ81X5wdI4YpJAOBJs90YGcGZMQSje5SzPtZJc3vtJrb2mNFT7uYTzdiKKNg+VD6DeVs7In
Bw+x3x2PcqgbvKZLV7dO+95TA9x9BwDYQbuPq+GcLpEAv/asB2ZJc+p6YAIwFCXCme7Zcs+56Ypn
O33RCniW/13ylOewZosfT0sn//kidfqxgYKBFYjWAFS2Mu2NH8UBEFcHuLfg7lMuwQZMYIMTIEAn
OPAVQBz+EBztacL5bv0MN5nx/4d9yydcSHZyLBdfzgeAv8Z8O3V9nmdn5XYPAyR7/1UWYJnGIFig
ceg3APBjfhPUAFnwfk42AQMgghI0AYz1BvLngRMkgm8wATEwAPLHCQC3CUJGgMTnckMmgMCmgCLW
gEUWeBeIac/3dwNXgHA2X11URjoYfdUXd+PXeHiRXxVogR22AzEgfyaoAzEwBwMQU+/3RskUA08G
B1/IgqH3givoCfXnB1NkQxwGQ3JoCBMiZXsggwTQgV4YBwQgf10YB1/Ih8BnhlggBzOohoUIC/fH
Q3E4h47oPo/DQTFoiHNwiCpYgnKAiXCAgny4A5a4A4PISwMQA6H4iI1AfKaYindgARqligaEiqsQ
iKTgAZ/YPpHlirhoCQQQe57Ii//yt4sq6IueCAcz+HubKAEEAHwEEIK8NAEkeImauIwzaInyR4tZ
cGpw8HseEIOnto0c+AZZAIzzowKRmIuHsIiuKIMMIgHA5wFnWI3syCBfKAHGQAASoIKHOAHIqIzO
SI+gKAHfSAAxYACc2IckCHyaWABf6Izx94fHWILqiAXxF4ijmIcABD/mGAg1mJFx8IzL+IXJCIog
6QYh2YdYgIkDEFVvcI+ZCHzPCI6lGIgeGYghuYkO+YIDoE8m+ZLf+JIc+ZNz0IZwAAPoqIoecI8Q
mYhHKZFniJNYSIIKKQcsCYrL6I8+OZUrCZCT2AD+OJUfKYtO6Ym/qAXx6JNAqQv/g7cHB9BAZ9kI
SVmCDvmWMAgH7BgD7miSccCSR4mQ7eiQWLkD9/h7oiWDPAmPFvOHJrmMBLl7DHKTbfmYkMmHbhCO
xDiZEYmFmBgDVkmX+PgGdimSZhiTpQiKMUgQLPmSg/iSOwmWoBmZRMIBrOmahqCPyuiPLxiP9ugT
9qiTLImM4FiCR/mV8niMBvmPfXiIAzCV4ZicwOeb7tiZmNmHpimOshkqRekHLPCYoTia2ykHg6gU
oAgHDRCS8VcAtLgD5nkVfciLBSCd2ZhlJWkMg5ievLSJNckgFlmd7rCRd8Cf+vmfAMoJNRCgBFqg
8xCbLyADBrqgDIoKCtqgEBqhJJVgL3PgAjZgAwjwBhmqoTawAx2AAEYSARkaFgggohJ6orgYBAA7

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://theoncologist.alphamedpress.org/javascript/ajax/xmlhttprequest.js

/*=0A=
=0A=
Cross-Browser XMLHttpRequest v1.2=0A=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=0A=
=0A=
Emulate Gecko 'XMLHttpRequest()' functionality in IE and Opera. Opera =
requires=0A=
the Sun Java Runtime Environment <http://www.java.com/>.=0A=
=0A=
by Andrew Gregory=0A=
http://www.scss.com.au/family/andrew/webdesign/xmlhttprequest/=0A=
=0A=
This work is licensed under the Creative Commons Attribution License. To =
view a=0A=
copy of this license, visit =
http://creativecommons.org/licenses/by-sa/2.5/ or=0A=
send a letter to Creative Commons, 559 Nathan Abbott Way, Stanford, =
California=0A=
94305, USA.=0A=
=0A=
Attribution: Leave my name and web address in this script intact.=0A=
=0A=
Not Supported in Opera=0A=
----------------------=0A=
* user/password authentication=0A=
* responseXML data member=0A=
=0A=
Not Fully Supported in Opera=0A=
----------------------------=0A=
* async requests=0A=
* abort()=0A=
* getAllResponseHeaders(), getAllResponseHeader(header)=0A=
=0A=
*/=0A=
// IE support=0A=
if (window.ActiveXObject && !window.XMLHttpRequest) {=0A=
  window.XMLHttpRequest =3D function() {=0A=
    var msxmls =3D new Array(=0A=
      'Msxml2.XMLHTTP.5.0',=0A=
      'Msxml2.XMLHTTP.4.0',=0A=
      'Msxml2.XMLHTTP.3.0',=0A=
      'Msxml2.XMLHTTP',=0A=
      'Microsoft.XMLHTTP');=0A=
    for (var i =3D 0; i < msxmls.length; i++) {=0A=
      try {=0A=
        return new ActiveXObject(msxmls[i]);=0A=
      } catch (e) {=0A=
      }=0A=
    }=0A=
    return null;=0A=
  };=0A=
}=0A=
// Gecko support=0A=
/* ;-) */=0A=
// Opera support=0A=
if (window.opera && !window.XMLHttpRequest) {=0A=
  window.XMLHttpRequest =3D function() {=0A=
    this.readyState =3D 0; // =
0=3Duninitialized,1=3Dloading,2=3Dloaded,3=3Dinteractive,4=3Dcomplete=0A=
    this.status =3D 0; // HTTP status codes=0A=
    this.statusText =3D '';=0A=
    this._headers =3D [];=0A=
    this._aborted =3D false;=0A=
    this._async =3D true;=0A=
    this._defaultCharset =3D 'ISO-8859-1';=0A=
    this._getCharset =3D function() {=0A=
      var charset =3D _defaultCharset;=0A=
      var contentType =3D =
this.getResponseHeader('Content-type').toUpperCase();=0A=
      val =3D contentType.indexOf('CHARSET=3D');=0A=
      if (val !=3D -1) {=0A=
        charset =3D contentType.substring(val);=0A=
      }=0A=
      val =3D charset.indexOf(';');=0A=
      if (val !=3D -1) {=0A=
        charset =3D charset.substring(0, val);=0A=
      }=0A=
      val =3D charset.indexOf(',');=0A=
      if (val !=3D -1) {=0A=
        charset =3D charset.substring(0, val);=0A=
      }=0A=
      return charset;=0A=
    };=0A=
    this.abort =3D function() {=0A=
      this._aborted =3D true;=0A=
    };=0A=
    this.getAllResponseHeaders =3D function() {=0A=
      return this.getAllResponseHeader('*');=0A=
    };=0A=
    this.getAllResponseHeader =3D function(header) {=0A=
      var ret =3D '';=0A=
      for (var i =3D 0; i < this._headers.length; i++) {=0A=
        if (header =3D=3D '*' || this._headers[i].h =3D=3D header) {=0A=
          ret +=3D this._headers[i].h + ': ' + this._headers[i].v + '\n';=0A=
        }=0A=
      }=0A=
      return ret;=0A=
    };=0A=
    this.getResponseHeader =3D function(header) {=0A=
      var ret =3D getAllResponseHeader(header);=0A=
      var i =3D ret.indexOf('\n');=0A=
      if (i !=3D -1) {=0A=
        ret =3D ret.substring(0, i);=0A=
      }=0A=
      return ret;=0A=
    };=0A=
    this.setRequestHeader =3D function(header, value) {=0A=
      this._headers[this._headers.length] =3D {h:header, v:value};=0A=
    };=0A=
    this.open =3D function(method, url, async, user, password) {=0A=
      this.method =3D method;=0A=
      this.url =3D url;=0A=
      this._async =3D true;=0A=
      this._aborted =3D false;=0A=
      this._headers =3D [];=0A=
      if (arguments.length >=3D 3) {=0A=
        this._async =3D async;=0A=
      }=0A=
      if (arguments.length > 3) {=0A=
        opera.postError('XMLHttpRequest.open() - user/password not =
supported');=0A=
      }=0A=
      this.readyState =3D 1;=0A=
      if (this.onreadystatechange) {=0A=
        this.onreadystatechange();=0A=
      }=0A=
    };=0A=
    this.send =3D function(data) {=0A=
      if (!navigator.javaEnabled()) {=0A=
        alert("XMLHttpRequest.send() - Java must be installed and =
enabled.");=0A=
        return;=0A=
      }=0A=
      if (this._async) {=0A=
        setTimeout(this._sendasync, 0, this, data);=0A=
        // this is not really asynchronous and won't execute until the =
current=0A=
        // execution context ends=0A=
      } else {=0A=
        this._sendsync(data);=0A=
      }=0A=
    }=0A=
    this._sendasync =3D function(req, data) {=0A=
      if (!req._aborted) {=0A=
        req._sendsync(data);=0A=
      }=0A=
    };=0A=
    this._sendsync =3D function(data) {=0A=
      this.readyState =3D 2;=0A=
      if (this.onreadystatechange) {=0A=
        this.onreadystatechange();=0A=
      }=0A=
      // open connection=0A=
      var url =3D new java.net.URL(new =
java.net.URL(window.location.href), this.url);=0A=
      var conn =3D url.openConnection();=0A=
      for (var i =3D 0; i < this._headers.length; i++) {=0A=
        conn.setRequestProperty(this._headers[i].h, this._headers[i].v);=0A=
      }=0A=
      this._headers =3D [];=0A=
      if (this.method =3D=3D 'POST') {=0A=
        // POST data=0A=
        conn.setDoOutput(true);=0A=
        var wr =3D new =
java.io.OutputStreamWriter(conn.getOutputStream(), this._getCharset());=0A=
        wr.write(data);=0A=
        wr.flush();=0A=
        wr.close();=0A=
      }=0A=
      // read response headers=0A=
      // NOTE: the getHeaderField() methods always return nulls for me :(=0A=
      var gotContentEncoding =3D false;=0A=
      var gotContentLength =3D false;=0A=
      var gotContentType =3D false;=0A=
      var gotDate =3D false;=0A=
      var gotExpiration =3D false;=0A=
      var gotLastModified =3D false;=0A=
      for (var i =3D 0; ; i++) {=0A=
        var hdrName =3D conn.getHeaderFieldKey(i);=0A=
        var hdrValue =3D conn.getHeaderField(i);=0A=
        if (hdrName =3D=3D null && hdrValue =3D=3D null) {=0A=
          break;=0A=
        }=0A=
        if (hdrName !=3D null) {=0A=
          this._headers[this._headers.length] =3D {h:hdrName, =
v:hdrValue};=0A=
          switch (hdrName.toLowerCase()) {=0A=
            case 'content-encoding': gotContentEncoding =3D true; break;=0A=
            case 'content-length'  : gotContentLength   =3D true; break;=0A=
            case 'content-type'    : gotContentType     =3D true; break;=0A=
            case 'date'            : gotDate            =3D true; break;=0A=
            case 'expires'         : gotExpiration      =3D true; break;=0A=
            case 'last-modified'   : gotLastModified    =3D true; break;=0A=
          }=0A=
        }=0A=
      }=0A=
      // try to fill in any missing header information=0A=
      var val;=0A=
      val =3D conn.getContentEncoding();=0A=
      if (val !=3D null && !gotContentEncoding) =
this._headers[this._headers.length] =3D {h:'Content-encoding', v:val};=0A=
      val =3D conn.getContentLength();=0A=
      if (val !=3D -1 && !gotContentLength) =
this._headers[this._headers.length] =3D {h:'Content-length', v:val};=0A=
      val =3D conn.getContentType();=0A=
      if (val !=3D null && !gotContentType) =
this._headers[this._headers.length] =3D {h:'Content-type', v:val};=0A=
      val =3D conn.getDate();=0A=
      if (val !=3D 0 && !gotDate) this._headers[this._headers.length] =
=3D {h:'Date', v:(new Date(val)).toUTCString()};=0A=
      val =3D conn.getExpiration();=0A=
      if (val !=3D 0 && !gotExpiration) =
this._headers[this._headers.length] =3D {h:'Expires', v:(new =
Date(val)).toUTCString()};=0A=
      val =3D conn.getLastModified();=0A=
      if (val !=3D 0 && !gotLastModified) =
this._headers[this._headers.length] =3D {h:'Last-modified', v:(new =
Date(val)).toUTCString()};=0A=
      // read response data=0A=
      var reqdata =3D '';=0A=
      var stream =3D conn.getInputStream();=0A=
      if (stream) {=0A=
        var reader =3D new java.io.BufferedReader(new =
java.io.InputStreamReader(stream, this._getCharset()));=0A=
        var line;=0A=
        while ((line =3D reader.readLine()) !=3D null) {=0A=
          if (this.readyState =3D=3D 2) {=0A=
            this.readyState =3D 3;=0A=
            if (this.onreadystatechange) {=0A=
              this.onreadystatechange();=0A=
            }=0A=
          }=0A=
          reqdata +=3D line + '\n';=0A=
        }=0A=
        reader.close();=0A=
        this.status =3D 200;=0A=
        this.statusText =3D 'OK';=0A=
        this.responseText =3D reqdata;=0A=
        this.readyState =3D 4;=0A=
        if (this.onreadystatechange) {=0A=
          this.onreadystatechange();=0A=
        }=0A=
        if (this.onload) {=0A=
          this.onload();=0A=
        }=0A=
      } else {=0A=
        // error=0A=
        this.status =3D 404;=0A=
        this.statusText =3D 'Not Found';=0A=
        this.responseText =3D '';=0A=
        this.readyState =3D 4;=0A=
        if (this.onreadystatechange) {=0A=
          this.onreadystatechange();=0A=
        }=0A=
        if (this.onerror) {=0A=
          this.onerror();=0A=
        }=0A=
      }=0A=
    };=0A=
  };=0A=
}=0A=
// ActiveXObject emulation=0A=
if (!window.ActiveXObject && window.XMLHttpRequest) {=0A=
  window.ActiveXObject =3D function(type) {=0A=
    switch (type.toLowerCase()) {=0A=
      case 'microsoft.xmlhttp':=0A=
      case 'msxml2.xmlhttp':=0A=
      case 'msxml2.xmlhttp.3.0':=0A=
      case 'msxml2.xmlhttp.4.0':=0A=
      case 'msxml2.xmlhttp.5.0':=0A=
        return new XMLHttpRequest();=0A=
    }=0A=
    return null;=0A=
  };=0A=
}=0A=

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://theoncologist.alphamedpress.org/javascript/ajax/utility.js

/************************************************************************=
*****=0A=
 * javascript/ajax/utility.js=0A=
 *=0A=
 * Utility functions for working with XMLHttpRequest data.=0A=
 *=0A=
 * Copyright 2006 Board of Trustees of the Leland Stanford Junior =
University.=0A=
 =
*************************************************************************=
***/=0A=
=0A=
/*=0A=
 * Copy XML nodes into an HTMLElement. This effectively=0A=
 * clones XML markup which uses XHTML naming conventions=0A=
 * into an HTML DOM.=0A=
 */=0A=
function copy_xml_to_html(src, dst) {=0A=
  if (src.nodeType =3D=3D 1) { /* Node.ELEMENT_NODE */=0A=
    var e =3D document.createElement(src.nodeName);=0A=
    for (var i =3D 0; i < src.childNodes.length; i++) {=0A=
	  copy_xml_to_html(src.childNodes[i], e);=0A=
    }=0A=
    for (var i =3D 0; i < src.attributes.length; i++) {=0A=
      var n =3D src.attributes[i].name;=0A=
      var v =3D unescape_xml_string(src.attributes[i].value);      =0A=
      e.setAttribute(n, v);=0A=
      if (n =3D=3D "class") {=0A=
        e.className =3D v;=0A=
      }=0A=
      else if (n =3D=3D "style") {=0A=
        set_css_style(v, e, "");=0A=
      }=0A=
    }=0A=
    dst.appendChild(e);=0A=
  }=0A=
  else if (src.nodeType =3D=3D 3) { /* Node.TEXT_NODE */=0A=
    dst.appendChild(document.createTextNode(src.nodeValue));=0A=
  }=0A=
}=0A=
=0A=
/* =0A=
 * It is unclear that this is the right thing to be calling=0A=
 * from copy_xml_to_html, but it appears that Safari decides=0A=
 * to convert &amp; to the NCR &#35;, and then encodes that=0A=
 * NCR to &%26%2338;.  So, I'm going to treat the DOM Attr=0A=
 * value as a plain string, and run our XML string input=0A=
 * through the decoding routine below.=0A=
 */=0A=
function unescape_xml_string(s) {=0A=
  return s.replace(/&apos;/g, "'")=0A=
          .replace(/&#39;/g,  "'")=0A=
          .replace(/&quot;/g, "\"")=0A=
          .replace(/&#34;/g,  "\"")=0A=
          .replace(/&gt;/g,   ">")=0A=
          .replace(/&#62;/g,  ">")=0A=
          .replace(/&lt;/g,   "<")=0A=
          .replace(/&#60;/g,  "<")=0A=
          .replace(/&amp;/g,  "&")=0A=
          .replace(/&#38;/g,  "&");=0A=
}=0A=
=0A=
/*=0A=
 * Parse set of CSS rules and apply them to an element.=0A=
 * This is quite horrifying, but I'm unable to determine=0A=
 * how else to handle this with IE 6.  FireFox and other=0A=
 * sane browsers let you simply set the style attribute=0A=
 * or use e.style.setProperty(rule, value, priority),=0A=
 * IE 6 appears to have neither of these capabilities..=0A=
 */=0A=
function set_css_style(css, e, priority) {=0A=
  var rules =3D css.split(";");=0A=
  for (var i =3D 0; i < rules.length; i++) {=0A=
    var nvpair =3D rules[i].split(":");=0A=
    if (nvpair.length =3D=3D 2) {=0A=
      try {=0A=
        var name  =3D nvpair[0]; /* style attribute */=0A=
        var value =3D nvpair[1]; /* attribute value */=0A=
  =0A=
        /*=0A=
         * For each possible style attribute, set the=0A=
         * appropriate style property in the element.=0A=
         */=0A=
        if (name =3D=3D "background") {=0A=
           e.style.background =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-attachment") {=0A=
          e.style.backgroundAttachment =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-color") {=0A=
          e.style.backgroundColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-image") {=0A=
          e.style.backgroundImage =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-position") {=0A=
          e.style.backgroundPosition =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-position-x") {=0A=
          e.style.backgroundPositionX =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-position-y") {=0A=
          e.style.backgroundPositionY =3D value;=0A=
        }=0A=
        else if (name =3D=3D "background-repeat") {=0A=
          e.style.backgroundRepeat =3D value;=0A=
        }=0A=
        else if (name =3D=3D "behavior") {=0A=
          e.style.behavior =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border") {=0A=
          e.style.border =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-bottom") {=0A=
          e.style.borderBottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-bottom-color") {=0A=
          e.style.borderBottomColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-bottom-style") {=0A=
          e.style.borderBottomStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-bottom-width") {=0A=
          e.style.borderBottomWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-collapse") {=0A=
          e.style.borderCollapse =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-color") {=0A=
          e.style.borderColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-left") {=0A=
          e.style.borderLeft =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-left-color") {=0A=
          e.style.borderLeftColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-left-style") {=0A=
          e.style.borderLeftStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-left-width") {=0A=
          e.style.borderLeftWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-right") {=0A=
          e.style.borderRight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-right-color") {=0A=
          e.style.borderRightColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-right-style") {=0A=
          e.style.borderRightStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-right-width") {=0A=
          e.style.borderRightWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-style") {=0A=
          e.style.borderStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-top") {=0A=
          e.style.borderTop =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-top-color") {=0A=
          e.style.borderTopColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-top-style") {=0A=
          e.style.borderTopStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-top-width") {=0A=
          e.style.borderTopWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "border-width") {=0A=
          e.style.borderWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "bottom") {=0A=
          e.style.bottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "clear") {=0A=
          e.style.clear =3D value;=0A=
        }=0A=
        else if (name =3D=3D "clip") {=0A=
          e.style.clip =3D value;=0A=
        }=0A=
        else if (name =3D=3D "color") {=0A=
          e.style.color =3D value;=0A=
        }=0A=
        else if (name =3D=3D "cssText") {=0A=
          e.style.Sets =3D value;=0A=
        }=0A=
        else if (name =3D=3D "cursor") {=0A=
          e.style.cursor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "direction") {=0A=
          e.style.direction =3D value;=0A=
        }=0A=
        else if (name =3D=3D "display") {=0A=
          e.style.display =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font") {=0A=
          e.style.font =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font-family") {=0A=
          e.style.fontFamily =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font-size") {=0A=
          e.style.fontSize =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font-style") {=0A=
          e.style.fontStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font-variant") {=0A=
          e.style.fontVariant =3D value;=0A=
        }=0A=
        else if (name =3D=3D "font-weight") {=0A=
          e.style.fontWeight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "height") {=0A=
          e.style.height =3D value;=0A=
        }=0A=
        else if (name =3D=3D "ime-mode") {=0A=
          e.style.imeMode =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-flow") {=0A=
          e.style.layoutFlow =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-grid") {=0A=
          e.style.layoutGrid =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-grid-char") {=0A=
          e.style.layoutGridChar =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-grid-line") {=0A=
          e.style.layoutGridLine =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-grid-mode") {=0A=
          e.style.layoutGridMode =3D value;=0A=
        }=0A=
        else if (name =3D=3D "layout-grid-type") {=0A=
          e.style.layoutGridType =3D value;=0A=
        }=0A=
        else if (name =3D=3D "left") {=0A=
          e.style.left =3D value;=0A=
        }=0A=
        else if (name =3D=3D "letter-spacing") {=0A=
          e.style.letterSpacing =3D value;=0A=
        }=0A=
        else if (name =3D=3D "line-break") {=0A=
          e.style.lineBreak =3D value;=0A=
        }=0A=
        else if (name =3D=3D "line-height") {=0A=
          e.style.lineHeight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "list-style") {=0A=
          e.style.listStyle =3D value;=0A=
        }=0A=
        else if (name =3D=3D "list-style-image") {=0A=
          e.style.listStyleImage =3D value;=0A=
        }=0A=
        else if (name =3D=3D "list-style-position") {=0A=
          e.style.listStylePosition =3D value;=0A=
        }=0A=
        else if (name =3D=3D "list-style-type") {=0A=
          e.style.listStyleType =3D value;=0A=
        }=0A=
        else if (name =3D=3D "margin") {=0A=
          e.style.margin =3D value;=0A=
        }=0A=
        else if (name =3D=3D "margin-bottom") {=0A=
          e.style.marginBottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "margin-left") {=0A=
          e.style.marginLeft =3D value;=0A=
        }=0A=
        else if (name =3D=3D "margin-right") {=0A=
          e.style.marginRight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "margin-top") {=0A=
          e.style.marginTop =3D value;=0A=
        }=0A=
        else if (name =3D=3D "min-height") {=0A=
          e.style.minHeight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "overflow") {=0A=
          e.style.overflow =3D value;=0A=
        }=0A=
        else if (name =3D=3D "overflow-x") {=0A=
          e.style.overflowX =3D value;=0A=
        }=0A=
        else if (name =3D=3D "overflow-y") {=0A=
          e.style.overflowY =3D value;=0A=
        }=0A=
        else if (name =3D=3D "padding") {=0A=
          e.style.padding =3D value;=0A=
        }=0A=
        else if (name =3D=3D "padding-bottom") {=0A=
          e.style.paddingBottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "padding-left") {=0A=
          e.style.paddingLeft =3D value;=0A=
        }=0A=
        else if (name =3D=3D "padding-right") {=0A=
          e.style.paddingRight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "padding-top") {=0A=
          e.style.paddingTop =3D value;=0A=
        }=0A=
        else if (name =3D=3D "page-break-after") {=0A=
          e.style.pageBreakAfter =3D value;=0A=
        }=0A=
        else if (name =3D=3D "page-break-before") {=0A=
          e.style.pageBreakBefore =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelBottom") {=0A=
          e.style.pixelBottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelHeight") {=0A=
          e.style.pixelHeight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelLeft") {=0A=
          e.style.pixelLeft =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelRight") {=0A=
          e.style.pixelRight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelTop") {=0A=
          e.style.pixelTop =3D value;=0A=
        }=0A=
        else if (name =3D=3D "pixelWidth") {=0A=
          e.style.pixelWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posBottom") {=0A=
          e.style.posBottom =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posHeight") {=0A=
          e.style.posHeight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "position") {=0A=
          e.style.position =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posLeft") {=0A=
          e.style.posLeft =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posRight") {=0A=
          e.style.posRight =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posTop") {=0A=
          e.style.posTop =3D value;=0A=
        }=0A=
        else if (name =3D=3D "posWidth") {=0A=
          e.style.posWidth =3D value;=0A=
        }=0A=
        else if (name =3D=3D "right") {=0A=
          e.style.right =3D value;=0A=
        }=0A=
        else if (name =3D=3D "ruby-align") {=0A=
          e.style.rubyAlign =3D value;=0A=
        }=0A=
        else if (name =3D=3D "ruby-overhang") {=0A=
          e.style.rubyOverhang =3D value;=0A=
        }=0A=
        else if (name =3D=3D "ruby-position") {=0A=
          e.style.rubyPosition =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-3dlight-color") {=0A=
          e.style.scrollbar3dLightColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-arrow-color") {=0A=
          e.style.scrollbarArrowColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-base-color") {=0A=
          e.style.scrollbarBaseColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-darkshadow-color") {=0A=
          e.style.scrollbarDarkShadowColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-face-color") {=0A=
          e.style.scrollbarFaceColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-highlight-color") {=0A=
          e.style.scrollbarHighlightColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-shadow-color") {=0A=
          e.style.scrollbarShadowColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "scrollbar-track-color") {=0A=
          e.style.scrollbarTrackColor =3D value;=0A=
        }=0A=
        else if (name =3D=3D "float") {=0A=
          e.style.styleFloat =3D value;=0A=
        }=0A=
        else if (name =3D=3D "table-layout") {=0A=
          e.style.tableLayout =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-align") {=0A=
          e.style.textAlign =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-align-last") {=0A=
          e.style.textAlignLast =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-autospace") {=0A=
          e.style.textAutospace =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-decoration") {=0A=
          e.style.textDecoration =3D value;=0A=
        }=0A=
        else if (name =3D=3D "textDecorationBlink") {=0A=
          e.style.textDecorationBlink =3D value;=0A=
        }=0A=
        else if (name =3D=3D "textDecorationLineThrough") {=0A=
          e.style.textDecorationLineThrough =3D value;=0A=
        }=0A=
        else if (name =3D=3D "textDecorationNone") {=0A=
          e.style.textDecorationNone =3D value;=0A=
        }=0A=
        else if (name =3D=3D "textDecorationOverline") {=0A=
          e.style.textDecorationOverline =3D value;=0A=
        }=0A=
        else if (name =3D=3D "textDecorationUnderline") {=0A=
          e.style.textDecorationUnderline =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-indent") {=0A=
          e.style.textIndent =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-justify") {=0A=
          e.style.textJustify =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-kashida-space") {=0A=
          e.style.textKashidaSpace =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-overflow") {=0A=
          e.style.textOverflow =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-transform") {=0A=
          e.style.textTransform =3D value;=0A=
        }=0A=
        else if (name =3D=3D "text-underline-position") {=0A=
          e.style.textUnderlinePosition =3D value;=0A=
        }=0A=
        else if (name =3D=3D "top") {=0A=
          e.style.top =3D value;=0A=
        }=0A=
        else if (name =3D=3D "unicode-bidi") {=0A=
          e.style.unicodeBidi =3D value;=0A=
        }=0A=
        else if (name =3D=3D "vertical-align") {=0A=
          e.style.verticalAlign =3D value;=0A=
        }=0A=
        else if (name =3D=3D "visibility") {=0A=
          e.style.visibility =3D value;=0A=
        }=0A=
        else if (name =3D=3D "white-space") {=0A=
          e.style.whiteSpace =3D value;=0A=
        }=0A=
        else if (name =3D=3D "width") {=0A=
          e.style.width =3D value;=0A=
        }=0A=
        else if (name =3D=3D "word-break") {=0A=
          e.style.wordBreak =3D value;=0A=
        }=0A=
        else if (name =3D=3D "word-spacing") {=0A=
          e.style.wordSpacing =3D value;=0A=
        }=0A=
        else if (name =3D=3D "word-wrap") {=0A=
          e.style.wordWrap =3D value;=0A=
        }=0A=
        else if (name =3D=3D "writing-mode") {=0A=
          e.style.writingMode =3D value;=0A=
        }=0A=
        else if (name =3D=3D "z-index") {=0A=
          e.style.zIndex =3D value;=0A=
        }=0A=
        else if (name =3D=3D "zoom") {=0A=
          e.style.zoom =3D value;=0A=
        }=0A=
      }=0A=
      catch (e) {=0A=
        /* ignore error on attempt to set e.style.[property] */=0A=
      }=0A=
    }=0A=
  }=0A=
}=0A=

------=_NextPart_000_0015_01C696A4.21509550
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://theoncologist.alphamedpress.org/javascript/entrez/callback.js

/************************************************************************=
*****=0A=
 * javascript/entrez/callback.js=0A=
 *=0A=
 * Entrez Linking callback to populate content box.=0A=
 *=0A=
 * Copyright 2006 Board of Trustees of the Leland Stanford Junior =
University.=0A=
 =
*************************************************************************=
***/=0A=
=0A=
/*=0A=
 * Execute callback to fill content box with Entrez Linking information.=0A=
 */=0A=
function entrez_callback(pmid, callback_url) {=0A=
  /*=0A=
   * MSIE 5.5 and below have issues with the JavaScript=0A=
   * used for Entrez Linking. For now we have to disable=0A=
   * the callback until we can track down a proper fix=0A=
   * (or everybody sanely upgrades to version 6 or 7!).=0A=
   */=0A=
  if (navigator) {=0A=
    var appname =3D navigator.appName;=0A=
    if (appname =3D=3D "Microsoft Internet Explorer") {=0A=
      var userAgent =3D navigator["userAgent"];=0A=
      var s =3D "MSIE ";=0A=
      var n =3D -1;      =0A=
      if ((n =3D userAgent.indexOf(s)) !=3D -1) {=0A=
        var v =3D parseFloat(userAgent.substring(n+s.length));=0A=
        if (v < 6) {=0A=
          return;=0A=
        }=0A=
      }=0A=
    }=0A=
  }=0A=
=0A=
  /*=0A=
   * Acquire table row element to update, initiate callback=0A=
   * to update table with Entrez Links.=0A=
   */=0A=
  var tr =3D document.getElementById('entrez_callback_'+pmid);=0A=
  if (!tr) {=0A=
    return;=0A=
  }=0A=
  var req =3D new XMLHttpRequest();=0A=
  if (!req) {=0A=
    return;=0A=
  }=0A=
  req.onreadystatechange =3D function() {=0A=
    if (req.readyState =3D=3D 4 && (req.status =3D=3D 200 || req.status =
=3D=3D 304)) {=0A=
      var src =3D req.responseXML.documentElement;=0A=
      var dst =3D document.createDocumentFragment();=0A=
      for (var i =3D 0; i < src.childNodes.length; i++) {=0A=
      	copy_xml_to_html(src.childNodes[i], dst);=0A=
      }=0A=
      var tbl =3D tr.parentNode;=0A=
      tbl.replaceChild(dst, tr);=0A=
    }=0A=
  }=0A=
  req.open('GET', callback_url, true);=0A=
  req.send(null);=0A=
}=0A=

------=_NextPart_000_0015_01C696A4.21509550--

